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ABSTRACT 
 
Cancer cells must reprogram their metabolic networks to adapt to stress 
conditions, which are commonly found in a tumor microenvironment.  To 
accomplish this, cancer cells alter expression and regulation of many target 
proteins.  Among these, the glycolytic enzyme pyruvate kinase M2 (PKM2) has 
been implicated as essential for cancer cell growth and survival in stress 
conditions. As with other pyruvate kinases, PKM2 catalyzes the final step of 
glycolysis, dephosphorylating phosphoenol pyruvate (PEP) to generate pyruvate 
and ATP.  PKM2 is differentially expressed in highly proliferating tissues 
including cancer cells, and has intrinsically lower activity than other pyruvate 
kinases. However, the role of PKM2 and its function in cancer cells remains 
poorly understood. 
In this study, we have identified a novel protein-metabolite interaction 
between PKM2 and the cellular metabolite succinyl-aminoimidazole 
carboxamide-ribosyl-5-phosphate (SAICAR) that promotes cancer cell growth.  
We found that SAICAR, a de novo purine nucleotide biosynthesis intermediate, 
accumulates in an oscillatory manner in glucose deprived cancer cells, but not in 
normal cells.  SAICAR activates PKM2 both in vitro and in vivo, and induces 
metabolic reprogramming by augmenting the Warburg effect.  Additionally, 
accumulation of SAICAR promotes long-term cancer cell survival in glucose-
limited conditions, in a PKM2-dependent manner.  The activation of PKM2 by 
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SAICAR demonstrates that cancer cells coordinate a delicate balance between 
metabolic pathways to optimize their survival in stress conditions. 
Recent literature has shown that PKM2 is capable of acting as a protein 
kinase, and phosphorylation of its targets promotes long-term cellular adaptation.  
However, the mechanism and extent of this novel function is not fully understood.  
In this study, we also identified SAICAR as an activator of PKM2 protein kinase 
function.  SAICAR binding renders PKM2 an efficient protein kinase both in vitro 
and in vivo.  Additionally, we identified that PKM2-SAICAR phosphorylates over 
100 cellular proteins, many of which are involved in cell proliferation and survival.  
Of these, we found that PKM2-SAICAR phosphorylates and activates Erk1/2, 
forming a positive feedback loop that is necessary for long term proliferative 
signaling. 
Taken together, our study demonstrates that cancer cells utilize the PKM2-
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Cancer Cell Reprogramming 
Metabolic reprogramming occurs in most cancer cells, regardless of origin 
or type (1-4, 9).  Specifically, cancer cells uptake more glucose than normal cells 
and metabolize glucose through oxygen-independent lactate fermentation, also 
known as aerobic glycolysis.  (6).  This process is deemed the Warburg effect 
and has been shown to be necessary for the growth, proliferation and survival of 
tumors (1-4, 9).  Surprisingly, most cancer cells rely upon aerobic glycolysis as 
the method of energy production, which produces much less energy than 
oxidative phosphorylation per glucose molecule consumed (3, 9, 13).  It has been 
suggested that aerobic glycolysis leads to an increase in the production of 
anabolic products, such as nucleotides, fatty acids, and amino acids, and 
generates lactate and protons. (3, 9).  These anabolic products can be utilized for 
the production of vital cellular components such as DNA, proteins, and lipids, 
which may give cancer cells a competitive advantage (3).  However, cells need 
sufficient amounts of energy for growth and proliferation using these cellular 
building blocks.  When cancer cells are in nutrient-rich conditions, they can 
compensate for an energy deficit by uptaking more glucose (15, 16).  However, 
as a tumor progresses, cancer cells transition into both nutrient-limited and 
oxygen-limited conditions.  To proliferate and survive, cancer cells must balance 
energy production and anabolic processes.  Currently, the molecular mechanism 
for the metabolic reprogramming of cancer cells in not fully understood and its 
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contribution to cancer cell growth and survival at the molecular level remains 
unclear. 
 
Pyruvate Kinase M2 is expressed in cancer 
Several proteins have been implicated as important for metabolic 
reprogramming in cancer and are necessary for the Warburg effect, including 
pyruvate kinase muscle form 2 (PKM2) (10).  PKM2 is one of four pyruvate 
kinases (PKM1, PKL, PKR) found in mammals, which all catalyze the final step of 
glycolysis from phosphoenolpyruvate (PEP) to pyruvate, while generating ATP 
from ADP (Figure 1-1A) (7). It is believed that cells express a specific isoform of 
pyruvate kinase dependent on the metabolic needs of the tissue.  PKM2 is 
expressed in some differentiated tissues, such as the lung and pancreatic islets, 
as well as cells with high rates of nucleic acid synthesis including highly 
proliferating normal cells, fetal cells, and malignant cancer cells (10).   The other 
isoforms, PKM1, PKR, and PKL, are expressed solely in normal somatic tissues. 
Specifically, PKR is expressed in red blood cells, PKL is the predominant form in 
the liver, and PKM1 is expressed in most adult tissues, including the brain and 
muscle.   
A single gene encodes PKM1 and PKM2 (PKM), and the same is true with 
PKL and PKR (PKLR).  The PKM gene consists of 12 exons and 11 introns 
(Figure 1-1B).  To produce each PKM isoform, an hnRNP-dependent splicing 
event occurs, choosing either exon 9 (PKM1) or exon 10 (PKM2) to be expressed  



























Sequence Di!ering Between M1/M2  
Figure 1-1. PKM2 is a typical pyruvate kinase. A) Pyruvate kinases catalyze 
the reaction from phosphonel pyruvate (PEP) to pyruvate and ADP to ATP.  B) 
Schematic representation of mRNA transcript after splicing of PKM1 and PKM2.  
PKM1 contain exons 1-8, 10, and 11.  PKM2 contains exons 1-9 and 11. C) 
Diagram representing the linear protein structure of PKM1/2.  PKM1/2 contains 
several protein domains, and differ between aa 378-434 (depicted in yellow).  D) 
Crystal structure of one subunit of PKM2. Structure is color matched to protein 
domain diagram (PBD 4FXJ). E) Structure of PKM2 homotetramer.  Sequence 
differing between PKM1 and PKM2 is highlighted in yellow; the four subunits are 
labeled using different colors (PBD 4FXJ).
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differentially (Figure 1B).   Despite the altered exon choice, PKM1 and PKM2 
differ at the protein level by only 23 amino acids at their carboxyl terminus out of 
531 total residues and are 95% identical (Figure 1C).  Structurally, PKM1 and 
PKM2 exist in a homotetramer, as a dimer of dimers, and theoretically can 
transition between homodimer and homotetramer.  Both PKM1 and PKM2 
consist of several domains on each of the four subunits: A, B, A2, and C (Figure 
1-1C-D).  The cleft between the A and B domain forms the active site (Figure 1-
1D-E). The A domain binds with another PK subunit to form a homodimer (aa 
378-434; figure 1-1C-E).  The tetramer is then form by contacts between the C 
domains. Interestingly, crystallographic studies show that most of the residue 
differences between PKM2 and PKM1 lie within the dimer-dimer interface of the 
PKM1/2 homotetramer (Figure 1-1D, 21).  Additionally, the C domain houses a 
putative nuclear localization sequence (NLS), which is buried upon 
tetramerization (Figure 1-1C, 21). 
PKM2 expression is known to be upregulated in a number of cancers. 
EGFR activation was shown to trigger a signaling pathway that leads to PKM2 
overexpression, through PLCg1-dependent PKCe ubiquitinylation and NF-kb 
activation.  NF-kb interacts with HIF1a and together, they bind together to the 
PKM promoter and then lead to increased transcription.  The increased 
expression of PKM2 correlated with increased glucose consumption, glycolytic 
flux, and lactate production (43).  The data linking PKM2 expression with cancer 
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cell proliferative signaling and metabolic flux implicates PKM2 as important for 
both the Warburg effect and tumorigenesis (43).  
 
PKM2 has distinct biochemical properties 
  Although PKM1 and PKM2 are highly similar in sequence and structure, 
these two proteins have distinct properties.  Biochemically, PKM2 is intrinsically 
much less active than its splice variant PKM1 (Figure 1-2A).   PKM1 has a 100-
fold lower Michaelis-Menten constant (Km) for its substrate PEP when compared 
to PKM2 (Figure 1-2A, 10 uM and 1 mM for M1 and M2, respectively) and the 
rate of turnover (kcat) is approximately four times higher than that of PKM2 (7, 
26). Additionally, the quaternary structure of PKM2 is much more dynamic than 
that of PKM1 or the other pyruvate kinases PKL and PKR.  As previously 
mentioned, pyruvate kinases exist as primarily as homotetramers; this form is 
considered to be an active pyruvate kinase.  Unlike PKM1 and other pyruvate 
kinases, PKM2 transitions between a homodimer and homotetramer in vitro and 
in vivo (Figure 1-2C, 27, 28).  The homodimeric form is often found in cancer 
cells, and its prevalence often correlates with the progression of cancer from 
benign to malignant (28, 29).  
  In addition to biochemical and quaternary structure differences, PKM2 
activity is regulated by cellular metabolites and post-translational modifications 
(25, 30).  The upstream glycolytic intermediate fructose 1-6 bisphosphate (FBP) 
binds to PKM2 at lysine 433 and increases its affinity for the substrate PEP to  
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Figure 1-2. PKM2 activity and structure is allosterically regulated.  A) PKM1 
is more active than PKM2 intrinsically. In an LDH-NADH coupled activity assay, 
PKM1 has a lower Km for substrate and higher kcat than that of PKM2.  B) FBP 
activates PKM2 approximately 2-fold.  C) Gel filtration analysis of PKM2 
quaternary structure.  PKM2 exists as a tetramer, dimer, and monomer (labeled 
4, 2, 1, respectively).  Upon addition of the allosteric activator FBP, PKM2 
quaternary structure shifts to a tetramer. 
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micromolar level, while prompting the quaternary structure change from 
homodimer to homotetramer (Figure 1-1B-C, 25).  Activation of PKM2 and 
stabilization of the tetramer by FBP is reversible through phosphorylation at 
tyrosine 105 by oncogenic fibroblast growth factor receptor under hypoxic 
conditions (30). Serine was also found to be a natural ligand and allosteric 
activator of PKM2, binding to PKM2 at histidine 464 and lowering the Km for PEP 
by 2.3 fold (38).  The activation of PKM2 by serine was found to operate in a 
rheostat manner, and allows cells to coordinate serine biosynthesis needed for 
cell proliferation and energy production by PKM2 (38). Furthermore, PKM2 is 
acetylated at lysine 305, which occurs only upon stimulation with high glucose. 
This acetylation event decreases PKM2 activity, promotes an interaction with 
HSC70, and leads to degradation of PKM2 by chaperone-mediated autophagy 
(44).   
As PKM2 is thought to be a nearly inactive pyruvate kinase, many have 
suggested that cancer cells use the M2 isoform to divert more glycolytic 
intermediates to biosynthetic processes, such as the pentose phosphate pathway 
(PPP), to promote cell growth and proliferation (Figure 1-3).  In normal cells, 
PKM1 is expressed and highly active, allowing flux to proceed through glycolysis 
into the TCA cycle and ultimately generate energy.  Cancer cells however, 
express PKM2.  The inactivity of PKM2 causes a bottleneck in glycolysis and 
feeds intermediates into the PPP, generating precursor molecules to produce  

























































Figure 1-3.  The role of PKM2 in cancer cells is unclear. A) Schematic 
diagram representing a common model in the field that PKM1 is highly active and 
promotes glycolytic flux, through the TCA cycle, and ultimately energy 
generation.  PKM2 is inactive and promotes flux through the pentose phosphate 
pathway (PPP) to generate precursor molecules.  B) Diagram representing the 
proposed flux in a scenario where pyruvate kinase activity is altered.  C) Figure 
adapted from Christofk et al. 2008.  Mass spectrometry signal ratio of lactate, 








	   10	  
proteins, fats, and nucleotides (Figure 1-3).  Although this model can explain 
some aspects of PKM2 in cancer cell metabolism, several key aspects from 
available data have not been factored in.  In the commonly proposed bottleneck 
model, upstream metabolites in the glycolytic pathway are expected to increase, 
while downstream intermediates, including pyruvate and lactate, would decrease.  
However, metabolites analyzed from H1299 cells expressing PKM2 showed an 
increased production of both pyruvate and lactate, in comparison to H1299 cells 
expressing PKM1 (Figure 1-3) (3).  Additionally, upstream metabolites, including 
FBP, were decreased in these cells (Figure 1-3)  (3).  These data contradict the 
bottleneck model, suggesting that the role of PKM2 in cancer cells is still unclear.  
Furthermore, cells in nutrient limited conditions, such as a those found in a tumor 
microenvironment, would become rapidly energy depleted without an active 
pyruvate kinase, as a great deal of energy is required for the production of 
anabolic intermediates.  Again, the bottleneck model is not supported by data. 
In addition, the expectation of the model is that pyruvate kinase activity is 
directly correlative to cancer cell growth and proliferation.  In contrast to this 
model, replacing PKM2 in cancer cells with any other pyruvate kinase isoform 
drastically reduces cancer cell survival in stress conditions (hypoxia (4) or 
glucose-depletion (8)) and suppresses tumorigenecity (4).  Thus, pyruvate kinase 
activity and cancer cell growth are not simply inversely correlated.  These 
findings suggest that unidentified subtle differences between the tumor-specific 
isoform PKM2 and its normal cell counterparts are essential for tumor growth and 
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survival in stress conditions (4).  The molecular mechanism defining the role of 
PKM2 in tumor growth in stress conditions is still unclear. 
 
PKM2 acts as a protein kinase 
A new role for PKM2 in cancer cells has been identified that appears to be 
important for growth and proliferation (38-41).  Surprisingly, PKM2 has been 
shown to act as a protein kinase in addition to its known function as a pyruvate 
kinase.  Unlike other protein kinases, studies have shown that PKM2 uses PEP 
as the phosphate donor rather than the traditional use of ATP.  ADP acts as a 
competitive inhibitor for protein substrate binding, suggesting that ADP and the 
protein substrates bind the same site (38).  Additionally, the quaternary structure 
of PKM2 appears to play an important role in its activity as a protein kinase.  As 
previously mentioned, PKM2 can exist as both a homodimer and a 
homotetramer.  Gel filtration chromatography experiments suggest that the PKM2 
dimer acts as a protein kinase, while the tetramer is an active pyruvate kinase 
(38).  FBP, although an activator of pyruvate kinase activity, does not affect 
protein kinase activity substantially (38).  Furthermore, the PKM2 mutant R399E 
exists primarily as a dimer and was found to be a very active protein kinase (38).  
Several proteins have been identified as PKM2 substrates.  Nearly a 
decade ago, it was suggested that PKM2 phosphorylates histone H1 at a lysine 
residue, but no functional consequences were identified and the low likelihood of 
phosphorylation at a lysine residue made the work controversial (41).  A serine-
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threonine phosphorylated PKM2 was found to phosphorylate prothymosin a, a 
protein involved in the immune response, but again no functional outputs were 
identified (42).  In an indirect study, PKM2 was suggested to phosphorylate the 
catalytic histidine of phosphoglycerate mutase, as the authors found that PEP 
was the phosphate donor.  However, PKM2 was never confirmed to be the 
protein kinase involved (43).  
In more recent years, the targets of PKM2 have become more defined and 
the functional outputs were clearly identified.  PKM2 phosphorylates the 
transcription factor stat3 at tyrosine 705 (Y705), thereby activating the 
transcription of MEK5 and potentially other genes regulated by STAT3 (38).  The 
upregulation of MEK5 contributes to increased cell proliferation in cancer, 
presumably through ERK5 signaling (38).  PKM2 has also been shown to bind to 
the phospho-tyrosine 333 (pY333) form of beta-catenin upon stimulation of 
epithelial growth factor receptor (EGFR) (40).  The binding of PKM2 and beta-
catenin is required to recruit both to the promoters of specific gene targets, and 
leads to increased expression of c-Myc, GLUT1, and LDHA (39).  Although not 
proven, PKM2 protein kinase activity is suspected to be involved in the 
transcriptional activation of these genes (40).   
Additionally, PKM2 has been shown to directly phosphorylate histone H3 
at threonine 11 (pT11).   Phosphorylation of histone H3 at T11 is necessary for 
the removal of the histone deacetylase HDAC3 from gene promoters, H3 
acetylation at lysine 9 (H3K9), and the expression of both the cell cycle regulator 
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cyclin D1 and proliferation factor c-Myc (40).  Thus, pT11 H3 directly promotes 
cancer cell growth and proliferation and this occurs through the action of PKM2 
as a protein kinase (40).  
 
PKM2 localization 
  Although PKM2 typically resides in the cytoplasm, some protein 
substrates, such as histone H3, exist solely in the nucleus.   Recent findings have 
shown that upon activation of EGFR, PKM2 localizes the nucleus where it is able 
phosphorylate nuclear protein targets (Figure 1-4) (41).  Additionally, only dimeric 
PKM2 was found in the nucleus, and has been shown to act as a robust protein 
kinase when used for in vitro studies (40).  In support of this finding, the mutant 
R399E, which exists predominantly as a dimer, was found to be constitutively 
nuclear regardless of condition and acts as an effective protein kinase (40).  To 
enter the nucleus, Erk1/2 binds directly to PKM2 at isoleucine 429 and leucine 
431, and subsequently phosphorylates PKM2 serine 37 (Figure 1-4) (39).  
Phosphorylated S37 PKM2 binds to peptidyl-proline isomerase PIN1 and leads to 
cis-trans isomerization.  The isomerization exposes a previously inaccessible 
NLS, which promotes binding to importin a5 and nuclear localization (Figure 4).  
Further support for this mechanism was found when a phosphorylation deficient 
mutant (PKM2 S37A) was unable to enter the nucleus and downstream targets 
were no longer activated.  The phospho-mimic mutant PKM2 S37D mutant was 
constitutively nuclear and was able to bind and activate gene targets.   













Figure 1-4. Schematic diagram illustrating the proposed entrance of PKM2 
into the cell nucleus.  Upon EGF binding to its cognate receptor, Erk1/2 
becomes activated and phosphorylates PKM2.  Additionally, through a separate 
pathway, p300 also is activated, and acetylates PKM2.  Both modifications are 
necessary for PKM2 to enter the nucleus, through its interaction with importins.  
Upon nuclear entry, PKM2 can act as a protein kinase and phosphorylate histone 
H3, promoting release of an HDAC and expression of the oncogene Myc.  
 
	   15	  
Upon EGF addition, Erk1/2 becomes activated and phosphorylates PKM2 
at serine 37.  Acetylase p300 also becomes activated and acetylates PKM2 at 
lysine 433.  Both marks are proposed to recruit PIN1, which binds and initiates a 
cis-trans isomerization and exposure of the nuclear localization signal.  The 
signal is recognized and PKM2 is transported into the nucleus with Importin 
alpha.  PKM2, once inside the nucleus can act as a protein kinase and activate a 
number of protein targets; H3 phosphorylation is depicted in Figure 1-4.  H3T11 
phosphorylation leads to removal of the HDAC and subsequent expression of 
genes, such as Myc. 
Another recent study revealed that PKM2 is able to enter the nucleus upon 
acetylation, as well as phosphorylation.  The p300 acetyltransferase acetylates 
PKM2 at lysine 433, the residue responsible for the binding of allosteric activator 
FBP (Figure 1-4) (44).  Acetylation promotes nuclear localization, presumably by 
interfering with FBP binding, which stabilizes the tetrameric form of PKM2.  
Conditions supporting cell growth, including cell cycle activation, EGF addition, 
and oncoprotein overexpression, enhanced acetylation of PKM2.  Acetylation of 
PKM2 was also found to enhance the protein kinase activity of PKM2 in vitro, and 
an acetylation-mimic of PKM2 (K433Q) was found to act as protein kinase.  
Furthermore, acetylation of PKM2 is enriched in human breast cancers, providing 
more support that PKM2 nuclear localization and protein kinase activity is 
important for tumorigenesis (43). 
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PKM2 has an unclear role in tumorigenesis 
PKM2 is overexpressed in a number of cancer cell types and tissues and 
has been thought to have a large role in tumorigenesis.  Low PKM2 pyruvate 
kinase activity is thought to lead to increased anabolic products and cell 
proliferation.  However, this bottleneck model is contradicted by many pieces of 
data, as outlined above.  Additionally, PKM2 acts as a protein kinase and has 
been shown to activate transcription of downstream proliferative signaling genes.  
Recombinant PKM2 purified from E. coli was unable to phosphorylate protein 
targets in vitro, suggesting that there is another factor required for this activity 
that is hereto unknown.  Recent data suggest that acetylation of PKM2 
transforms PKM2 into a protein kinase in vitro, however little structural analysis 
was performed and the basis for this activity is unclear (44).   
A controversy about the requirement of PKM2 for tumorigenesis has been 
persistent within the field.  According to recent data, all tumor cells do not require 
PKM2.  In fact, in the Brca1-loss driven mouse model, PKM2 deletion 
accelerated tumor formation, and leads to heterogeneous PKM1 expression (45).  
Additionally, the authors found that PKM2 expression is variable within human 
cancers and that those cancers with PKM2 possess point mutations in this gene 
(45).  The authors conjecture that these data imply that inactive PKM2 is required 
for tumor growth and formation, while active pyruvate kinases are not necessary 
(45).  Although the data certainly support this hypothesis, studies by numerous 
other groups produce some doubt that this finding may be context specific.  
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Regardless of the controversy, PKM2 and its regulation are far from being 
completely understood; much of the mystery is still waiting to be uncovered. 
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Thesis Overview 
Despite the many findings describing PKM2 activity and its role in cancer 
cell metabolism, how cells circumvent the energy deficit associated with a 
deficient pyruvate kinase activity remains unknown.  Additionally, the molecular 
mechanism behind PKM2 protein kinase activity is still poorly understood. 
In the second chapter of this study, we show that a novel interaction exists 
between PKM2 and the de novo purine biosynthesis intermediate SAICAR.  We 
found that SAICAR co-purifies with PKM2 in glucose depleted cancer cells and 
activates PKM2 isozyme-specifically both in vitro and in vivo.  SAICAR 
accumulates in a physiologically relevant manner in glucose-depleted cancer 
cells, but does not accumulate in normal cells.  Using cells with modified SAICAR 
metabolism, we found that cellular SAICAR concentration correlates with PKM2 
activity, as well as with glucose uptake and lactate production, two components 
of the Warburg effect.  Increased cellular SAICAR protect cells from cell death in 
glucose depleted cancer cells, and in a PKM2-dependent manner.   
This chapter provides insight into the mechanism by which cancer cells 
coordinate metabolic pathways in response to external stimuli.   Additionally, 
identifying the interaction between catabolic and anabolic pathways could 
elucidate the major differences in cancer and normal cell metabolism, which 
would prove valuable in creating therapeutics that specifically target cancer cells.  
Furthermore, the methodology described in this chapter can be used to identify 
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many other metabolite-protein interactions that are previously unrecognized in 
both normal cells and cancer cells (32-34). 
 In the third chapter of this study, we show that cellular SAICAR 
concentration increases upon EGFR activation.  SAICAR induces the protein 
kinase activity of PKM2 both in vitro and in vivo, and promotes nuclear 
localization of PKM2.  PKM2-SAICAR phosphorylates over 100 cellular proteins, 
many of which are involved in proliferative signaling pathways.  Of these, we 
found that Erk1 is directly phosphorylated by PKM2-SAICAR in the activation 
loop at threonine 202.  Phosphorylation of T202 leads to partial activation of 
Erk1.  Phosphorylation of PKM2 by Erk1/2 rendered PKM2 hypersensitive to 
SAICAR, leading to a positive feedback loop between PKM2-SAICAR and MAPK 
signaling.  Finally, we found that the mutual phosphorylation of PKM2 and Erk1/2 
is necessary for sustained proliferative signaling.   
This chapter identifies a molecular mechanism by which PKM2 becomes 
an active protein kinase, and emphasizes that the scope of PKM2ʼs activity in 
cancer cells was not fully appreciated previously.  Additionally, our findings show 
that cancer cells couple metabolic status with cell proliferation and growth 
signaling.  Furthermore, this study offers new evidence that allosteric ligands are 
capable of altering protein function, rather than just activity, suggesting that there 
are potentially many other metabolite-protein interactions that are not yet known.  
 In chapter four of this study, we found that cellular SAICAR concentration 
increases upon addition of a number of growth factors (BDNF, GDNF, HGF, IGF, 
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TGF, VEGF), but not in conditions inducing differentiation or cell death (Retinoic 
Acid or TNF).  We found that regulation of the protein level of the SAICAR 
synthetase PAICS is likely responsible for increased cellular SAICAR production.  
Cellular SAICAR level correlates with PAICS protein level, Erk1/2 
phosphorylation, PKM2 nuclear localization, histone H3T11 phosphorylation, and 
cell proliferation.  Furthermore, we found that growth factors that lead to cellular 
SAICAR increases also stabilize PAICS protein level, potentially through 
phosphorylation, but not through translation. 
 The appendices of this thesis provide results found in several preliminary 
studies.  In the first study, we utilized a high throughput screen to find 
compounds that inhibit or activate the enzymatic activity of the SAICAR cleavage 
enzyme ADSL activity.  However, upon further investigation, we found that some 
potential hits of the screen were likely due to non-specific interactions.  The 
second study examines the relationship between SAICAR and GLUT1 
localization.  We found that GLUT1 localization differs in the presence versus the 
absence of cellular SAICAR.  In the third appendix, we found evidence for a 
PKM2 stimulating factor of unknown identity.  The factor was identified in yeast 
extracts and we attempted to purify the compound utilizing many biochemical 
techniques.  Finally, we examined the effect of various ligands and mutations of 
the quaternary structure of PKM2.  Among the mutants, we found that the R399V 
mutation was predominantly a dimer, similar to the published R399E mutant.  
This mutant is hypersensitive to SAICAR, implying that SAICAR may bind to the 
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dimer.  Although SAICAR does not significantly affect the overall quaternary 
structure of PKM2, activation of PKM2 by SAICAR is specific to the dimer. The 
preliminary findings of this thesis provide the groundwork for future studies on the 
role of SAICAR and PKM2 in many cellular processes, as well as for the 
biochemical and biophysical bases for the activation of PKM2 by SAICAR. 
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*This chapter was previously published in Science (Keller et al, 2012).  Figures 2-
5 to 2-7 were generated by the co-author Irene Tan and Figures 2-2 and 2-3 
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ABSTRACT 
Pyruvate kinase isoform M2 (PKM2) plays an important role in the growth 
and metabolic reprogramming of cancer cells in stress conditions. Here, we 
report that SAICAR (succinylaminoimidazolecarboxamide ribose-5'-phosphate, 
an intermediate of the de novo purine nucleotide synthesis pathway) specifically 
stimulates PKM2. Upon glucose starvation, cellular SAICAR concentration 
increases in an oscillatory manner and stimulates PKM2 activity in cancer cells. 
Changes in SAICAR levels in cancer cells alter cellular energy level, glucose 
uptake, and lactate production. The SAICAR-PKM2 interaction also promotes 
cancer cell survival in glucose-limited conditions. SAICAR accumulation is not 
observed in normal adult epithelial cells or lung fibroblasts regardless of glucose 
conditions. This allosteric regulation may explain how cancer cells coordinate 
different metabolic pathways to optimize their growth in the nutrient-limited 
conditions commonly observed in the tumor microenvironment. 
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INTRODUCTION 
An emerging hallmark of cancer cells is metabolic reprogramming, which 
includes elevated glucose uptake and oxygen-independent lactate fermentation 
known as the Warburg effect (1-3). This reprogramming is necessary for the 
growth and survival of tumors (4) in stress conditions and in xenografts. 
However, the molecular basis for this event and its role in cancer growth has 
remained unclear.  
Several proteins, including PKM2, play important roles in the metabolic 
reprogramming and growth of cancer cells (4-6). PKM2 is one of four pyruvate 
kinases (PKs) found in mammals (7). It is highly expressed in fetal cells and 
cancer cells, whereas the other isoforms (PKM1, PKR, and PKL) are expressed 
in normal somatic tissues. Replacement of PKM2 in cancer cells with any other 
PK isoform drastically reduces cancer cell survival in stress conditions (hypoxia 
(4) or glucose-depletion (8)) and suppresses tumorigenicity (4). This suggests 
that subtle differences between this tumor-specific isoform and its normal cell 
counterparts are essential for tumor growth (4).  
Biochemically, PKM2 is less active than its splice variant PKM1 due to its 
higher Michaelis-Menten constant (Km) for phosphoenolpyruvate [PEP, (7)]. It has 
been hypothesized that the PKM2 isoform allows cancer cells to divert more 
glycolytic intermediates to biosynthetic processes like the pentose phosphate 
pathway to promote cell growth (2, 9). Although this model explains many 
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aspects of PKM2ʼs role in cancer cell metabolism and growth, new data suggest 
that this may not be the entire story. For example, knocking down PKM2 without 
supplying additional PK limits cell growth (4), indicating that the relationship 
between PK activity and cell growth is not a simple inverse correlation. Similar 
results were seen with inhibitors specifically targeting PKM2 (8). It has been 
suggested that PKM2 can balance both cell growth and energy generation in 
cancer, but the mechanism remains unclear (10).  
We speculated that this delicate balance of cell growth and energy 
generation may be explained by assuming that there is an allosteric regulator of 
PKM2 coordinating the PK activity (and thus energy generation) in response to 
the cell's metabolic demands. PKM2 is activated by the upstream glycolytic 
intermediate fructose-1,6-bisphosphate [FBP; (7)]. However, other PK isoforms 
(PKL and PKR) also activated by FBP cannot replace PKM2 for cancer cell 
growth in stress conditions (4, 7).  
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RESULTS 
To identify unrecognized metabolites that interact with PKM2 in a glucose-
dependent manner, we extracted cellular metabolites from A549 human lung 
cancer cells treated with high (25 mM) or no glucose media (for 0.5 hrs). 
Metabolites binding to recombinant PKM2 were then identified using liquid-
chromatography mass spectrometry (LC-MS, Fig. 2-1A). When metabolite 
extracts from cells grown in glucose-rich conditions were used, peaks 
corresponding to known PKM2-binding metabolites (FBP and pyruvate) could be 
identified. When metabolites from glucose-depleted cells were used, a metabolite 
peak (m/z in positive ion mode: 455.0817) was found (* in Fig. 2-1A). This 
compound was identified as SAICAR (succinylaminoimidazolecarboxamide 
ribose-5'-phosphate, Fig. 2-1B), a purine nucleotide biosynthesis intermediate, 
based on its mass (calc. exact mass, [M×H]+: 455.0815) and its fragmentation 
pattern (Fig. 2-2). There were several peaks other than SAICAR, but none were 
specific to PKM2 as they also co-eluted with PKM1. 
To test whether SAICAR affects PKM2's function, we synthesized SAICAR 
(11) (Fig. 2-3) and tested its effect on PKM2 using a lactate dehydrogenase 
(LDH)-coupled method. SAICAR activates PKM2 with an effective concentration 
at the half-maximal effect (EC50) of 0.3 ± 0.1 mM (Fig. 2-1C). Increasing the 
incubation time (to 3 hours) did not alter the EC50. SAICAR did not affect other 
PKs tested (Fig. 2-1 and 2-4). SAICAR-binding increased the catalytic turnover 
number (kcat) of PKM2 by 2-3-fold while reducing the Km for PEP from ~2 mM to  
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Figure 2-1. Identification of SAICAR as a regulator of PKM2. (A) LC-MS total 
ion current chromatographs of PKM2-copurified metabolites from glucose-rich 
(top) and glucose-free cells (bottom). A metabolite further characterized (Fig. 2-
2) is noted with an asterisk (*). A549 cells were incubated in fresh DMEM (10% 
dialyzed FBS) containing either 25 mM or no glucose for 30 min, and metabolites 
extracted.  Extracted metabolites were mixed with recombinant human PKM2 for 
30 min at 37°C, cooled on ice, and subjected to a gel-filtration chromatography 
(exclusion limit: 10 kDa) at 4°C. Metabolites that co-purified with PKM2 were 
subjected to LC-MS analysis [C18, electron-spray ionization (ESI), positive mode]. 
(B) Structure of SAICAR. (C) Effect of enzymatically synthesized SAICAR (Fig. 
2-3) on PK activities of (•) PKM2 and (o) PKM1. Avg.± s.d. (n=3).
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Figure 2-2. MS/MS (positive ion mode) analysis of the metabolite from 
glucose-starved cancer cells bound to PKM2. Peaks corresponding to 
decarboxylated SAICAR (408.0), SAICAR minus C4H6O4 (337.0), and further loss 
of phosphate (239.1) are noticeable. LCQ Ion trap mass spectrometer was used. 
 





Figure 2-3. Analytical anion exchange chromatograph of starting material 
AICAR (black line) and enzymatically synthesized SAICAR (red line). 
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Figure 2-4. SAICAR has no effect on PKR or PKL. Effect of SAICAR on 
recombinant PKR or PKL was measured using a lactate dehydrogenase coupled 
assay as described.  Avg. ± s.d. (n = 3). 
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~0.1 mM. SAICAR did not affect the Km for ADP. Overall, the binding of SAICAR 
rendered PKM2's pyruvate kinase activity similar to that of PKM1.  
When effects of other compounds related to SAICAR were tested (Fig. 2-
5), succinyl-AMP stimulated PKM2, but the EC50 value several-fold higher than 
that of SAICAR (1.5 ± 0.4 mM vs. 0.3 ± 0.1 mM). None of the other tested 
compounds affected PKM2 activity significantly. SAICAR did not affect LDH 
activity (Fig. 2-6). The stimulation of PKM2 by SAICAR and by FBP was not 
additive (Fig. 2-7). Although this could be consistent with a competitive binding 
between FBP and SAICAR for an identical binding site, the study of mutant 
PKM2 proteins discussed later argues against this possibility. 
To assess the physiological significance of this interaction, we measured 
SAICAR concentrations in several cell lines by LC-MS. In all human cancer cells 
tested (HeLa cervical cancer, A549, U87 glioblastoma, and H1299 non-small cell 
lung cancer cells), cellular levels of SAICAR were elevated upon glucose 
starvation from 0.02-0.1 to 0.3–0.7 mM (Fig. 2-9A-C). The concentration of 
SAICAR is similar to that measured in glucose-rich leukemia cells [40uM, (12)]. 
The increase in cellular SAICAR level is oscillatory in HeLa (Fig. 2-9A) and 
H1299 cells (Fig 2-8). Pyruvate, lactate, and the ATP/ADP ratio also changed in 
a manner similar to the oscillation of SAICAR levels (Fig 2-9A and 2-8). SAICAR 
accumulation of HeLa cells was observable even after a 12-hour incubation in 
glucose-free media. At a fixed time point (30 min), cellular SAICAR levels in HeLa 
cells increased as extracellular glucose concentration decreased [Fig 2-9B;  
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Figure 2-5. Effects of succinyl-AMP (S-AMP, yellow symbols), AMP (red), 
fumarate (empty), succinate (green), and ZMP (black) on PKM2. 
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Figure 2-6. Effect of SAICAR on rabbit muscle lactate dehydrogenase 
(LDH). Effect of SAICAR on commercial rabbit muscle LDH was measured by 
monitoring NADH consumption using pyruvate as a substrate. 
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Figure 2-7. SAICAR-mediated PKM2 stimulation is not additive to the FBP-
mediated PKM2 stimulation. Effect of SAICAR (0.1 mM) on the activity of 
PKM2 pre-incubated with various concentrations of FBP was measured.  FBP-
bound PKM2 is not activated further by the addition of SAICAR. 
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Time in no glucose media (min) 
Figure 2-8. Oscillation of SAICAR and other metabolites in (left) H1299 cells 
and (right) HeLa cells in glucose-free media. (Left) SAICAR concentration of 
H1299 cells plotted against incubation time in glucose-free media. (Right) 
SAICAR concentration change of HeLa cells is shown in gray line and symbol 
while the ratio of ATP and ADP LC-MS peak areas (red circles) are overlaid to 
show the correlation between these two parameters. 
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Figure 2-9. SAICAR binds to PKM2 in glucose-depleted cancer cells. (A) Cellular 
concentration of SAICAR in HeLa cells in response to glucose-depletion. HeLa 
cells were incubated in glucose-free media, and changes in SAICAR, pyruvate, 
and lacate concentration were measured using LC-MS. (B) Effect of extracellular 
glucose concentration on cellular SAICAR amount in (o) HeLa and (∇) NIH 3T3 
cells after incubating with various glucose concentrations. (C) Effect of cell type. 
HeLa, H1299, HuMEC, and HuALF were incubated in 25 mM (filled box) or in no 
glucose media (gray box) for 30 min and used for the analysis of SAICAR level. 
Avg.± s.d. (n = 3). Other cancer cell lines tested also showed glucose-depletion 
dependent increase of cellular SAICAR level. (D) LC-MS peak area of SAICAR 
co-purified with PKM1, PKM2, or StrepII tag from H1299 cells incubated for 30 
min in fresh 25 mM or no glucose media. (E) Amount of FBP that co-purified with 
the protein of interest analyzed as in (D). 
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physiological blood glucose level in healthy patients: 4-7 mM (13)]. In NIH 3T3 
mouse embryonic fibroblast cells, an increase in SAICAR level was observed 
only when extracellular glucose concentrations were far below the physiological 
range. In normal human mammary epithelial (HuMEC) and in adult lung fibroblast 
(HuALF) cells, SAICAR accumulation was not observed even in glucose-free 
media (Fig. 2-9C). In all cells tested, FBP levels were gradually decreased upon 
glucose depletion (Fig. 2-10). These results suggest that the cellular 
concentration of SAICAR increases to a level sufficient to stimulate PKM2 in 
glucose-deprived cancer cells. It also suggests that SAICAR accumulation in 
glucose-depleted conditions may be limited to highly proliferating cells, perhaps 
because these cells use the de novo nucleotide synthesis pathway more than 
normal cells. However, other proliferating normal cells expressing PKM2 may 
also use this regulatory mechanism.   
To determine if the PKM2-SAICAR interaction also occurs in cancer cells, 
we used an approach similar to the global metabolite-protein interaction mapping 
in yeast (14). HeLa cells were transfected with plasmids coding StrepII-tagged 
PKM2 or PKM1. These proteins were affinity purified. Metabolites co-purified with 
these proteins were then analyzed by LC-MS (Fig. 2-9D). Co-purification of 
SAICAR with PKM2 was observed when PKM2 was purified from glucose-
depleted cells. SAICAR was not enriched with PKM1 (Fig 2-9E). FBP co-purified 
with PKM2 from glucose-rich cells as expected. These results suggest that the 
isozyme-specific PKM2-SAICAR interaction occurs in cells.
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Figure 2-10. Cellular level of FBP upon glucose depletion in HeLa cells. 
Data were collected and analyzed as in Fig. 2-1A. 
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We then examined the effect of SAICAR on the pyruvate kinase activity of 
PKM2 in cancer cells. We prepared HeLa and H1299 cells stably transfected with 
shRNA vectors targeting expression of the SAICAR synthase PAICS and the 
SAICAR cleavage enzyme ADSL (adenylosuccinate lyase; Fig 2-11A). In cells 
where PAICS is knocked down (paics-kd), cellular SAICAR concentration was not 
inducible while adsl-kd cells have constitutively elevated SAICAR levels (Fig. 2-
11B). Depletion of glucose for 30 min further increased cellular levels of SAICAR 
in adsl-kd cells. Prolonged (>12 hrs) glucose depletion eventually led to a 
decrease in cellular SAICAR levels in adsl-kd cells (Fig 2-12). In paics-kd adsl-kd 
double-knockdown cells, no increase in SAICAR levels was observed. When PK 
activity in cell extracts was measured, the PK activity was higher in adsl-kd cells 
(Fig 2-13). Addition of SAICAR to the cell extract elevated pyruvate kinase 
activity of control-kd (cells transfected with scrambled shRNA) and paics-kd cell 
extracts, and only slightly in adsl-kd cell extracts (Fig 2-13). These results 
support our hypothesis that elevated cellular level of SAICAR stimulates PKM2.  
Next, we measured whether SAICAR affects cancer metabolism. The 
glucose consumption rate of paics-kd cells was reduced in comparison with 
control-kd and adsl-kd cells (Fig. 2-11C). The lactate fermentation rate of adsl-kd 
cells was increased in comparison with control-kd and paics-kd cells (Fig. 2-
11D). Similar results were obtained using LC-MS analysis of cellular metabolites 
(Fig 2-14). Both adsl-kd and paics-kd cells showed increased glutamine   
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Figure 2-11. SAICAR level affects glucose metabolism, cancer cell survival, 
and proliferation. (A) A schematic diagram showing in the synthesis and 
metabolism of SAICAR. (B) Cellular levels of SAICAR in HeLa control-kd (black 
box), adsl-kd (open box), and paics-kd (gray box) before and after 30 min 
incubation in glucose-free media. Avg.±s.d. (n = 3). (C and D) Effect of SAICAR 
on (C) glucose uptake and (D) lactate fermentation. The amount of glucose or 
lactate in the media was measured using enzymatic assays and LC-MS analysis, 
respectively (normalized with total cellular protein concentration). Black and blue 
bars note Avg. and SD, respectively. (E) Survival of HeLa control-kd (control; 
cells transfected with random shRNA vector), adsl-kd, paics-kd, and paics-kd 
adsl-kd cells in glucose-free media was measured using a Trypan blue exclusion 
method. Avg ± s.d. (n=3, where over 50 cells were counted to calculate % live 
cells in each measurement).  
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Figure 2-12. Cellular level of SAICAR in adsl-kd (open circles) and in paics-
kd (grey circles) HeLa cells after prolonged incubation in glucose-free 
media. 
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Figure 2-13. Pyruvate kinase activity in cell extracts. (A) Cells grown in 25 
mM glucose media (black boxes) or treated with no glucose media for 12 hours 
(open boxes) were lysed on ice. PK activity was measured and normalized 
against total protein amounts. (B) To the extract of cells grown in 25 mM glucose 
media (black boxes; from A), SAICAR was added to final concentration of 1 mM. 
The mixture was incubated at 4°C for 1hr followed by PK activity measurements 
(gray boxes). Avg.± s.d (n=3). 
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Figure 2-14. Effect of SAICAR on cellular levels of glycolytic intermediates. 
(A) LC-MS peak area of (black circles) control-kd, (open circles) adsl-kd, and 
(gray circles) paics-kd cells. Avg.± s.d. (n=3). (B) Ratio of glycolytic intermediate 
LC-MS peak areas as compared to controls; all cells were grown in high glucose 
media.  These glycolytic intermediates represent the overall general state of cell 
metabolism in normal oxygen and glucose conditions. 
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Figure 2-15. Amount of glutamine in media after 30 min incubation with 
equal number of cells. Adherent cells in 96-well plates were incubated for 30 
min in glucose-free media (4 mM glutamine) at 37°C. Amount of glutamine (m/z: 
145.042) remaining in media after the incubation were measured using LC-MS as 
described in the method. Amount of glutamate (m/z: 146.046) was measured and 
is ~1% of the glutamine signal. 
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consumption (Fig 2-15). These results show that commonly observed metabolic 
phenotypes of cancer cells are either directly or indirectly affected by SAICAR 
levels. In addition, in a glucose-limited condition (30 min), adsl-kd cells had more 
ATP than the control-kd or paics-kd cells (Fig. 2-16 and 2-17), suggesting that 
the cellular metabolism of SAICAR-overproducing cells is altered in glucose-
limiting conditions.  
Because metabolic flux and cellular energy balance were altered by the 
changes in SAICAR concentration, we investigated whether SAICAR affected 
cancer cell survival in a glucose-dependent manner (Fig. 2-11E). In glucose-
limited conditions, cells with higher SAICAR concentrations (adsl-kd cells or cells 
overexpressing PAICS, Fig 2-18) survived better, while paics-kd cells died earlier 
than control-kd cells (Fig. 2-11E). Double knockdown of PAICS and ADSL (paics-
kd adsl-kd) had an effect similar to the PAICS knockdown alone. These results 
indicate that SAICAR promotes cancer cell survival in glucose-limited conditions.  
To confirm the necessity of the PKM2-SAICAR interaction for increased 
cell survival in glucose-limited conditions, we searched for a PKM2 mutant that is 
insensitive to SAICAR while retaining its other properties. Because PKM1 (only 
23 amino acids different from PKM2) is insensitive to SAICAR (Fig 2-1), we 
prepared several PKM2 mutants where PKM2-specific residues were mutated to 
their corresponding PKM1 counterparts. The Q393K mutant was SAICAR-
insensitive (Fig. 2-20A) and retained wild-type basal activity (Fig 2-19). This 
Q393K mutant was also stimulated by FBP (Fig. 2-20B). In contrast, the known 
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phosphotyrosine–insensitive mutant, K433E [(15); K433 is also the residue 
contacting FBP (Structure: PDB 3ME3)], was still stimulated by SAICAR (Fig. 2-
20A).  
We used the Q393K mutant to test whether the effect of cancer cell 
survival in adsl-kd cells is due to the PKM2-SAICAR interaction. By a previously 
described method (4), endogenous PKM2 was knocked down and rescued with 
plasmid-coded PKM2 or PKM2 Q393K (M2-rescue and Q393K rescue cells, 
respectively). Western blot analysis showed more than 90 % of endogenous 
PKM2 expression was knocked down without detectable effects on plasmid-
coded PK expression. The PK activity of the Q393K-rescue cells was similar to 
the level observed in paics-kd cells, but the activity was not stimulated by 
SAICAR (Fig. 2-18B). The PKM2-rescue cells behaved similarly to the cells with 
endogenous PKM2 in both glucose rich and glucose-limited conditions (Fig. 2-
20C). The expression level of PKM2 was similar in untransfected and in Q393K-
rescue cells. Q393K-rescue cells behaved nearly identical to cells with 
endogenous PKM2 in glucose-rich conditions. However, knockdown of ADSL in 
Q393K-rescue cells no longer promoted cell survival in glucose-limited conditions 
(Fig. 2-20D), indicating that the effect of SAICAR on cell survival in this condition 
is due to the SAICAR-PKM2 interaction.  
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Figure 2-16. Enzymatic analysis of cellular nucleotide levels. Cells were 
incubated for 30 min in media containing 25, 1, or 0 mM glucose and lysed. ATP 
amounts in cell extracts were measured using yeast hexokinase and yeast 
glucose-6-phosphate dehydrogenase in the presence of excess glucose and 
NADP+ (26).  Avg.± s.d. (n=3). 
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Figure 2-17. Cellular levels of metabolites in control-kd, adsl-kd, and paics-
kd cells incubated for 30 min in media containing 1 mM glucose. Avg. ± s.d. 
(n =3). Due to inherent differences, each nucleotide has a different detection limit 
in mass spectrometry.  Due to this phenomenon, the LC-MS area of one 
nucleotide may appear much larger or smaller than the area observed in another 
nucleotide, although the concentrations of both are very similar.  For instance, 
the above data shows a larger peak area for AMP as compared to ATP in all 
three of the cell types.  However, the molar amount of AMP is likely much lower 
than that of ATP in the cell.  The apparent difference is due to the ability of AMP 
to “fly” better than ATP, thus yielding a higher signal.  Therefore, comparison in 
the concentration one nucleotide between cell types can be monitored, but 
comparisons between nucleotide concentrations cannot be made using this 
system. 
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Figure 2-18. Effects of PAICS overexpression on cell survival in glucose-
limited conditions. (A) Western analysis of HeLa cells transfected with vector 
[p31-N-HtS, (21)] or with PAICS overexpression vector (CMV-PAICS in p31-N-
HtS vector). With CMV-PAICS, the total level of PAICS is elevated ~2-fold. (B) 
Effect of PAICS overexpression on HeLa cell survival in glucose-free media. Cell 
survival was measured. Avg. ± s.d. (3 independent measurements of more than 
50 cells per measurements). 
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Figure 2-19. Pyruvate kinase activity of the Q393K mutant. (A) Activity of the 
Q393K mutant (•) was measured by varying the concentration of PEP (1.5 mM 
ADP, 10 nM enzyme) and comparing with wild-type (wt) PKM2 (o). Avg.±s.d. 
(n=3). (B) Pyruvate kinase activity of Q393K-rescue cell extract (black box) and 
the activity after 1 hr incubation with 1 mM SAICAR at 4°C (gray box). The PK 
activity is similar to that observed in paics-kd cells, but cannot be stimulated by 
incubation with SAICAR. 
 
















































Figure 2-20. SAICAR-PKM2 interaction is responsible for the promotion of 
cancer cell survival. (A and B) Identification of a PKM2 mutant insensitive to 
SAICAR. Effect of (A) SAICAR and (B) FBP on pyruvate kinase activities of 
PKM2 Q393K (o) and PKM2 K433E (•) mutants is shown. Avg ± s.d. (n = 3). (C 
and D) Cell viability in glucose-depletion conditions was measured in HeLa cells 
expressing (C) PKM2* and (D) PKM2* Q393K mutant while endogenous PKM2 
expression is knocked down. Avg ± s.d. (n = 3, over 50 cells were counted for 
each measurement). Control: cells transfected with scrambled shRNA vectors. 
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DISCUSSION 
Based on these results, we conclude that at least some aspects of PKM2's 
role in tumor biology can be explained by SAICAR-mediated allosteric 
stimulation. This feature of PKM2 may allow cells to adjust their energy 
generation in response to nutritional and metabolic demands. When sufficient 
levels of glucose are provided, diverting glycolytic intermediates to biosynthetic 
processes like the pentose phosphate pathway can promote cell growth. 
However, in energy-depleting conditions such as nutrient-limitation, continued 
diversion of glycolytic intermediates to biosynthetic processes can hamper cells 
by depleting cellular energy below the minimal level required. The SAICAR-PKM2 
interaction described here can be a molecular mechanism for this delicate 
balance. Ribose-5-phosphate, the starting material of nucleotide biosynthesis, is 
produced from the pentose phosphate pathway, which diverts glycolytic 
intermediates away from energy production (16). Connecting PKM2's PK activity 
with an intermediate of the de novo purine nucleotide biosynthesis pathway could 
give cells fine-tuned control of their metabolism in demanding conditions. 
SAICAR is produced from l-aspartate, a byproduct of glutaminolysis, which is 
known to be important in cancer cell metabolism (17), and the cleavage of 
SAICAR yields fumarate, which contributes to the citric acid cycle in mitochondria 
(18). SAICAR is therefore positioned to convey cellular metabolic demands to 
PKM2.  
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MATERIALS AND METHODS 
Plasmids 
Plasmids are maintained and propagated in appropriate E. coli cells 
[ccdB-survival 2 T1R (Invitrogen) for plasmids containing ccdB, DH5a and 
TOP10 for other purposes]. Plasmids constructed in this study were sequenced 
from both ends of inserts. Site-directed mutagenesis was done using Quikchange 
II XL mutagenesis kits (Agilent). Bacterial expression vector for PKM2, which was 
originally constructed by C. Arrowsmith lab [the Structural Genomics Consortium 
(SGC) at the University of Toronto] was obtained from Addgene (plasmid 25538). 
Bacterial expression vector for PKM1 was constructed by amplifying PKM1-
specific region from IMAGE:5296639 (OpenBiosystems) and by replacing the 
corresponding region of the PKM2 expression vector with this PCR product using 
In-Fusion PCR Cloning kit (Clontech). PKM1 and PKM2 entry vectors were 
constructed by amplifying genes from these bacterial expression vectors and 
inserting them into pDONR221 vector (Invitrogen). Entry vector coding PKR 
(IMAGE:5221697) was from OpenBiosystems. Recombination of Entry vectors 
and Destination vectors were done using Gateway LR Clonase II enzyme mix 
(Invitrogen).  Plasmids for ADSL expression were obtained from Prof. R. F. 
Colman (Univ. Delaware; (11)) and from SGC Stockholm (PDB|2J91). Dual-
tagging Gateway Destination vectors (21), including p31-N-HtS, were gifts from 
Dr. Y. Wang (National Institute of Health). Plasmid sets coding shRNAs, in 
pGFP-V-RS (puromycin-resistant), targeting ADSL and PAICS were purchased 
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from Origene. Supersilencing shRNA plasmids (neomycin-resistant) targeting 
PAICS were purchased from Qiagen. Plasmids coding shRNA for PKM1/2 and 
control shRNA (4) in pLKO.1 vectors were originally constructed by the RNAi 
Consortium, which were purchased from OpenBiosystems. To replace original 
puromycin-markers of pLKO.1-based vectors, zeocin-resistance marker was 
amplified from psiRNA-DUO (Invivogen) and inserted to BamHI/KpnI-sites of 
pLKO.1 or its derivatives. 
 
Proteins 
Protein purities were assessed using SDS-PAGE and either Coomasssie 
or Sypro-Ruby (Invitrogen) staining. Protein concentrations were determined by 
measuring absorbance at 280 nm (A280) in denaturing conditions (22). Functional 
ADSL was prepared as in literature (11). PKM2 and other pyruvate kinases were 
expressed from BL21 Codonplus RIL (DE3) cells using a procedure modified 
from the procedure originally developed by the Structural Genomics Consortium 
(http://www.thesgc.org/structures/details?pdbid=1ZJH/). Pyruvate kinase 
expression was induced by the addition of isopropyl-β-d-galactopyranoside 
(IPTG) for 18 hours at 20oC.  All purification steps were carried out at 4oC or on 
ice unless noted otherwise. Cells were centrifuged (5,000g 20 min), and the 
pellet resuspended with 20 mM HEPES, 150 mM NaCl, 1 mM DTT, and 0.25% 
CHAPS buffer.  Cells were lysed by sonication, and the debris was removed by 
centrifugation (15,000xg 20 min). All following chromatographic steps were 
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carried out using an AkTA Purifier 10 (GE Lifesciences) at 4oC. The supernatant 
was injected into a 5 mL HiTrap Chelating column (GE Lifesciences) charged 
with zinc chloride and equilibrated in buffer IA (20 mM HEPES, pH 7.4, 500 mM 
NaCl, 1 mM DTT, 30 mM imidazole, 5 % glycerol). After washing the resin with 
buffer IA until A280 reached baseline, bound proteins were eluted with a linear 
gradient of buffer IB (20 mM HEPES, pH 7.4, 500 mM NaCl, 1 mM DTT, 5 % 
glycerol, 250 mM imidazole).  Fractions containing desired proteins were 
combined, concentrated with an Amicon Ultra-15 centrifugal filter, and passed 
through a HiTrap Desalt (5 mL; GE Lifesciences) column (elution buffer: 20 mM 
HEPES, 500 mM NaCl, 1 mM magnesium acetate, 5 % glycerol, 1 mM tris(2-
carboxyethyl)-phosphine (TCEP)). After concentrating the protein solution and 
determining the protein concentration (ε280: 30,535M-1×cm-1), 4 molar equivalents 
ADP were added to the protein solution. Aliquots were stored at -80oC.   
 
Identification of protein-binding metabolite 
Cellular metabolites were extracted from adherent A549 cells as in 
literature (23) with modifications.  For the identification of protein-binding 
metabolites, cellular metabolites extracted using methanol were first filtered 
through an Amicon Ultra-4 (molecular weight cut off, mwco, 3 kDa; Millipore) at 4 
°C to remove macromolecules. This filtrate was dried in vacuum at 25 °C using a 
Speed-Vac or freeze-dried. Dried materials were dissolved in aqueous 20 mM 
ammonium acetate, pH 7.0. Recombinant protein (25 uM final concentration) and 
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cellular metabolites in 1 mL running buffer 1 (20 mM ammonium acetate, pH 7.0, 
1 mM DTT, 1 mM magnesium acetate) were incubated at 37°C for 30 min, cooled 
on ice, and injected to a HiPrep 26/10 Desalt column (GE Lifesciences) 
equilibrated at 4°C in the running buffer 1 with a flow rate of 3 mL/min using the 
running buffer 1 as an eluent. The void volume fraction containing protein and 
protein-bound metabolites were collected, and passed through an Amicon Ultra-4 
(mwco 3 kDa) centrifugal filter at 25°C (3,000 g). The filter was then washed with 
methanol. Combined filtrates were dried in vacuum using a freeze drier or a 
speed vac. Dried materials were dissolved in minimal amount of solvent 
(aqueous 0.1 % formic acid for reverse-phase HPLC – mass spectrometry or 20 
mM ammonium acetate in methanol for hydrophilic interaction chromatography 
HPLC – mass spectrometry) and subjected to mass spectrometric analysis as 
described below.  
 
Pyruvate kinase activity assay  
Pyruvate kinase activity was measured using a lactate dehydrogenase 
(LDH) coupled method. In typical experiments, pyruvate kinase (20 nM) in assay 
buffer (50 mM HEPES, pH 7.4, 100 mM KCl, 6.2 mM MgSO4, 1 mM DTT) 
containing ADP (1.5 mM for typical experiments) was incubated for 30 min at 37 
°C in the presence of SAICAR or other ligands. To the solution, LDH (final: 5 
units/mL; Roche) and then NADH (final concentration 220 µM for typical 
experiments) were added. The reaction was then initiated by the addition of PEP 
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(0.15 or 1.5 mM for typical experiments). The decrease of NADH was monitored 
spectroscopically at 340 nm in quartz cuvettes using a Beckman DU-650I 
spectrophotometer or in UV-transparent bottom 96-well plates using a Tecan 
Infinity M2 microplate reader. Rate was determined by dividing the change of 




Recombinant ADSL was prepared as in literature (11). ADSL activity was 
measured spectroscopically using S-AMP (Sigma-Aldrich) as substrate (11). 
SAICAR was synthesized from 5-aminoimidazole-4-carboxamide ribose-5'-
phosphate (AICAR; Toronto Research Chemicals) and fumarate. In brief, AICAR 
powder (free acid form) was dissolved in 50 mM ammonium acetate (pH 7.0) 
immediately before use. The concentration of AICAR was spectroscopically 
determined using UV absorbance (ε269: 12,600 M-1×cm-1; (24)). A 2-mL solution 
containing 20 mM HEPES, pH 7.4, 50 mM KCl, 1 mM DTT, 2 mM EDTA, 50 mM 
ammonium acetate, 40 mM AICAR, 50 mM disodium fumarate, and 4 µM 
recombinant ADSL was incubated at 37°C for 4 – 12 hrs. The solution was 
cooled on ice, diluted with 8 mL 30 mM ammonium acetate and injected to a 
Mono Q 5/50 GL column (GE Life Sciences) equilibrated in 30 mM ammonium 
acetate (flow rate: 0.40 mL/min at 4°C). The column was washed with 30 mM 
ammonium acetate until A269 reached baseline, and bound materials were eluted 
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with a linear gradient of 3 N ammonium acetate over 3 hours. Fractions 
containing SAICAR, which was eluted when conductance was ~ 65 – 80 mS/cm2, 
were pooled, dried extensively in vacuum at 25 °C using a rotary evaporator, and 
dissolved in water. Dissolved solution was stored at 4 °C for at least several 
weeks without any evidence of degradation. ESI-TOF (positive mode, water with 
0.1 % formic acid): m/z 455.079 ([M+H]+, calc. 455.082); ESI-TOF (negative 
mode, 5 mM ammonium acetate-ammonium hydroxide, pH 9.9): m/z: 453.055 
([M-H]-, calc. 453.066).  Concentration of SAICAR solution was calculated based 
on UV absorbance (ε269: 13,800 M-1cm-1; (25)). Purity was assessed by analyzing 
it using anion-exchange chromatography in a smaller scale as described above. 
[13C4]-SAICAR was prepared as above in a smaller scale using [13C4]-fumaric 
acid (Cambridge Isotope Laboratory) as a substrate.  
 
Cell culture and transfection 
Cells were maintained in high glucose Dulbeccoʼs Modified Eagle Media 
(DMEM) with 4.5 g/L (25 mM) glucose and L-glutamine, supplemented with 10% 
fetal bovine serum (FBS).  Cells were grown at 37°C, 5% CO2, and 85% 
humidity.  Cells were passaged using 0.05% Trypsin-EDTA. Dialyzed FBS 
(Invitrogen) was in all experiments to avoid the effect of glucose in FBS. Cells 
were transfected with desired plasmids using Neon Nucleotransfector (Invitrogen) 
as in the vendor's instruction. Transfected cells were recovered in antibiotic-free 
media for 24 hours and then in selection media for 1–2 weeks. Transfection 
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efficiency was measured by monitoring GFP expression, when it is available, 
after 24 hours. Typical transfection efficiency was higher than 90%. Cell numbers 
were counted using Moxi-Z cell counter (Orflo). To measure cell numbers, cells 
were detached with trypsin-EDTA and diluted with isotonic buffer (Beckman 
Coulter).  In the case of adsl-kd and paics-kd cells, decrease of target proteins 
were measured using Western analysis ( >60 % and > 80 % reduction of PAICS 
and ADSL protein levels, respectively). 
 
Metabolite extraction and analysis 
For the analysis of metabolites in medium and in cells, cells (5×106 cells 
per dish) were seeded in 150 cm2 dishes. After 1 – 2 days, cell numbers were 
counted, and the medium (25 mL from each dish) was transferred to 50 mL 
tubes. These tubes were stored at – 80 °C or analyzed immediately. Adherent 
cells (1×107 – 2×107 cells per dish) were quenched with ice cold DI water and 
liquid nitrogen was poured onto plates (23).  Metabolites were extracted adding 
2.0 mL 50% MeOH, 50% 25 mM ammonium acetate and cells were scraped off 
the dish at 4oC. The solution was incubated on ice while rocking for 15 minutes. 
The cell debris was removed by centrifugation. The solution was transferred to a 
chilled Amicon Ultra-15 centrifugal filter device (MWCO 3 kDa). The dish was 
washed again with fresh 2.0 mL ice-cold extraction buffer. Combined solution 
was filtered through the centrifugal filter device. When desired, the filtrate was 
freeze-dried and reconstituted in 0.150 mL of 15 mM ammonium acetate 
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aqueous solution or in 0.150 mL buffered methanol (95% methanol, 5% water, 5 
mM ammonium acetate), and insoluble materials were removed by centrifugation 
(15,000 g for 15 min at 4°C). This cellular metabolite sample was stored at – 
80°C or analyzed immediately. Amounts of selected metabolites were analyzed 
using enzymatic analysis methods (26) and  using LC-MS as described below. 
When desired, [13C4]-SAICAR of known concentration was added to the 
extraction buffer.   
 
Pulldown of metabolite-protein complexes 
HeLa cells transfected with p31-N-HtS-PKM1 or p31-N-HtS-PKM2, which 
code His6-TEV cleavage site-StrepII-tagged PKM1 or PKM2, were grown in 10-
cm dishes in media until they became ~80% confluent. When desired cells were 
washed three times with glucose-free media and then incubated in glucose-free 
media for 30 min. The dish was placed on ice, and cells were washed once with 
phosphate buffered saline (PBS). Cells were lysed with 2 mL ice-cold modified 
RIPA buffer, and debris was removed by centrifugation (16,000g 5 min 4°C). 
Subsequent steps were carried out at 4°C or on ice unless specifically noted 
otherwise. Cleared lysate was then applied to Strep-tactin magnetic beads 
(Qiagen) and incubated for 1 hour with agitation. Beads were separated with a 
magnet, and washed three times (5 min each) with 20 mM ammonium acetate in 
water. Metabolites bound were recovered with methanol, and the solution was 
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subjected to LC-MS analysis. Proteins were eluted with buffer containing 2 mM d-
biotin and then subjected to SDS-PAGE and Western analysis. 
 
Reverse-phase LC-MS 
A 5-µL portion of sample (typically in aqueous 0.01-0.1 % formic acid) was 
injected to a reverse-phase column (Phenomenex Luna C18 (2) 3 µm bead, 20 
mm column) connected to an Agilent 1200 LC – 6210 AccurateMass ESI-TOF 
mass spectrometer. Chromatography solvent system used was:  0-4 min: 100 % 
solvent A (0.01 % formic acid in water, flow rate: 0.50 mL/min at ambient 
temperature), 4 -14 min: linear gradient to 100 % solvent B (0.01 % formic acid in 
acetonitrile), 14 – 16 min: 100 % B, 16 – 18 min: back to A, 18 – 22 min: solvent 
A. Mass range from 50 to 1000 was monitored (positive ion mode, 1 Hz).  
 
Hydrophilic interaction chromatography LC-MS 
  A 50-µL portion of sample in methanol was injected to a Luna-NH2 column 
(Phenomenex; 3um beads, 150x 2 mm) equilibrated in solvent C (acetonitrile) 
with a flow rate of 1 mL/min. Bound metabolites were eluted with solvent D 
(water, 5 mM ammonium bicarbonate – ammonium hydroxide, pH 9.9) as in 
literature (23). All LC-MS data were analyzed using Agilent MassHunter software 
package. For the determination of absolute SAICAR amount in sample, a sample 
was mixed with [13C4]-labeled SAICAR standard solution (10 nM-100 µM) during 
the metabolite extraction step, and the amount of SAICAR in cell extract was 
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Anti-ADSL (mouse monoclonal) and anti-PKM2 (rabbit monoclonal) 
antibodies were from Signalway. Anti-PAICS (mouse monoclonal) and anti-
GAPDH (rabbit monoclonal) antibodies were from Sigma-Aldrich. Horseradish-
peroxidase conjugated anti-mouse and anti-rabbit immunoglobulin antibodies 
were from Cell Signaling and Thermo Scientific, respectively. Cells were lysed in 
ice-cold RIPA buffer, and cellular proteins were separated by SDS-PAGE. 
Proteins in gels were then transferred to nitrocellulose membranes using an 
iBLOT gel transfer device (Invitrogen), and probed with primary antibodies. 
Antibodies were then detected using horseradish-peroxidase conjugated 
secondary antibodies. 
 
Cell survival test 
Cells (103 cells) were seeded in a well of a 96 well plate coated with 
fibronectin. Cells were allowed to adhere and grow for 24 hours in high glucose 
DMEM supplemented with FBS. Cells were washed with target media (high or no 
glucose DMEM with 10% dialyzed FBS) several times. Cells were incubated with 
target media for 0- 48 hours.  Media were aspirated, and cells were stained with 
0.4 mM Trypan Blue solution for less than five minutes. Excess trypan blue was 
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washed away with PBS. Images of cells (bright field) were obtained using a Zeiss 
Axiovert 40 CFL with a 10× objective. More than 50 cells were counted in each 
well, and three wells were counted per experiment. 
 
Identification of SAICAR-insensitive PKM2 mutant 
Because PKM1, which is only 23 amino acids different from PKM2, is 
insensitive to SAICAR, we speculated that mutating one or two of these PKM2-
specific residues may yield a PKM2 mutant insensitive to SAICAR but still retains 
the basal activity and the FBP-sensitivity. We have screened PKM2 mutants by 
mutating each of residues noted below (red type in the sequence alignment 
shown below) to corresponding ones in PKM1 Among mutants tested (K433E, 
Q393K, L392R, R399V), only the Q393K mutant was insensitive to SAICAR and 
sensitive to FBP.  
HsPKM1          LSGETAKGDYPLEAVRMQHLIAREAEAAMFHRKLFEELVRASSHSTDLMEAMAMGSVEAS 420 
HsPKM2          LSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAPITSDPTEATAVGAVEAS 420 
                ****************************::* :***** * :. ::*  ** *:*:**** 
 
HsPKM1          YKCLAAALIVLTESGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQE 480 
HsPKM2          FKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQE 480 
                :** :.*:****:*********************************************** 
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SAICAR Induces Protein Kinase Activity of PKM2 that 





*This chapter was previously published in Molecular Cell (Keller et al, 2014).  
Figure 3-6 and 3-9 were generated with help from Zainab Doctor and Figure 3-10 
was generated with help from Zach Dwyer.  All other results presented in this 
chapter represent original work. For the purposes of this dissertation, 
modifications to the text and figures were made.   
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ABSTRACT 
Abnormal metabolism and sustained proliferation are hallmarks of cancer. 
Pyruvate kinase M2 (PKM2) is a metabolic enzyme that plays important roles in 
both processes. Recently, PKM2 was shown to have protein kinase activity 
phosphorylating histone H3 and promoting cancer cell proliferation. However, the 
mechanism and extent of this novel protein kinase in cancer cells remain unclear. 
Here, we report that binding of SAICAR, a metabolite abundant in proliferating 
cells, induces PKM2ʼs protein kinase activity in vitro and in cells. Protein 
microarray experiments revealed that more than 100 human proteins– mostly 
protein kinases– are phosphorylated by PKM2-SAICAR. In particular, PKM2-
SAICAR phosphorylates and activates Erk1/2, which in turn sensitizes PKM2 for 
SAICAR-binding through phosphorylation. Additionally, PKM2-SAICAR was 
necessary to induce sustained Erk1/2 activation and mitogen-induced cell 
proliferation. Thus, the ligand-induced protein kinase activity from PKM2 is a 
mechanism that directly couples cell proliferation with intracellular metabolic 
status. 
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INTRODUCTION 
Highly proliferative cells, such as cancer cells, display metabolic properties 
distinct from their neighboring normal cells (Vander Heiden, Cantley, Thompson, 
2009). For example, cancer cells uptake more glucose than their neighboring 
normal cells and ferment lactate even when sufficient oxygen is supplied (Vander 
Heiden, Cantley, Thompson, 2009). The observed altered metabolism is 
regarded as a hallmark of cancer (Hanahan and Weinberg, 2011). However, the 
molecular basis connecting altered metabolic status to cell proliferation is still not 
completely understood.  
Pyruvate kinase isoform M2 (PKM2) is a metabolic enzyme enriched in 
highly proliferating cells and most types of cancer cells (Mazurek et al., 2002; 
Christofk et al., 2008). PKM2 was recently identified as a major contributor for 
altered cellular metabolism and the growth of tumors, as replacing PKM2 with 
other isoforms of pyruvate kinases in cancer cells alleviates abnormal cellular 
metabolism, renders cells susceptible to stress in vitro, and limits the growth of 
tumor in xenografts (Christofk et al 2008). In addition, various pharmacological 
reagents targeting PKM2 in an isozyme-specific manner influence cell growth 
and proliferation (Chen et al., 2011; Anastasiou et al., 2012), suggesting that 
PKM2 may be a potential target of clinical applications (Vander Heiden, 2013). 
Since the identification of PKM2 as a major contributor to cancer cell 
growth (Christofk et al 2008), research has focused on identifying the underlying 
mechanism of this isozyme-specific action to develop therapeutics and/or 
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diagnostic tools (for review, see Gupta and Bamezai, 2010; Luo and Semenza, 
2012; Mazurek, 2011). Recent results revealed that PKM2 in cancer cells has 
previously unrecognized properties distinct from other pyruvate kinase isoforms. 
First, PKM2 translocates from the cytoplasm to the nucleus of cancer cells upon 
stimulus, suggesting that PKM2 may have functions beyond glycolysis (Yang, et 
al., 2011). Indeed, PKM2 interacts with transcription factors and activates their 
functions (Luo et al., 2011).  
Furthermore, PKM2 extracted from cancer cells shows protein kinase 
activity (Gao et al, 2012; Yang, et al., 2012a). Normally, pyruvate kinases 
catalyze the phosphotransfer reaction between phosphoenolpyruvate (PEP) and 
ADP, producing pyruvate and ATP. Surprisingly, PKM2 purified from cancer cells 
is capable of phosphorylating histone H3 threonine 11 (H3 T11) in vitro using 
PEP as a phospho-donor (Yang et al., 2012a). As expected, ADP inhibits the 
reaction in vitro (Yang et al., 2012a), suggesting that the same active site is used 
for both pyruvate kinase and protein kinase activity. Additionally, the 
phosphorylation of H3 by PKM2 was found in cells, and leads to increased cell 
proliferation by inducing expression of several genes including MYC and CCND1 
(Yang et al., 2012a).   
Although this reaction occurs in cancer cells, the results observed by in 
vitro phosphorylation of H3 T11 by PKM2 purified from cancer cells imply that the 
reaction may not be robust enough to be significant in a biologically relevant 
context (Yang et al., 2012a). Additionally, recombinant PKM2 expressed and 
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purified from E. coli did not display H3 T11 kinase activity (Yang et al., 2012a). 
Thus, protein kinase activity of PKM2 is dependent on alternative modifications or 
ligand-binding, while pyruvate kinase activity is not.  Indeed, phosphorylation of 
PKM2 by Erk1/2 appears to promote its protein kinase activity in cells (Yang et 
al., 2012b). However, the Erk1/2-mediated phosphorylation of PKM2 has not 
been shown to fully induce protein kinase activity in vitro.  
To determine the mechanism defining how PKM2 contributes to cancer 
growth in an isozyme-specific manner, we previously searched for cellular 
metabolites that bind to PKM2 in an isozyme-selective manner (Keller et al., 
2012). From our study, we found that SAICAR (succinyl-5-aminoimidazole-4-
carboxamide-1-ribose-5'-phosphate), an intermediate of the de novo purine 
nucleotide biosynthesis process, accumulates in glucose-starved cancer cells 
and isozyme-selectively and directly activates pyruvate kinase activity of PKM2 in 
vitro and in cultured cancer cells, promoting survival in glucose-deprived 
conditions (Keller et al, 2012).  
Here we report that the PKM2-SAICAR interaction is necessary and 
sufficient to induce robust protein kinase activity from PKM2 in vitro and in cancer 
cells. We also report that the PKM2-SAICAR complex phosphorylates over 100 
human proteins – mostly protein kinases – that were previously unrecognized 
substrates. In particular, PKM2-SAICAR directly activates Erk1 in vitro and within 
cells.  As has been previously shown (Yang et al, 2012b), activated Erk1/2 
phosphorylates PKM2. We found that the phosphorylation of PKM2 by Erk1/2 
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sensitizes PKM2 for SAICAR-binding, leading to a positive feedback loop. 
Additionally, upon EGFR activation, cellular SAICAR concentration is elevated, 
which is necessary to induce sustained activation of Erk1/2 and proliferative 
signaling via PKM2. These results provide a detailed molecular mechanism 
describing how two hallmarks – altered metabolism and sustained proliferative 
signaling – are interrelated in highly proliferating cells.  
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RESULTS 
SAICAR-binding induces protein kinase activity of recombinant PKM2 
Unlike purified recombinant PKM2, PKM2 extracted from cancer cells is 
capable of phosphorylating histone H3 threonine 11 (H3 T11) using PEP as a 
phosphate donor (Yang et al., 2012a). We attempted to reconstitute the activity in 
vitro using purified recombinant PKM2 (rPKM2) and PEP as the sole phosphate 
donor. First, we tested whether allosteric activators of PKM2, such as FBP 
(Mazurek et al., 2002) or SAICAR, can induce protein kinase activity from rPKM2 
(Fig. 3-1A). When the phosphorylation of recombinant histone H3 T11 by rPKM2 
was probed in vitro, rPKM2 alone was not sufficient to efficiently phosphorylate 
H3 T11, as noted by Lu and coworkers (Yang, et al. 2012a; Fig. 3-1B). The 
addition of FBP (Mazurek et al., 2002), slightly improved PKM2 protein kinase 
activity, while the addition of SAICAR drastically stimulated PKM2ʼs H3 T11 
kinase activity (Fig. 3-1B). In typical reactions, less than 10 nanomolar PKM2 
was sufficient to completely phosphorylate excess (1- 2 µM) recombinant H3 T11 
within 10 - 15 min, in the presence of SAICAR (kcat 6 s-1), suggesting that the 
PKM2-SAICAR complex is capable of carrying out a multiple turnover reaction. 
The Michaelis-Menten constant (Km) of the complex was measured to be 
approximately 1-2 uM for monomeric histone H3.1 (Fig. 3-1C) and 5 uM for PEP 
(Fig. 3-1D). The low uM Km for PEP of the PKM2-SAICAR complex indicates that 
it is likely a relaxed form of PKM2 that is responsible for the phosphorylation of 
H3 T11. We would like to note that this reaction does not include any nucleotides. 
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Figure 3-1. SAICAR induces protein kinase activity from recombinant 
PKM2. (A) A schematic representation of the experiment. (B) Phosphorylation of 
recombinant histone H3.1 monomer (2 uM) by recombinant PKM2 (rPKM2, 10 
nM) in the presence of PEP (0.10 mM) and ligands (FBP or SAICAR, 0.5 mM). 
The reaction mixture was incubated at 37°C for 5 min, quenched by the addition 
of SDS PAGE gel loading buffer, and subjected to SDS-PAGE. Phosphorylation 
of H3.1 T11 was monitored using anti-phospho-T11 H3 antibody as described in 
the Experimental Procedures. (C) Effect of H3.1 concentration on PKM2ʼs protein 
kinase activity. In the presence of SAICAR (0.5 mM), the reaction follows a 
typical Michaelis-Menten kinetics. FBP (0.5 mM) only marginally activates the 
kinase activity of PKM2. (D) Effect of PEP concentration on the phosphorylation 
of H3.1 T11 by the PKM2-SAICAR complex. (E and F) The inhibition of the 
PKM2-SAICAR mediated H3.1 T11 phosphorylation (E) by ADP and (F) by FBP. 
(G) Phosphorylation of purified and dephosphorylated Xenopus laevis 
nucleosome by PKM2-ligand complexes. (H) Effect of glucose and SAICAR 
concentration on cellular H3 T11 phosphorylation and the level of Myc.  
 
*Figure is presented on the following page. 
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Thus, we have shown that PEP is likely the direct source of phosphate. To further 
ensure that PEP is the phosphate donor, we measured the production of 
pyruvate using lactate dehydrogenase varying protein substrate concentrations 
(Fig. 3-2A).  We found that pyruvate is indeed formed upon the addition of 
histone H3.1. The rate of pyruvate formation was dependent on the concentration 
of H3.1 and SAICAR. The kcat (~ 5 s-1) and the Km (~ 1µM H3.1) values measured 
using this method (Fig. 3-2A) were similar with values obtained by monitoring 
H3.1 phosphorylation (Fig. 3-1C). The H3.1-dependent pyruvate production rate 
was stimulated by SAICAR (EC50 ~ 250 µM).  The activation of protein kinase 
activity by SAICAR was barely observable when the SAICAR-insensitive mutant 
PKM2 Q393K was utilized (Keller et al., 2012; Fig. 3-2C). Together these results 
indicate that PEP is indeed a phosphate donor for the histone H3.1 mediated by 
the PKM2-SAICAR complex. 
The protein kinase activity of the PKM2-SAICAR complex was inhibited by 
ADP (Fig. 3-1E) in a manner similar to PKM2 purified from cancer cell 
nucleoplasm (Yang et al., 2012a) suggesting that the PKM2-SAICAR complex 
uses an identical active site for both protein and pyruvate kinase activities. The 
protein kinase activity of the SAICAR-PKM2 complex was inhibited by FBP, a 
glycolysis intermediate that activates PKM2ʼs pyruvate kinase activity (Fig. 3-1F). 
Suppression of protein kinase activity of PKM2-SAICAR by FBP indicates that 
these PKM2-activating metabolites regulate PKM2 in two distinct mechanisms:  
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Figure 3-2. PKM2-SAICAR complex phosphorylates histone H3.1. (A) Protein 
kinase activity was measured by monitoring the production of pyruvate using a 
lactate dehydrogenase coupled assay while varying PEP and recombinant 
histone H3.1 concentrations. PKM2 pre-incubated with 500 uM SAICAR or 
without any ligand were used (avg. ± s.e.m.)  (B) Protein kinase activity was 
carried out as in (A) varying SAICAR concentrations with histone H3.1 (1 mM) as 
the substrate (EC50: ~250 mM SAICAR).  (C) Phosphorylation of recombinant 
histone H3.1 (1 mM) by PKM2 Q393K (10 nM) in the presence of varying 
SAICAR concentrations and 0.5 mM PEP (10 minutes reaction time at ambient 
temperature). Wild type PKM2 (WT) phosphorylation of H3.1 in the absence or 
presence of 125 mM SAICAR was included for comparison.  (D) Phosphorylation 
of different subtype of recombinant histone H3 monomers (1 uM) by PKM2 (10 
nM)-SAICAR (0.5 mM). ʻ3.1/H4ʼ denotes H3.1/H4 heterotetramer. (E) 
Phosphorylation of HA-tagged H3.1 and H3.3 in HeLa cells. H3.3 was not 
robustly phosphorylated in any of the conditions tested.  In the right panel, HeLa 
cells were transfected with HA-H3.3.  HA or total H3 was immunoprecipitated and 
pT11 H3 was monitored.  As expected, when total H3 is IPʼed, pT11 is detected.  
However, when only H3.3 is pulled down, no phosphorylation is detected. In the 
left panel, minor phosphorylation is seen in the adsl-kd cells, however, this is not 
seen in the subsequent right blot.  It is possible that the brightness of the signal 
of pT11 H3 in wild-type HeLa cells (IP: H3) washed out the signal of bands of 
very low signal.  *Figure is presented on the following page.
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Figure 3-2. PKM2-SAICAR complex phosphorylates histone H3.1 (*continued 
from previous page)
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FBP primarily induces PKM2ʼs pyruvate kinase activity while SAICAR activates 
both pyruvate (Keller et al., 2012) and protein kinase activities of PKM2.  
Because there are three different subtypes of H3 and each plays distinct 
roles in mammals (Hake and Allis, 2006), we asked whether the PKM2-SAICAR 
complex displays H3 subtype specificity (Fig. 3-2D and 3-2E). Among H3 
subtypes, only H3.1 was robustly phosphorylated by the PKM2-SAICAR 
complex, while phosphorylation of other H3 subtypes (H3.2 and H3.3) was not as 
efficient in vitro (Fig. 3-2D). These findings suggest that PKM2-SAICAR may 
distinguish between H3 subtypes.   
Histone H3.1 is incorporated into nucleosomes in a replication-dependent 
manner and mostly found as a component of nucleosomes (Hake and Allis, 
2006). Thus, we tested whether PKM2-SAICAR phosphorylates H3 in a 
nucleosome. When dephosphorylated nucleosomes purified from Xenopus laevis 
were used as a substrate, H3.1 T11 in the nucleosomes was phosphorylated by 
PKM2-SAICAR as efficiently as the H3.1 monomer (Fig. 3-1G).   
Next, we asked if SAICAR induces the phosphorylation of histone H3 T11 
in cancer cells. Using HeLa cells with altered SAICAR metabolism (Keller et al., 
2012) we monitored the phosphorylation of H3 T11 and subsequent 
accumulation of c-Myc (Fig. 3-1H). Previously, we reported that the cellular 
concentration of SAICAR is elevated when HeLa and other cancer cells were 
deprived of glucose (Keller et al, 2012). In addition, we also reported that 
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knocking down the expression of the SAICAR cleavage enzyme 
adenylosuccinate lyase (adsl-kd) constitutively elevates the cellular concentration 
of SAICAR while knocking down SAICAR synthase (paics-kd) prevents the 
accumulation of SAICAR (Keller et al, 2012). When HeLa cells were subjected to 
a SAICAR-accumulating condition (30 min in glucose-free medium), the 
phosphorylation of H3 T11 and the level of Myc protein were both elevated (Fig. 
3-1H). In cells constitutively accumulating SAICAR (adsl-kd cells), H3 T11 
phosphorylation and Myc expression were both constitutively elevated (Fig. 3-
1H). Meanwhile, cells in which the SAICAR synthase was knocked down (paics-
kd) did not show any evidence of H3 T11 phosphorylation nor Myc expression 
regardless of glucose conditions (Fig. 3-1H). These results indicate that the 
elevation of SAICAR concentration is necessary to induce H3 T11 
phosphorylation and Myc expression in HeLa cells.  
In accordance with our previous in vitro result describing the H3-subtype 
specificity of the PKM2-SAICAR complex (Fig. 3-2D), the SAICAR-dependent 
phosphorylation of H3 T11 in HeLa cells was also H3-subtype specific (Fig. 3-
2E). When HeLa, adsl-kd, and paics-kd cells were transfected with plasmids 
encoding hemagglutinin (HA)-tagged H3.1 or H3.3 (Kim et al., 2011), we 
observed subtype specific phosphorylation of H3 T11, which also correlates with 
cellular level of SAICAR. In HeLa cells, HA-tagged H3.1 T11 was phosphorylated 
in conditions accumulating SAICAR while phosphorylation of HA-tagged H3.3 
T11 was never observed. In adsl-kd cells, H3.1 T11 was constitutively 
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phosphorylated while the phosphorylation could not be induced in paics-kd cells. 
Phosphorylation of H3.3 T11 was not detectable in either HeLa or paics-kd cells.  
Marginal H3.3 phosphorylation was detectable in adsl-kd cells, albeit at far lower 
levels than H3.1. The level of Myc correlated with the phosphorylation of H3.1 
T11 in all conditions tested. These results indicate that SAICAR accumulation is 
necessary to induce H3.1 T11 phosphorylation and Myc expression in HeLa 
cells.  
SAICAR accumulation induces nuclear localization of PKM2 
Most pyruvate kinases are localized in the cellular cytoplasm where 
glycolysis occurs. In normal conditions, PKM2 is also localized in cytoplasm and 
is excluded from the nucleus (Yang et al., 2011). However, stimulation of cells 
with epidermal growth factor (EGF) induces partial nuclear localization of PKM2 
in glioblastoma cells (Yang et al., 2011).  
As we found that SAICAR stimulates PKM2-mediated phosphorylation of a 
nuclear protein (histone H3.1) both in vitro and in cells (Fig. 3-1), we speculated 
that SAICAR accumulation might be connected with the nuclear localization of 
PKM2. To test this possibility, cellular localization of endogenous PKM1/2 was 
probed in various conditions (Fig. 3-3). In HeLa cells maintained in glucose-rich 
medium in the absence of EGF, PKM2 was excluded from nucleus as expected 
(Fig. 3-3A). However, upon glucose depletion, PKM2 localized partially to the cell 
nucleus (Fig. 3-3A) in a manner similar to PKM2 in EGF-treated glioblastoma 
cells (Yang et al., 2011). Similar to glucose-deprivation, EGF-treatment also  
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Figure 3-3. Effect of SAICAR on the subcellular localization of endogenous 
PKM2. (A) Effect of glucose withdrawal on the subcellular localization of PKM2 
(ʻ+Glcʼ and ʻ-Glcʼ denote DMEM with 25 mM glucose and in glucose-free DMEM 
for 4 hours, respectively). (B) Effect of EGF on the subcellular localization of 
PKM2 (ʻ-EGFʼ and ʻ+EGFʼ denotes medium without EGF and in medium 
containing 10 ng/mL human EGF for 3 hours, respectively). (C) Effect of 
constitutive SAICAR accumulation on PKM2 subcellular localization. (D) Effect of 
SAICAR-insensitive PKM2 mutant (PKM2 Q393K). (E) Effect of constitutive 
SAICAR accumulation on the localization of the SAICAR-insensitive PKM2 
mutant. (F) Subcellular localization of PKM2 in cells whose SAICAR synthase 
expression was knocked down.  
produced a similar localization pattern of endogenous PKM2 in HeLa cells (Fig. 
3-3B). Cells constitutively accumulating SAICAR (adsl-kd cells) showed nuclear 
localization of PKM2 regardless of condition (Fig. 3-3C). When endogenous 
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PKM2 was replaced with a SAICAR-insensitive PKM2 Q393K mutant (Keller et 
al., 2012) in HeLa cells, the subcellular localization change was not inducible by 
EGF, glucose withdrawal, or adsl-kd (Fig. 3-3D-E). These results indicate that 
the interaction between PKM2 and SAICAR is necessary for the nuclear 
localization of PKM2.  
Due to the observed role of SAICAR in the nuclear localization of PKM2, 
we decided to examine the effect of SAICAR on the constitutively nuclear mutant 
PKM2 R399E (Gao et al. 2012; Fig. 3-4).  Recombinant PKM2 R399E was 
purified from E. coli and the kinetic parameters measured.  PKM2 R399E had a 
significantly lower Km for PEP than wild type PKM2 (20 mM), indicating that this 
mutant exists in the relaxed form (Fig. 3-4A).  PKM2 R399E is hypersensitive to 
SAICAR both in pyruvate kinase activity (Fig. 3-4B; R399E EC50 SAICAR: 12 
mM, PKM2 wild-type EC50 SAICAR: 300 mM) and in protein kinase activity using 
H3.1 as a substrate (Fig. 3-4C; R399E EC50 SAICAR: ~30 mM, PKM2 EC50 
SAICAR: ~200-300 mM).  
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Figure 3-4. Constitutively nuclear PKM2 mutant is hypersensitive to 
SAICAR. (A) Pyruvate kinase activity assay with varying amount of PEP 
indicates that a constitutively nuclear PKM2 mutant (R399E; Gao et al., 2012) is 
in its relaxed form (Km for PEP in low µM) instead of the tense form typically 
found in the wild-type PKM2. (B and C) PKM2 R399E mutant is also 
hypersensitive to SAICAR (EC50 12 µM SAICAR, in comparison with EC50 value 
of 0.3 mM SAICAR for the wild-type PKM2) when its pyruvate kinase activity (B) 
and histone H3.1 T11 kinase activity (C) were measured in the presence of 
varying amount of SAICAR. (D) Protein kinase activity of PKM2 Q393K was 
measured using Erk1 (1 µM) as a substrate (0.5 mM PEP, 30 min at ambient 
temperature). Phosphorylation of Erk1 by Wild-type PKM2 (WT, 10 nM) in the 
presence or absence of 125 mM SAICAR is also included.
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PKM2-SAICAR phosphorylates many proteins involved in cell proliferation 
Our results show that SAICAR induces protein kinase activity of PKM2 in 
vitro, and that this activity is necessary for histone H3.1 T11 phosphorylation in 
HeLa cells. Next, to better understand the extent of this novel protein kinase 
activity, we searched for additional human proteins phosphorylated by PKM2-
SAICAR. For this purpose, a human proteome microarray representing 9,479 
recombinant human proteins was incubated in a solution containing PEP and 
PKM2 in the presence or absence of SAICAR (Fig. 3-5). Phosphorylated proteins 
were then visualized using ProQ Diamond stain. Because PEP is the only 
phosphate donor in this experiment, it is unlikely that the results will be influenced 
by the presence of immobilized protein kinases, which use ATP. 
Using this approach, more than 150 proteins were identified as potential 
substrates for PKM2-SAICAR (Table 3-1). To our surprise, the vast majority of 
these proteins were protein kinases (more than 80 human protein kinases; Table 
3-1; Gene ontology (GO) term enrichment: p < 1e-77; 12.6-fold enrichment of 
GO:0004672, "protein kinase activity"). These potential PKM2-SAICAR 
substrates include both receptor kinases such as EGFR and non-receptor protein 
kinases. In particular, many protein kinases involved in the mitogen-activated 
protein kinase (MAPK) pathway (MAPK1, MAPK3, MAP2K1, MAP2K2, 
MAP3K11, MAP3K2, MAP3K3) (Chang and Karin, 2001) were identified as 
potential substrates of PKM2-SAICAR. Among the proteins phosphorylated by 
the PKM2-SAICAR complex, at least 23 (ABL1, ABL2, ALK, CCDC6, CHEK2, 
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EGFR, ERBB2, FGFR1, FGFR2, FGFR3, JAK2, JAK3, KDR, KIT, MAP2K1, 
MAP2K2, MET, NTRK3, PCM1, PDGFRA, RET, ROS1, and SYK) have been 
implicated in cancer at the genetic level, according to the Cancer Gene Atlas 
database (http://cancergenome.nih.gov/). Several additional proteins (e.g. 
Cdc25A, Cdk2, Cdk4) involved in cell cycle progression (Nilsson and Hoffmann, 
2000; Bartek et al., 2004) were also identified as potential substrates for PKM2-
SAICAR.  Interestingly, recent work has identified Bub3, a spindle assembly 
checkpoint point, as a substrate for PKM2 (Jiang et al., 2013).  It is not yet clear 
what features of these proteins are recognized by PKM2-SAICAR. However, 
these results clearly indicate that preferred substrates for PKM2-SAICAR are 
protein kinases and other proteins involved in cell proliferation.  
Next, we individually tested phosphorylation of several selected potential 
substrates (Fig. 3-6). Because proteins involved in the MAPK pathway (Pearson 
et al., 2001; Chang and Karin, 2001) were enriched in our protein microarray 
results, we focused on validating these proteins as substrates of PKM2-SAICAR. 
As Erk1/2 (also known as MAPK3 and MAPK1, respectively; Roskoski, 2012) 
has been reported to be involved in the regulation of PKM2 (Yang et al., 2012b), 
we first tested whether PKM2-SAICAR phosphorylates Erk1 using PEP as a 
phosphate donor (Fig. 3-6A). Indeed, PKM2-SAICAR phosphorylates 
recombinant Erk1 expressed and purified from E. coli, when the reaction product 
was analyzed using ProQ Diamond phosphoprotein staining. The 
phosphorylation was inhibited by ADP and, to a lesser degree, by FBP, in a  
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Figure 3-5. Protein microarray analysis revealed proteins phosphorylated 
by the PKM2-SAICAR complex. Schematic overview of the protein microarray 
used is shown. The array contains 48 (4x12) sub-arrays. In each sub-array, there 
are 484 (22x22) spots, including Alexa-labeled antibody spots used to align the 
array images. Proteins or controls were spotted in doublets. Most proteins were 
also immobilized in another subarray (total 4 spots). The protein array was 
incubated with 5 mL solution containing rPKM2 with or without SAICAR for 30 
min followed by the addition of PEP. After a 30 min reaction, phosphorylated 
proteins were detected with ProQ Diamond.  A representative protein microarray 
result is shown along with zoomed images.  













AKT3 ALK ABL1 ALS2CR8 ADD1 
BRSK1 CSF1R ABL2 CARF ALDOC 
CAM2KB EGFR BLK CASZ1 BEAN1 
CAMKK2 EPHA1 BMX HMBOX1 BIN1 
CHEK1 EPHA2 DYRK1B HSF1 BMI1 
CHEK2 EPHA5 DYRK3 MEF2A C10orf47 
CHUK EPHA8 FER MEF2D C19orf26 
DCAMKL2 EPHB3 JAK2 MEF2D C20orf67 
DCLK2 EPHB4 JAK3 NFIC CASS4 
DYRK1B ERBB2 PTK2 NFYA CCDC6 
DYRK3 FGFR1 SYK NR1D1 CDC25A 
GSK3A FGFR2 TTN NR4A1 CYPF12 
HIPK1 FGFR3   RP5-860F19.3 DIXDC1 
IKBKB FGFR4   RXRA EIF4G3 
IKBKE FLT1   RXRA EP400NL 
MAP2K1 FLT4   SOX5 EPB49 
MAP2K2 KDR   TOX2 FAM122A 
MAP3K11 KIT   TSC22D4 FSD1 
MAP3K2 LTK   WDR62 GRB7 
MAP3K3 MERTK   ZXDC PM_2148 
MAP4K2 MET     IL1B 
MAPK12 MST1R     KANK4 
MAPK13 NTRK2     KBTBD7 
MAPKAPK2 NTRK3     KIAA1509 
MAPKAPK3 PDGFRA     KIF26A 
MAPKAPK5 PDGFRA alpha     NUP35 
MARK2 RET     PAPOLA 
NEK1 ROS1     PCM1 
NEK6 TEK     PEPD 
NLK TYRO3     PHACTR4 
PAK2       PSCD1 
PAK6       R3HDM2 
PAK7       RAG1AP1 
PBK       SC4MOL 
PDPK1       SDCCAG3 
PRKAA2       SNAP91 
PRKCE       SOCS3 
PRKCQ       TFF2 
PRKD1       WAC 
PRKD3       ZFAND5 
PRKG2         
RPS6KA2         
RPS6KA3         
RPS6KA5         
STK25         
STK33         
STK4         
TAOK2         
TBK1         
TSSK2         
TTN         
WNK2         
 
Table 3-1. List of proteins identified as potential PKM2-SAICAR substrates from 
the protein microarray experiment.
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manner similar to the phosphorylation of H3.1 T11 by PKM2-SAICAR. When the 
reaction product was probed with an antibody specific to Erk1/2 phosphorylated 
at its activation loop threonine (T202 in human Erk1) and/or tyrosine (Y204 in 
human Erk1) residues, the antibody effectively recognized Erk1 phosphorylated 
by PKM2-SAICAR. This suggests that PKM2-SAICAR may phosphorylate either 
T202 or Y204 of Erk1. As discussed later, we indeed found that T202 is the likely 
site of phosphorylation. Similar to histone H3.1, the activation of protein kinase 
activity by SAICAR was abolished when the SAICAR-insensitive PKM2 Q393K 
mutant was utilized (Fig. 3-4D).   
As PKM2-SAICAR phosphorylates the activation loop of Erk1 in vitro, we 
tested the effect of this phosphorylation on its enzymatic activity. Erk1, like other 
canonical MAPKs, is an inefficient catalyst without activation. Full activation of 
Erk1 requires two phosphorylation reactions of the activation loop T202 and Y204 
(Roskoski, 2012).  The phosphorylation by PKM2-SAICAR activated Erk1 more 
than 150-fold (Fig. 3-6B). In comparison, dually phosphorylated Erk2 (denoted 
with an ʻAʼ in Fig. 3-6B) was even more active than Erk1 phosphorylated with 
PKM2-SAICAR. This result is consistent with the reported kcat value of Erk1/2 
phosphorylated at T202 alone (reported kcat values for non-phosphorylated, pT, 
pY, and pT-pY Erk2 are 1, 227, 620, and 8940 s-1, respectively; Sugden et al., 
2011).  SAICAR-insensitive PKM2 Q393K mutant did not phosphorylate Erk1 
even in the presence of SAICAR (Fig. 3-4D). Thus, Erk1 was indeed 
phosphorylated and partially activated by PKM2-SAICAR, at least in vitro.  
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Typically, in MEK-mediated phosphorylation of Erk1/2, the 
phosphorylation of the activation loop tyrosine precedes the phosphorylation of 
the activation loop threonine (Haystead et al., 1992). However, threonine mono-
phosphorylated Erk1/2 was also has been detected in cells (Sugden et al., 2011).  
To further locate the phosphorylation site, we used recombinant Erk1 mutants 
whose activation loop residues were mutated (T202A and Y204F).  PKM2-
SAICAR was unable to phosphorylate Erk1 T202A, but was still able to 
phosphorylate the Y204F mutant (Fig. 3-6C).  These data show that the T202 is 
the likely site of phosphorylation, and the phosphorylation of Erk1 by PKM2-
SAICAR appears distinct from the MEK-mediated Erk1/2 activation. 
In addition to Erk1, we also tested the phosphorylation by PKM2-SAICAR 
of several additional selected recombinant proteins found to be phosphorylated 
by PKM2-SAICAR in the protein microarray experiment (Fig. 3-5 and 3-6D). 
When commercial recombinant epidermal growth factor receptor (EGFR; 
Carpenter, 1987) expressed and purified from insect cells was tested as a 
substrate, it was phosphorylated in a manner dependent on PKM2, SAICAR, and 
PEP. Similar results were observed with other recombinant proteins (MEK1 and 
PAK2) identified as potential PKM2 substrates from the microarray experiment. 
MAPK pathway proteins (B-Raf and Grb2) not phosphorylated by PKM2-SAICAR 
in the microarray experiment were subjected to individual tests; none were 
phosphorylated by PKM2-SAICAR.  
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Figure 3-6. Phosphorylation of EGFR/MAPK signaling proteins by PKM2-
SAICAR complex. (A) Phosphorylation of recombinant Erk1 by the PKM2-
SAICAR complex. Recombinant Erk1 was subjected to phosphorylation by PKM2 
in the presence or absence of various ligands (0.5 mM each) and probed with 
ProQ Diamond phosphoprotein staining, Western blotting with anti-active Erk1/2 
antibody, with anti-Erk1/2 antibody, and with anti-PKM2 antibody. (B) Effect of 
PKM2-SAICAR on the activity of Erk1. Protein kinase activity of Erk1, after 
treatment with PKM2 in the absence or in the presence of 0.50 mM SAICAR, was 
monitored using a fluorogenic Erk1/2 activity assay kit. ʻAʼ denotes the use of 
commercial active Erk2 instead of Erk1. Means +/- SEM are noted (n = 3). (C) 
Identification of the residue(s) phosphorylated by PKM2-SAICAR.  Recombinant 
Erk1, Erk1 T202A, and Erk1 T204F were subjected to phosphorylation in the 
presence or absence of 0.5 mM SAICAR and probed with anti-active Erk1/2 
antibody. (D) Phosphorylation of other proteins by the PKM2-SAICAR complex. A 
few positive hits (EGFR, MEK1, PAK2) and negative hits (B-Raf and Grb2) were 
individually tested for the phosphorylation by PKM2 in the presence of various 
ligands.  
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PKM2-SAICAR complex phosphorylates protein substrates in cells  
Our results indicate that there is an intimate relationship between PKM2-
SAICAR and EGF/MAPK signaling. Next, we asked if SAICAR is functionally 
involved in EGF/MAPK signaling in cancer cells. We first measured cellular levels 
of SAICAR in HeLa and in H1299 cells before and after EGF addition (Fig. 3-7A). 
Cellular SAICAR levels were elevated rapidly in these cells upon EGF addition 
(Fig. 3-7A and 3-8) to a level sufficient to activate PKM2 (EC50 300 mM; Keller et 
al. 2012). Thus, SAICAR may be a relevant ligand for PKM2 upon EGFR 
activation, in addition to glucose deprivation as previously reported.  
Next, we asked if the interaction between PKM2 and SAICAR is involved 
in EGF-induced protein phosphorylation in cells. We first tested the 
phosphorylation of total H3 T11 in cells, as the antibody does not distinguish 
subtypes (Fig. 3-7B and C). H3 pT11 and Myc levels were both elevated upon 
EGFR activation in HeLa cells as previously reported (Yang et al., 2012a). In 
cells constitutively accumulating SAICAR (adsl-kd; Keller et al, 2012), both H3 
pT11 and Myc levels were constitutively elevated (Fig. 3-7B and C). When 
endogenous PKM2 was replaced with SAICAR-insensitive PKM1 (Fig. 3-7B) or 
PKM2 mutant (Q393K; Keller et al., 2012; Fig. 3-7C), EGF addition was not able 
to induce H3 T11 phosphorylation or Myc expression (Fig. 3-7B and C) 
regardless of cellular SAICAR level. Our data suggest that PKM2-SAICAR is 
necessary for EGF-induced phosphorylation of H3 T11 and the subsequent  
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Figure 3-7. SAICAR-PKM2 interaction is necessary and sufficient to induce 
H3 T11 and Erk1/2 phosphorylation. (A) Addition of EGF (10 ng/mL; 2 hrs) is 
sufficient to induce cellular concentration of SAICAR in HeLa and in H1299 cells. 
Mean +/- SEM are noted (n = 3). (B and C) Effect of PKM2-SAICAR interaction 
on EGF-dependent phosphorylation of H3 T11 and MYC expression. Cells were 
incubated in EGF-free DMEM (DMEM, 25 g/L glucose, 10% dialyzed FBS) or for 
3 hrs in medium supplemented with 10 ng/mL EGF. ʻM1*ʼ and ʻQKʼ denote cells 
in which endogenous PKM1 and PKM2 were knocked down, and knockdown 
resistant PKM1 or SAICAR-insensitive PKM2 Q393K mutant from plasmids were 
expressed, respectively. (D) Effect of PKM2-SAICAR interaction on Erk1/2 
activation.  




Figure 3-8. Effect of EGF addition on the cellular concentration of SAICAR 
in HeLa cells. HeLa cells were incubated in DMEM supplemented with dialyzed 
FBS (10%) for 24 hrs. The medium was replaced with medium supplemented 
with dialyzed FBS and 10 ng/mL recombinant human EGF. Cells were harvested 
at each time point and cellular concentration of SAICAR was analyzed using LC-
MS as previously described (Keller et al., 2012).  
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accumulation of Myc. The phosphorylation of H3 T11 by PKM2-SAICAR in EGF-
treated cells was also specific to H3.1 subtype (Fig. 3-2).  
In a similar manner, we probed the activation of Erk1/2 in HeLa cells 
(Figure 3-7D). In HeLa cells, addition of EGF induces activation of Erk1/2 as 
expected. Cells with constitutively elevated levels of SAICAR (adsl-kd) showed 
constitutive activation of Erk1/2, while paics-kd cells were unable to activate 
Erk1/2 in response to EGF (Fig. 3-7D). Additionally, the PKM2-SAICAR 
interaction was required for Erk1/2 activation in cells, as replacing endogenous 
PKM2 with the SAICAR-insensitive PKM2 Q393K mutant (QK in Fig. 3-7D) was 
sufficient to prevent Erk1/2 activation in adsl-kd cells. Overall, our results show 
that PKM2-SAICAR phosphorylates protein substrates (histone H3 and Erk1/2) in 
cancer cells.  
 
Positive feedback regulation between PKM2-SAICAR and Erk1/2 
 Recently, Erk2 was reported to phosphorylate PKM2, which is required for 
PKM2ʼs nuclear translocation and subsequent protein kinase activity (Yang et al., 
2012b). Along with our data, these results indicate that PKM2-SAICAR and 
Erk1/2 may form a positive feedback regulation loop, where the activation of one 
protein renders the other more likely to be activated. To test this possibility, we 
phosphorylated recombinant PKM2 with constitutively active Erk2. After 
phosphorylation, recombinant PKM2 was re-purified and subjected to pyruvate 
kinase (Fig. 3-9A) and histone H3 T11 kinase (Fig. 3-9B) activity assays. Upon 
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Erk2-mediated phosphorylation, PKM2 became far more sensitive to SAICAR 
(EC50 shifts from 0.3 mM to 10 µM SAICAR). Considering that the cellular 
concentration of SAICAR in non-stimulated cancer cells ranges between 10-100 
µM (Keller et al, 2012), our results indicate that Erk-mediated phosphorylation 
sensitizes PKM2 to SAICAR, even when the cellular concentration of SAICAR is 
restored to the original level.  Thus, our results support the previous finding that 
the phosphorylation of PKM2 alone induces nuclear localization and cell 
proliferation in cells (Yang et al, 2012b). Together, these results indicate that 
PKM2-SAICAR and Erk1/2 are mutually sensitizing each other to promote MAPK 
protein kinase signaling (Fig. 3-9C).  
 
PKM2-SAICAR is necessary and sufficient for proliferation signaling 
A common consequence of a positive feedback loop is a switch-like 
behavior (Mitrophanov and Groisman, 2008). Because PKM2-SAICAR and 
Erk1/2 form a positive feedback loop in vitro, PKM2-SAICAR may contribute to 
sustained proliferative signaling, a hallmark of cancer cells (Hanahan and 
Weinberg, 2012). To test this possibility, HeLa cells and their derivatives were 
briefly (30 min) incubated with medium containing EGF. The medium was then 
replaced with medium lacking EGF, and the activation of Erk1/2 over time was 
monitored (Fig. 3-9D). In comparison with non-transfected HeLa cells, adsl-kd 
cells showed a more rapid activation of Erk1/2, which supports our view that 
PKM2-SAICAR primes Erk1/2 activation (Fig. 3-7A-B). In addition, the activation  
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Figure 3-9. SAICAR-PKM2 interaction is necessary and sufficient for 
sustained proliferative signaling. (A and B) Phosphorylation of PKM2 by active 
Erk1 sensitizes PKM2 for SAICAR binding. Recombinant PKM2 was 
phosphorylated by active GST-tagged Erk1. The effect of the phosphorylation on 
PKM2ʼs sensitivity was measured (A) by monitoring pyruvate kinase activity 
(mean +/- SEM. are noted; n =3) and (B) by monitoring H3.1 T11 kinase activity. 
Upon phosphorylation by Erk1/2, PKM2 becomes more sensitive (EC50 0.30 mM 
and 12 µM SAICAR before and after phosphorylation by Erk1/2, respectively). (C) 
A schematic summary. (D) Effect of SAICAR-PKM2 on the activation of Erk1/2. 
HeLa, adsl-kd, QK, and adsl-kd QK, SA, and adsl-kd SA cells were grown in 
DMEM supplemented with dialyzed FBS, briefly incubated in medium containing 
10 ng/mL recombinant EGF, and then incubated in EGF-free medium. Cells were 
harvested, and Erk1/2 activation was monitored by Western blot, probing with 
antibody activated Erk1/2. (E) Effect of SAICAR-PKM2 on cell proliferation.  Cells 
with increased SAICAR had an increased proliferation rate, regardless of the 
addition of EGF.  Those cells without inducible SAICAR levels or those where the 
PKM2-SAICAR interaction was disrupted showed less sensitivity to growth factor 
addition.  
*Figure presented on following page 
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Figure 3-9. SAICAR-PKM2 interaction is necessary and sufficient for 
sustained proliferative signaling 
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of Erk1/2 in adsl-kd cells was sustained for a longer period of time (Fig. 3-9D). 
Replacing PKM2 with the SAICAR-insensitive PKM2 Q393K (or QK) mutant in 
wild-type or adsl-kd cells showed only marginal activation of Erk1/2 in 
comparison to HeLa cells, indicating that PKM2-SAICAR is a core component 
required to sustain Erk1/2 activation (Fig. 3-9D).  
To further examine our proposed positive feedback loop, we next replaced 
PKM2 with the PKM2 S37A mutant that is insensitive to Erk1/2 (Yang et al. 
2012b). First, we purified recombinant PKM2 S37A and determined the kinetic 
parameters.  In our hands, the activity of PKM2 S37A is slightly lower than wild 
type PKM2 (Fig. 3-10A, kcat: 0.5 s-1, wild type kcat: 2-4 s-1).  PKM2 S37A is still 
sensitive to SAICAR in both pyruvate kinase activity (Fig. 3-10B, EC50 ~ 250 µM 
SAICAR) and protein kinase activity (Fig. 3-10C) assays.  We then replaced wild 
type PKM2 with PKM2 S37A mutant in HeLa and adsl-kd cells (ʻSAʼ and ʻSA 
adsl-kdʼ in Fig. 3-10D). When Erk1/2 signaling in these cells was monitored, the 
activation of Erk1/2 in PKM2 S37A cells was more rapidly diminished (Fig. 3-9D). 
This result is consistent with the mutual sensitization model (Fig. 3-9C). 
We next sought to determine whether the PKM2-SAICAR interaction is 
necessary for mitogen-induced cell proliferation (Fig. 3-9E). HeLa cells and their 
derivatives were incubated for one day in the presence or absence of EGF, and 
the population size increase was monitored. As expected, EGF stimulated the 
proliferation of HeLa cells, while adsl-kd cells showed constitutive hyper-
proliferation. Conversely, EGF only marginally stimulated the proliferation of 
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paics-kd cells. Additionally, cells where endogenous PKM2 was replaced with the 
PKM2 Q393K mutant were also nearly insensitive to EGF. Thus, our results 
support that SAICAR and its interaction with PKM2 are necessary for the 
mitogen-induced proliferation of cancer cells.  Finally, we replaced endogenous 
PKM2 is replaced with the non-phosphorylatable S37A mutant, which is reported 
to be excluded from the nucleus (Yang et al. 2012b).  EGF did not significantly 
stimulate proliferation in HeLa cells with PKM2 S37A mutant (Fig. 3-9 and 3-
10E). Cells over-accumulating SAICAR (adsl-kd) were also affected by the 
replacement of PKM2 with PKM2 S37A mutant, and were not stimulated by EGF 
or SAICAR. These results show that the sustained Erk signaling mediated by the 
mutual sensitization of PKM2-SAICAR and Erk is a necessary component for the 
mitogen-induced proliferation.  
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Figure 3-10. Characterization of PKM2 S37A mutantʼs enzyme activities  (A) 
Pyruvate kinase activity assay (rate constants) with varying amount of PEP 
indicates that PKM2 S37A mutant has pyruvate kinase activity similar to the wild-
type PKM2 although kinetic parameters are slightly different (k: 0.5 s-1; Km: 600 
mM PEP). (B and C) PKM2 S37A mutant is as sensitive to SAICAR as wild type 
PKM2 in both pyruvate kinase activity (B) and histone H3.1 T11 kinase activity 
(C). (D) Effect of phosphorylation of PKM2 on Erk1/2 signaling.  Disruption of 
phosphorylation of PKM2 by S37A mutant lead to decreased Erk1/2 signaling in 
both wild type and adsl-kd cells.  (E) Effect of SAICAR-PKM2 on cell proliferation. 
Non-phosphorylatable PKM2 mutant containing cells showed less sensitivity to 
growth factor addition. 
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DISCUSSION 
Protein kinases are known to play important regulatory roles in many 
biological processes. In eukaryotic cells, well-defined families of protein kinases 
catalyze protein phosphorylation. These typical protein kinases use ATP as a 
phosphate donor, and share common structural and sequence features. In 
addition to these classical protein kinases, there has been speculation that other 
energetic molecules, like PEP, may play a role in protein phosphorylation in 
mammalian cells, but an enzyme catalyzing this reaction was not identified 
(Jeyasingham and Carlson, 1998; Khandelwal et al., 1983). In bacteria, PEP can 
be used for protein phosphorylation, as shown in the PEP-dependent sugar 
phosphotransferase system of Bacillus (Postma et al., 1993). PKM2 is the first 
identified mammalian protein, to our knowledge, that phosphorylates protein 
substrates using PEP as a phosphate donor. However, because recombinant 
PKM2 alone was unable to reproduce the results obtained with PKM2 purified 
from cancer cells, investigating the molecular basis of this novel protein kinase 
activity was difficult. In this paper, we showed that metabolite binding is sufficient 
to induce the protein kinase activity of PKM2. Our results can expand our 
understanding of protein kinases by identifying a new dimension of regulation.  
  In addition to the previously known substrate histone H3 (Yang et al., 
2012a), we also identified many human proteins as potential substrates for 
PKM2-SAICAR, with the vast majority of proteins involved in the regulation of cell 
proliferation. Further investigation on how PKM2-SAICAR recognizes its 
	   109	  
substrates may reveal a previously unrecognized feature common to these 
proteins involved in cell cycle regulation. 
Previous work on PKM2 has revealed an interaction between MAPK 
activity and PKM2, showing that Erk1/2 phosphorylates PKM2 (Yang et al., 
2012b). In our work, the reciprocal reaction – phosphorylation of MAPK protein 
kinases by PKM2 – also occurs in vitro and in cells upon the binding of SAICAR 
to PKM2. Our result challenges the view that PKM2 is a passive recipient of 
MAPK protein kinase signaling and suggests that PKM2 is a more active 
component that is necessary for the MAPK protein kinase signaling.  
Intricately related to MAPK activity is cell cycle control and proliferation.  
As has been well documented, malignant tumor cells frequently display sustained 
proliferation. Many different mechanisms such as mutations in genes encoding 
MAPK signaling contribute to the sustained proliferation of cancer cells. However, 
many types of cancer cells show sustained proliferation without showing any 
mutations in these genes. The altered metabolism associated with most cancer 
cells, including upregulation of PKM2, may thus be a mechanism to sustain cell 
proliferation in those cells.   
	   110	  
 
MATERIALS AND METHODS 
Materials 
The preparation of SAICAR, analysis of cellular SAICAR concentration, 
recombinant PKM2, and pyruvate kinase assays were performed as previously 
described (Keller et al., 2012). Plasmids for bacterial expression of human Erk1 
(Addgene plasmid 29578) and active Mek2 (Addgene plasmid 29580), which 
were originally constructed by D. Maly (U. Washington), were obtained from 
Addgene. Expression plasmid for GST-PAK2 (Addgene plasmid 31671) was 
originally constructed by A. Brunet lab (Banko et al, 2011). Plasmids encoding 
mutant Erk1 and PKM2 were constructed using QuikChange Lightening site 
directed mutagenesis kit (Agilent). Plasmids constructed in our lab were 
sequenced from both ends of inserts or mutation sites.  
 
Proteins 
Recombinant Erk1 (and its mutants), constitutively active MEK2, MAPK11, 
and GST-PAK2 were expressed in E. coli BL21 Codonplus RIL (DE3) cells 
harboring appropriate plasmids. Cells were grown in 0.50 liter Terrific Broth 
supplemented with chloramphenicol (25 µg/mL) and ampicillin (50 µg/mL) or 
kanamycin (50 µg/mL) at 37°C until optical density at 600 nm (OD600) reached 
0.6-0.8. Protein expression was induced by the addition of isopropylthio-β-d-
galactopyranoside to 0.5 mM followed by incubation at 22°C for 12-18 hours. All 
subsequent steps were carried out at 4°C or on ice unless specifically noted 
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otherwise. Cells were collected by centrifugation (5,000 g 20 min), and the cell 
pellet was resuspended in lysis buffer (20 mM HEPES, 500 mM NaCl, 5% 
glycerol, 1 mM DTT, 10 mM imidazole, pH 7.4 for His-tag proteins; 50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 1 mM DTT for GST-tagged proteins) supplemented 
with phenylmethylsulfonyl fluoride (0.3 mM). Cells were lysed by sonication, and 
cell debris was removed by centrifugation (15,000g for 20 min). Cleared lysate 
was applied to 5 mL HiTrap Chelating column (for His-tagged proteins; charged 
with zinc chloride) or 5 mL GST Capture Column (for GST-tagged proteins). After 
washing with lysis buffer until A280 reached baseline, bound proteins were eluted 
with linear gradient of the lysis buffer supplemented with 500 mM imidazole (for 
His-tagged proteins) or 10 mM reduced glutathione (for GST-tagged proteins). 
SDS-PAGE and Commassie Blue staining determined the fractions containing 
protein. Desired fractions were combined and dialyzed against 10 mM sodium 
phosphate, 1.8 mM potassium phosphate, pH 7.4, 137 mM NaCl, 2.7 mM KCl, 
5% glycerol, 0.5 mM EDTA, 2 mM DTT buffer. Proteins were concentrated, if 
desired, using Amicon Ultracel centrifugal filters. Protein concentrations were 
determined by measuring absorbance at 280 nm in denaturing conditions as in 
literature (Edelhoch, 1969), and stored at -80°C or at 4°C. Recombinant Erk1 
was stable only for about a week after its purification in our hands, and was thus 
used within a week of lysis. Recombinant histone H3, H3/H4 tetramer, and 
H2A/H2B tetramer were purchased from New England Biolabs. Purified 
nucleosomes were gifts from G. Bowmanʼs lab (Johns Hopkins University). The 
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purified nucleosomes were found to contain H3 pT11, according to our Western 
analysis. Thus, the nucleosome was treated with biotinylated alkaline 
phosphatase (NEB).  The alkaline phosphatase was removed from the reaction 
using 25 uL magnetic avidin beads (Pierce) and then the remaining 
dephosphorylated nucleosome was used for Figure 1. Recombinant human EGF 
was purchased from Sigma-Aldrich.  Recombinant Grb2, Mek2, B-Raf, and 
EGFR expressed and purified from insect cells were purchased from Invitrogen. 
 
Cell culture 
Mammalian cells were maintained and propagated in Dulbecco's Modified 
Eagle Medium (DMEM; 4 g/L glucose, 4 mM glutamine, without pyruvate) 
supplemented with 10% undialyzed fetal bovine serum (FBS), penicillin, and 
streptomycin at 37°C, 5% carbon dioxide, and humid conditions unless 
specifically noted otherwise. For glucose depletion or controlled EGF 
experiments, dialyzed FBS (Invitrogen) was used instead of normal FBS. For 
glucose depletion experiments, glucose-free DMEM (Invitrogen) was used. For 
controlled EGF experiments, recombinant EGF (10 ng/mL; Sigma-Aldrich) was 
added to medium containing dialyzed FBS. Cells were transfected with plasmids 
using the Neon Nucleotransfector (Invitrogen) using cell-type specific parameters 
provided by the vendor. Cell viability was determined using tryphan blue cell 
staining. To count cell numbers, cells were resuspended in trypsin/EDTA 
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solution, diluted immediately with isotonic buffer, and then counted using a Moxi-
Z cell counter.  
 
Subcellular localization of PKM2 
HeLa cells grown on coverslips were washed with PBS, fixed with 4% 
paraformaldehyde in phosphate buffered saline (PBS) for 5 min at room 
temperature, permeabilized with 0.01% Triton-X-100 in PBS for 5 min at room 
temperature, incubated in 5% goat serum in PBS for 1 hour, and stained with 
rabbit anti-PKM2 antibody (Sigma) for 45 min. Following incubation with solution 
containing DAPI and TRITC-conjugated secondary antibody (Sigma), 
microscopic images were obtained using a Zeiss AxioVert 200 fluorescence 




Human Protein Microarray ProtoArray v5.0 slide (Invitrogen) was blocked 
in 5% protease-free BSA (Roche) diluted in HPLC grade water (Fisher) for 30 
minutes at room temperature without rocking and subsequently washed three 
times with HPLC grade water. The slide was then immersed into a 5-mL solution 
containing 10 nM rPKM2, 5% glycerol, 6.2 mM MgCl2, 150 mM KCl, 10 mM 
HEPES, pH 7.4, and 0 or 0.5 mM SAICAR at 37°C for 30 minutes, followed by 
the addition of 0.5 mM PEP and incubated at 37°C for another 30 minutes.  The 
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slide was washed three times with HPLC grade water.  A Pro-Q Diamond 
Phosphoprotein Stain Kit (Invitrogen) was used to stain phosphorylated proteins 
using the protocol provided by the vendor for staining of nitrocellulose blots.  
Fluorescence signals were detected using a Typhoon 9410 Variable Mode 
Imager (excitation 550 nm, excitation 580 nm, 600 PMT, 10 um particle size; 
Integrated Imaging Center, Johns Hopkins University). Images were analyzed 
using ImageJ software with a microarray plugin.  Sub-arrays were aligned using 
AlexaFluor-conjugated protein spots in each subarray. 
 
Spectroscopic analysis of PKM2ʼs protein kinase activity 
 Assay performed under similar condition to typical pyruvate kinase 
assays.  The experiment was carried out in the absence of ADP or other 
nucleotides.  In short, PKM2 (10 nM) was incubated for 30 minutes at 37°C with 
varying recombinant histone H3.1 concentrations in buffer (10 mM HEPES pH 
7.4, 100 mM KCl, 6.2 mM MgSO4) in the presence or absence of 500 uM 
SAICAR.  After incubation, NADH (0.2 mM) and LDH (50 U/mL) were added, and 
immediately before detection, PEP (200 uM) was added.  Change in 
fluorescence was measured for 30 minutes (excitation: 540 nm/emission: 590 
nm), using the Tecan Infinite Series 200 Pro. 
 
Protein kinase assays 
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The reaction solution [0.1-10 nM PKM2, 0-4 µM histone (NEB, typically 1 
uM H3 monomer concentration), 150 µM PEP, 50 mM HEPES, pH 7.4, 100 mM 
potassium chloride, 6.2 mM magnesium acetate, and 5% glycerol] was incubated 
at 25°C for 1-120 minutes (typically 5 min). After the reaction, the solution was 
mixed with an equal volume of SDS-gel loading buffer (375 mM Tris-HCl, pH 8, 
10% SDS, 50% glycerol, 1 mM DTT, 0.1% bromophenol blue) and incubated at 
95oC for 10 minutes.  All other protein kinase assays were performed as 
described, with a fixed concentration of PKM2 (10 nM), for 30 minutes, unless 
specifically noted otherwise. Solutions were subjected to SDS-PAGE, staining 
with ProQ Diamond (Invitrogen), or Western blot analysis. For the determination 
of catalytic efficiency (kcat), a reaction was carried out with higher concentration of 
PKM2 (10 nM) for 1 hour, and the resulting signal was assumed to represent the 
completed reaction.  
 
Western Blot 
Western blots were performed as described by AbCam.  In brief, cells 
were lysed in ice-cold RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate) supplemented with 1 
mM phenylmethylsulfonyl fluoride and 1 mM sodium fluoride, and total protein 
amount was measured using a Pierce 660 reagent (Thermo Scientific) with 
bovine serum albumin as a standard.  Proteins were separated by SDS-PAGE, 
and transferred to nitrocellulose membranes. The membrane was blocked with 
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phosphate-buffered saline (PBS) supplemented with 5% bovine serum albumin, 
and probed with the appropriate primary antibody (rabbit anti-phospho-p42/p44, 
rabbit anti-p42/p44, rabbit anti-pT11-Histone H3, and rabbit anti-Histone H3 from 
Cell Signaling; rabbit anti-GAPDH and mouse-anti-Myc from Sigma-Aldrich) 
overnight at 4°C.  After primary antibody incubation, membranes were probed 
with horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG or goat anti-
mouse IgG secondary antibodies (Bio-Rad). HRP-conjugated secondary 
antibodies were then detected using commercial chemiluminescence substrates 
(Pierce). Chemiluminescence images were acquired using a FluorChem M 
FM0455 imager.   
 
Protein microarray experiments 
Protein microarray experiments were carried out using Invitrogen Human 
protein microarrays, recombinant PKM2, and PEP in the presence and in the 
absence of SAICAR. Phosphorylated proteins were detected using ProQ 
Diamond stain (Invitrogen). An extensive description of this experiment is 
provided in the Supplementary Information. 
 
Phosphorylation of PKM2 
Recombinant PKM2 (1 µM) and recombinant GST-Erk1 (10 nM) were 
incubated together in a buffer containing 1 mM ATP, 50 mM Tris-HCl, pH 7.0, 
150 mM NaCl, 1 mM DTT, 1 mM MgCl2 for 30 minutes at 25°C.  The reaction 
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solution was passed through glutathione-agarose resin (Sigma-Aldrich) to 
deplete GST-Erk1. Unbound proteins were eluted with 50 mM Tris, pH 8.0, 150 
mM NaCl, 1 mM DTT, 1 mM MgCl2 buffer. Fractions were then subjected to 
SDS-PAGE and either Coomassie or Pro-Q diamond staining (Invitrogen).  
Fractions containing phosphorylated PKM2 were identified using Pro-Q diamond 
staining. Concentration of phosphorylated PKM2 was determined by measuring 
A280 in denaturing conditions (Edelhoch, 1969) using a calculated extinction 
coefficient (28,910 M-1 cm-1).  
 
Erk1/2 activity assay 
A 10 µL reaction (25 nM rPKM2, 1 µM rErk1, 150 µM PEP, 50 mM HEPES 
pH 7.4, 100 mM potassium chloride, 10% glycerol, 6.2 mM magnesium chloride, 
and 1 mM DTT) was incubated for 30 minutes at room temperature. The Erk1 
reaction was serially diluted using water, and 8 µL of diluted solution was added 
to 32 µL Omnia Kinase Assay solution (10 µM Omnia Peptide 17, 1 mM ATP, 0.2 
mM DTT, and proprietary buffer components from the vendor; Invitrogen) in a 
black transparent bottom 96-well plate. The emission at 485 nm (excitation at 
360 nm) was recorded every minute for 60 minutes at 30°C using a Tecan Infinity 
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Investigating the elements and mechanism of 
SAICAR accumulation in cancer cells 
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ABSTRACT 
 The cellular metabolite SAICAR has been shown to be important for 
cancer cell proliferation and survival by activating the pyruvate kinase and protein 
kinase activities of PKM2.  As a response to both glucose starvation and EGF 
addition, SAICAR levels accumulate in cells, but the mechanism leading to this 
accumulation were not understood.  Here, we report that SAICAR accumulation 
is not limited to glucose-depletion or EGF addition, but is more likely a common 
phenomenon upon growth stimulating conditions.  Compounds promoting cell 
differentiation, apoptosis, or those without their cognate receptor did not lead to 
cellular SAICAR accumulation.  Additionally, the protein level of the SAICAR 
synthetase, PAICS, was elevated in conditions that lead to SAICAR 
accumulation, but not in those in which SAICAR levels remained unchanged.  
Downstream elements, including Erk1/2 activation, histone H3 phosphorylation, 
and PKM2 nuclear localization occurred in a manner consistent with cellular 
SAICAR levels.  PAICS protein level was stabilized by the addition of growth 
factor, independent of transcription or translation.  Furthermore, metabolic flux in 
SAICAR accumulating conditions is consistent with activation of PAICS protein, 
rather than inhibition of SAICAR cleavage through ADSL.  Finally, we found that 
PAICS protein level is elevated by at least two-fold in 95% of human cancers.  
Taken together, these data suggest that cancer cells rely upon a common 
mechanism to couple cell proliferation and metabolic flux in a variety of 
conditions.  Additionally, PAICS protein appears to be a previously unrecognized 
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target of the MAPK cascade, adding a layer of complexity to cell coordination 
upon external stimuli. 
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INTRODUCTION 
Cancer cells must coordinate their cellular response with external stimuli 
to thrive in the tumor microenvironment (1).  However, it has been well 
documented that tumor cells have reduced dependence on external growth factor 
signaling (2).  In some cases, cancer cells produce growth factors themselves or 
express constitutively active mutants of proteins involved in signaling cascades 
(2).   
To accomplish this, cancer cells express distinct proteins that differ from 
their normal cell counterparts.  Among these expressed proteins is the glycolytic 
enzyme pyruvate kinase M2 (PKM2).  PKM2 is one of four isoforms of pyruvate 
kinase in humans, which all catalyze the final step of glycolysis, generating 
pyruvate and ATP from phosphoenol pyruvate (PEP) and ADP (3).  Unlike the 
other isoforms, PKM2 is highly expressed in highly proliferating cells, including 
both fetal and cancer cells. (3,4).  Although PKM2 is less active biochemically 
than its counterpart PKM1, PKM2 is known to play important roles in both cancer 
cell growth and proliferation in stress conditions (3,4).  
Recently, PKM2 was shown to be activated by the cellular metabolite 
succinyl-aminoimidazole-carboaximide ribosyl-5ʼ-phosphate (SAICAR) in both 
pyruvate and protein kinase activity (5,6).  Cellular SAICAR accumulates upon 
glucose starvation and epidermal growth factor (EGF) addition and binds to 
PKM2 (6).  The interaction between PKM2-SAICAR prolongs the MAPK signaling 
cascade by activating Erk1/2 and participating in a positive feedback loop (6).  
	   126	  
Additionally, SAICAR promotes nuclear localization of PKM2 and the 
phosphorylation of histone H3, enhancing expression of target genes such as c-
Myc (6).  Furthermore, the PKM2-SAICAR complex was shown to phosphorylate 
over 100 cellular proteins, many with roles in cell proliferation and growth (6). 
While the role of the PKM2-SAICAR interaction is now more defined, the 
mechanism by which SAICAR accumulates and conditions in which accumulation 
occurs are both unexplored.  The biosynthetic pathway in which SAICAR is 
generated and degraded is well defined, although little research has investigated 
the regulation of these specific enzymatic steps.  SAICAR generation is step 
seven of the de novo purine nucleotide synthesis pathway and is produced by the 
enzyme phosphoribosylaminoimidazole carboxylase (PAICS, also known as 
SAICAR synthetase, (7)).  PAICS catalyzes two sequential steps in the purine 
biosynthesis pathway (7): 
(1) AIR1 + CO2 à = CAIR2 
(2) CAIR + L-aspartate + ATP à SAICAR + ADP + Pi 
Cancer cells often utilize de novo nucleotide synthesis instead of the salvage 
pathways most normal cells use.  Thus, many cancers exhibit increased 
sensitivity to perturbations in de novo nucleotide synthesis pathways, and have 
become targets for anti-cancer drugs (8, 9).  As of yet, PAICS regulators have 
not been studied.  However, the enzymatic activity of PAICS has been targeted.  
L-alanosine, an analog of L-aspartate, can be metabolized by PAICS into a 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  5ʼ-phosphoribosyl-5-aminoimidazole = AIR  
2	  5ʼ-phosphoribosyl-4-carboxy-5-aminoimidazole = CAIR	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potent inhibitor of adenylosuccinate synthetase, which performs the first 
committed step of de novo AMP biosynthesis, and is currently on the market as 
an anti-cancer drug (8).  However, the sensitivity to this drug is limited to cancers 
with a deficiency in methylthioadenosine phosphorylase.   
SAICAR is cleaved by ADSL in step eight of de novo purine biosynthesis.  
Interestingly, ADSL also performs two enzymatic reactions, but the reactions are 
non-sequential (11): 
 (3) SAICAR à AICAR3 + fumarate 
 (4) Adenylosuccinate4 à AMP + fumarate   
Beyond its role in generating purines needed for DNA replication, ADSL is 
thought to regulate cellular processes by controlling both AMP and fumarate 
levels in cells (12). Again, little research has been conducted on the regulation of 
ADSL protein activity or its expression. 
Here, we report that SAICAR accumulates upon addition of growth factors, 
but not in conditions leading to cell death, differentiation, or in conditions in which 
the cognate receptor is not present in the cell.  SAICAR accumulation correlates 
with phosphorylation of Erk1/2, PKM2 nuclear localization, and phosphorylation 
of histone H3.  We also found that PAICS protein level correlates with SAICAR 
accumulation, and is likely responsible for the observed SAICAR increase.  
PAICS appears to be stabilized by the addition of growth factor, most likely 
through a phosphorylation event, and appears independent of transcription and 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3	  5-­‐aminoimidazole-­‐4-­‐carboxamide	  ribotide	  =	  AICAR	  	  
4	  Adenylosuccinate	  is	  also	  denoted	  succinyladenosine	  monophosphate	  or	  SAMP	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translation.  Additionally, we found that PAICS protein is overexpressed in over 
95% of human cancers.  Furthermore, metabolic flux in SAICAR accumulating 
conditions is consistent with activation of PAICS protein, rather than inhibition of 
ADSL.  From these data, we show that the PAICS protein is a key factor in 
cancer cell response to growth factors and other external stimuli, leading to 
increased cellular SAICAR and downstream activation of PKM2 as a protein 
kinase.  Our findings highlight that PAICS is a peripheral, but important, member 
of the MAPK cascade, which may potentially be regulated in other cellular 
contexts beyond cancer biology. 
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RESULTS 
Cellular SAICAR levels increase upon both glucose deprivation and EGF 
addition (6).  However, it remains unclear whether SAICAR accumulation was 
limited to these two conditions or if it represented a broader response to a variety 
of conditions.  To establish the breadth of SAICAR accumulation in response to 
external stimuli, we incubated HeLa cells with eleven different signaling factors 
(BNDF, EGF, GDNF, FGF, IGF, HGF, NGF, Ret A, TGF, TNF, VEGF) or a 
phosphate-buffered saline control, and subsequently measured cellular SAICAR 
concentration using liquid-chromatography mass spectrometry (LC-MS) after one 
hour of stimulation (5, Table 4-1, Figure 4-1A).  As expected, EGF addition led to 
increased cellular SAICAR.  We also found that a number of growth factors lead 
to SAICAR accumulation, including BDNF, GDNF, FGF, IGF, HGF, TGF, and 
VEGF (Figure 4-1).  Interestingly, each compound stimulated SAICAR production 
to a different degree, and the overall result represented a gradient of cellular 
concentrations (Figure 4-1).  The conditions that did not lead promote SAICAR 
accumulation either led to apoptosis (TNF), cell differentiation (Retinoic Acid), or 
the cognate receptor was not present (NGF) (Figure 4-1A).  Of note, the 
presence of the GDNF receptor in HeLa cells is not yet defined.  However, GDNF 
is known to be capable of binding other receptor tyrosine kinases (RTKs), albeit 
at a lower affinity, potentially explaining the observed phenomenon.   
Next, we sought to ensure that effectors of SAICAR accumulation were 
also activated in these conditions.  When cells were incubated with growth factor,  
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Table 4-1. List of the factors utilized in this study and amounts of each 
added to cell culture media.  Factors were reconstituted in phosphate buffered 
saline with 0.5% BSA. 
 
 













































































Figure 4-1. Signaling factors lead to an increase in cellular SAICAR.   A) 
Amount of cellular SAICAR measured by LC-MS.  HeLa cells were incubated with 
the various signaling factors (amounts listed in Table 4-1) for one hour, 
metabolites extracted, and cellular SAICAR measured.  SAICAR was quantified 
using a 13C-SAICAR standard of a known amount and normalized to total 
metabolite absorbance at A260 nm.  B) Cell number increases with the addition of 
some signaling factors.  HeLa cells were incubated with various signaling factors 
for twenty-four hours and the cell number was measured. 
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Erk1/2 phosphorylation was increased in all conditions that lead to SAICAR 
accumulation, with the exception of VEGF (Figure 4-2).  Additionally, after a six-
hour incubation, SAICAR accumulating conditions promoted PKM2 nuclear 
localization and subsequent phosphorylation of histone H3 threonine 11 (Figure 
4-3).  Conditions in which SAICAR was not elevated did not show activation of 
Erk1/2, phosphorylation of H3 (data not shown), nor relocalization of PKM2 
(Figure 4-2 and 4-3).   Finally, cell proliferation correlated to cellular SAICAR level 
(Figure 4-1B).  Thus, all conditions in which there is an accumulation of SAICAR 
lead to a common output: activation of proliferative signaling. 
Accumulation of SAICAR can be the result of several different scenarios, 
including activation of SAICAR synthesis, inhibition of SAICAR cleavage, and/or 
increased flux through the de novo purine nucleotide biosynthetic pathway. To 
begin to differentiate between the possibilities, the concentrations of up- and 
downstream metabolites were examined by LC-MS.  The expectation is that if 
elevated SAICAR levels are due to increased flux, the upstream metabolite 
AICOR, SAICAR, and the downstream metabolite AICAR will increase together.  
If SAICAR synthesis is upregulated, AICOR will be depleted while SAICAR and 
AICOR levels will increase, while if SAICAR cleavage is inhibited, AICOR and 
SAICAR will increase.  If AICOR levels decrease (Figure 4-4A,B). Upon growth 
factor addition, we found that the upstream metabolite AICOR is depleted in 
phase with SAICAR accumulation, while AICAR accumulates with SAICAR 
(Figure 4-4A, B).  











































































Figure 4-2. Signaling factors lead to an increase in phosphorylated Erk1/2 
in HeLa.  HeLa cells were incubated with the various signaling factors (amounts 
listed in Table 4-1) for one hour and then lysed.  Phosphorylated and total Erk1/2 
levels were visualized by Western blot. Phosphorylated Erk1/2 was found in 
nearly all conditions with elevated SAICAR levels, with the exception of VEGF. 





























Figure 4-3. Signaling factors lead to PKM2 nuclear localization.  HeLa cells 
were incubated with the various signaling factors (amounts listed in Table 4-1) for 
six hours and PKM2 localization was visualized by immunofluorescence.  Growth 
factors leading to SAICAR accumulation also lead to PKM2 nuclear localization; 
in all other conditions, PKM2 was excluded from the nucleus.     









































































Figure 4-4.  SAICAR and downstream metabolites accumulate upon 
signaling factor addition.  A) Schematic representation of SAICAR metabolism. 
PAICS (red) generates SAICAR, while ADSL (blue) cleaves SAICAR.  HeLa cells 
were incubated with signaling factors for one hour and metabolites were 
analyzed by LC-MS. B) Fold change relative to PBS control in upstream and 
downstream metabolites.  C) Heat map showing relative metabolite level change 
(red refers to upregulation; green refers to down regulation).
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This was true in all SAICAR accumulating conditions (including glucose 
depletion).  Additionally, our previously published data support that upstream 
activation is likely.  In adsl-kd cells, which over-accumulate SAICAR in normal 
conditions, produce additional SAICAR upon glucose starvation (5).  Further 
SAICAR accumulation would not be expected if downstream proteins were 
inhibited, as ADSL is knocked down by over 90% in this cell line.   These findings 
support the hypothesis that activation of upstream elements leads to SAICAR 
accumulation. 
To probe the question more directly, we next examined PAICS protein 
levels upon addition of signaling factors.  PAICS protein was elevated in all 
conditions leading to SAICAR accumulation, but not in conditions in which 
SAICAR levels remained the same (Figure 4-5A and B).   We also found that the 
amount of PAICS protein correlate linearly with cellular SAICAR concentration 
(Figure 4-5C).  In contrast, ADSL, the SAICAR cleavage enzyme, seems slightly 
decreased upon adding signaling factors, although this result is not limited to 
SAICAR accumulating conditions (Figure 4-5A). Furthermore, the PAICS protein 
level in glucose-depleted cells was elevated in an oscillatory manner in phase 
with SAICAR accumulation (data not shown).  To determine if the increase of 
PAICS was due to stabilization of the protein or from increased translation of the 
mRNA, the translation elongation inhibitor cycloheximide was added to cells pre-
incubated with the SAICAR stimulating growth factor EGF.  
























































































Figure 4-5. PAICS protein is elevated upon signaling factor addition.  A) 
HeLa cells were incubated with signaling factors for one hour. PAICS and ADSL 
protein levels were monitored by Western blot.  PAICS protein was elevated in 
conditions where SAICAR accumulates, while ADSL levels appeared to decrease 
regardless of condition, as compared to PBS.  B) PAICS protein was quantified 
from Western blots and normalized to GAPDH loading control.  Conditions that 
did not lead to SAICAR accumulation also had lower levels of PAICS protein 
overall. C) PAICS protein level is plotted against cellular SAICAR levels.  PAICS 
protein and SAICAR levels are positively correlated.
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PAICS protein was elevated for up to 4 hours with EGF addition; after 6 hours 
protein level reached baseline levels (Figure 4-6).  Cycloheximide increased 
PAICS protein levels after thirty min and maintained elevated levels for six hours 
(Figure 4-6).  Furthermore, cycloheximide alone elevates PAICS levels, indicating 
that PAICS and SAICAR may potentially act as general stress response 
elements (Figure 4-6).  These pieces of data together suggest SAICAR synthesis 
is stimulated upon signaling factor addition, potentially through the stabilization of 
the PAICS protein. 
As these results suggest that PAICS protein level should be important for 
cancer cell signaling and proliferation, we next searched available databases for 
PAICS expression level in various cancer types and tissues.  Our search 
revealed that PAICS is expressed in 100% of cancer tissues, as visualized by 
immunohistochemistry (Figure 4-7A).  Over 75% of samples were deemed to 
have high PAICS expression, while only 1.5% had low expression (Figure 4-7B).  
In contrast, high expression of the SAICAR cleavage enzyme ADSL does not 
appear correlated with cancer (Figure 4-7A).  Less than 10% of samples have 
high ADSL protein expression, while over 30% have little or no detectable ADSL 
(Figure 4-7B).  Additionally, in a published microarray study examining cancers 
with overexpressed c-Myc, the authors found that PAICS is overexpressed in 
95% of cancers tested by approximately two-fold or more, while ADSL 
expression is either unaltered or diminished.   
.   
















































Figure 4-6. PAICS protein is stabilized by the addition of cycloheximide 
(CHX) and EGF.  HeLa cells were incubated with 10 ng/mL EGF for one hour.  
CHX was added to the media for the noted amount of time, then cells were lysed, 
and PAICS protein level and GAPDH protein were measured by Western blot.  
EGF stabilized PAICS protein for up to 4 hours, while CHX stabilized PAICS 
protein after thirty minutes and for as long as 6 hours. 
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Figure 4-7.  PAICS protein is elevated in many cancer tissue types, while 
ADSL protein level is more variable.  The data in this figure were compiled 
from the Protein Atlas Database from immunohistochemistry staining of cancer 
tissue samples from a tissue database.  A) PAICS protein level (top panel) and 
ADLS (bottom panel) in various cancer tissue types denoted in the figure.  Data 
represented as a percentage of all tissue samples analyzed for protein presence.  
B) Percent of samples of all cancer cell tissues that have high, medium, low, or 
not detectable levels of either PAICS or ADSL protein. 
 
*Figure is on the next page.












































































































































Figure 4-7. PAICS protein is elevated in many cancer tissue types, while 
ADSL protein level is more variable.  *Figure legend is located on the previous 
page.
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DISCUSSION 
Cells must respond to their environment in order to regulate their growth 
and proliferation.  To do so, different external signals must be integrated to yield 
similar outcomes, as are those observed by growth factor addition.  Here, we 
show that many growth factors lead to an increase in the protein PAICS and the 
metabolite this protein generates, SAICAR.  The increase in cellular SAICAR 
promotes MAPK signaling, PKM2 protein kinase activity, and transcription of 
genes responsible for growth and proliferation.  The data suggest that SAICAR 
acts as a more general signal to promote cancer cell growth and proliferation.   
Cancer cells are less reliant on external growth factors for signaling, potentially 
due to SAICAR accumulation.  However, glucose-deprivation and cyclohexamide 
addition also lead to an increase in PAICS protein and SAICAR accumulation, 
indicating that SAICAR elevation may also reflect a response to stress 
conditions, not just growth factors.  As SAICAR activates PKM2 pyruvate kinase 
activity to promote energy generation in stress conditions, increased PAICS 
expression and thus increased cellular SAICAR would prove beneficial to cancer 
cells. Indeed, PAICS protein is expressed highly in many cancer types and 
tissues.  Further entangling the roles for SAICAR, the apoptosis factor TNF and 
the differentiation factor retinoic acid, which can be considered stress conditions, 
did not lead to an increase in either cellular SAICAR or PAICS protein, indicating 
that cells can discriminate between various signals and this response is only a 
suited for a subset of these signals.    
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The increase of cellular SAICAR and PAICS protein in stress conditions 
(glucose-deprivation and CHX treatment) may represent a cancer specific 
regulatory pathway that has not yet been identified.  Low glucose conditions are 
commonly found in tumor microenvironments, as well as hypoxia, but cancer 
cells are able to proliferate regardless (1, 2).  Interestingly, hypoxia has been 
shown to inhibit mRNA translation, similar to the CHX treatment (14).  To 
counteract the inhibitory signals upon both hypoxia and glucose deprivation, and 
to thrive in these environments, cancer cells may integrate these signals 
differently and promote growth and proliferation through SAICAR and PKM2.   
As of yet, the mechanism underlying PAICS stabilization and SAICAR 
accumulation is not clear, although this study represents a step forward in 
identifying conditions that lead to this outcome.  Interestingly, large proteomic 
studies have shown that PAICS protein is phosphorylated in a number of cancer 
cell lines at tyrosine 22 (16-19).  This site shows some homology to an Src-
kinase consensus sequence, providing some insight into a possible mechanism 
for protein stabilization (20).  Furthermore, a protein of a higher mass (or slower 
mobility) was observable when probing for PAICS, either due to non-specific 
interactions or indicating that a post-translational modification was present.  In 
either case, it remains clear that PAICS and cellular SAICAR concentration are 
important to cancer cell metabolism and proliferative signaling.    
The importance of the PAICS protein and SAICAR accumulation may not 
be limited to cancer cell biology, but could represent a more general response to 
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external stimuli in undifferentiated tissues.  Fetal and stem cells express the 
PKM2 isoform and readily utilize growth factors to trigger growth and 
proliferation.  Stimulation of de novo nucleotide biosynthesis through PAICS and 
the subsequent oscillation of SAICAR levels can promote both generation of 
important anabolic precursors and energy production through the allosteric 
activation of PKM2, to allow the cell to grow and divide when signaled to do so.  
The link between cellular metabolism and growth signaling would provide a 
developmental advantage, as cells would only proceed if the appropriate 
conditions were met. 
A full-scale study of both conditions that lead to SAICAR accumulation and 
cell types that have inducible SAICAR concentration must be explored to 
determine the overall role for both PAICS and SAICAR in cell biology.  
Furthermore, the PAICS protein may prove to be a viable therapeutic target, 
which could provide a blockade to the proliferative signaling due to SAICAR-
PKM2, while specifically targeting cancer cells while sparing adult differentiated 
cell types. 
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Materials and Methods 
Materials 
Analysis of cellular SAICAR levels and other metabolite levels were 
performed as previously described (6, 7).  In brief, the data was analyzed using 
Agilent MassHunter and all treatments were repeated in triplicate.  For the 
determination of SAICAR concentration, [13C4]-labeled SAICAR standard solution 
was mixed with the extracted metabolites, and the amount of SAICAR in cell 
extract was determined by comparing LC-MS peak areas of [12C]-SAICAR with 
that of [13C4]-labeled SAICAR.  Additionally, AICAR, AIR, CAIR, and fumarate 
peaks were integrated and normalized to the A260 of the corresponding sample.  
Each result is presented as a fold change of each metabolite in comparison to 




HeLa cells were maintained and grown in Dulbeccoʼs Modified Eagle 
Medium containing 4g/L glucose and 4 mM glutamine (DMEM) and 
supplemented with 10% fetal bovine serum (FBS), penicillin, and streptomycin. 
Cells were kept at 37°C, 5% carbon dioxide, and humid conditions.  For all 
experimental conditions, dialyzed FBS (Invitrogen) was added to DMEM in place 
of normal FBS.  Prior to the start of the experiment, cells were seeded to 25% 
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confluency and grown to 80% confluency.  Cells were incubated in dialyzed FBS 
containing DMEM for at least 24 hours. 
 
Signaling Factor Addition 
  Signaling factors were resuspended as suggested by the vendor, typically 
in phosphate buffered saline (PBS) supplemented with 0.5% BSA or in PBS 
alone.  HeLa cells were incubated in DMEM with dialyzed FBS for 24 hours 
before the experiment start.   Growth factors [EGF (10 ng/mL Sigma-Adlrich), 
BDNF (1000 ng/mL, Sigma-Aldrich), FGF (500 ng/mL, Invitrogen), GDNF (10 
ng/mL, Gibco), HGF (10 ng/mL Sigma-Aldrich), IGF (2 ng/mL, Gibco), NGF (1 
ng/mL), retinoic acid (300 ng/mL), TGF (0.2 ng/mL, Gibco), TNF (0.1 ng/mL, Cell 
Signaling Technology), or VEGF (1 ng/mL, Sigma-Aldrich)] were added to the 
media.  The amount of signaling factor added was the experimentally determined 
EC50 for cell proliferation, differentiation, or cell death (dependent on factor 
added) as provided by the literature of the vendor.  For cellular SAICAR 
concentration measurement, via LC-MS, PAICS protein level, ADSL protein level, 
or the phosphorylation of Erk1/2 proteins, cells were incubated with the growth 
factor for one hour in dialyzed FBS containing DMEM.  For phosphorylation of 
histones or PKM2 localization studies, HeLa cells were incubated with the 
signaling factors for six hours, and for cell proliferation measurement, incubation 
time with the various signaling factors was twenty-four hours.  Cell number was 
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counted using a Moxi-Z cell counter (n=3-5) after cells were trypsinized and 
diluted in PBS.  
 
Subcellular localization of PKM2 
Prior to the experiment, HeLa cells were grown on coverslips in a six-well 
dish in DMEM supplemented with dialyzed FBS.  Signaling factors or PBS were 
added to cells and incubated for six hours.  The coverslips were then washed 
thoroughly with PBS, fixed with 4% paraformaldehyde and permealized with 
0.01% Triton X-100.  Cells were blocked in 5% goat serum diluted in PBS for 1 
hour and stained with rabbit anti-PKM2 antibody (Sigma-Aldrich) in 5% goat 
serum (1:200 dilution) for forty-five minutes. Coverslips were then washed with 
PBS and incubated with DAPI, briefly.  After washing with PBS, TRITC-labeled 
goat ant-rabbit antibody (Sigma Aldrich) in PBS (1:400) was added to coverslips 
for two hours. Coverslips were mounted on slides and microscopic images were 
obtained using a Zeiss AxioVert 200 fluorescence microscope (Integrated 
Imaging Center, Johns Hopkins University, 40X optical zoom).  
 
Western Blot 
Cells were first washed in PBS and then lysed in ice-cold non-denaturing 
buffer (20 mM Tris HCl, pH 8, 137 mM NaCl, 1% NP-40, 2 mM EDTA) 
supplemented with 1 mM phenylmethylsulfonyl fluoride and 5 mM sodium 
fluoride.  Total protein concentration using the Pierce 660 kit (Thermo Scientific), 
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using bovine serum albumin as a standard (Cell Signaling Technology).  
Membranes were probed with primary antibody (rabbit anti-phospho-p42/p44, 
rabbit anti-p42/p44, rabbit anti-pT11-Histone H3, and rabbit anti-Histone H3 from 
Cell Signaling; rabbit anti-GAPDH, mouse anti-PAICS, mouse anti-ADSL, and 
mouse-anti-Myc from Sigma-Aldrich) overnight at 4°C.  Membranes were then 
probed with horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG or 
goat anti-mouse IgG secondary antibodies (Bio-Rad). HRP-conjugated 
secondary antibodies were then detected using a commercial 
chemiluminescence substrate kit (Pierce). Chemiluminescence images were 
acquired using a FluorChem M FM0455 imager.   
 
Cyclohexamide Addition 
HeLa cells were grown in high glucose DMEM supplemented with 10% 
dialyzed FBS and PS for 24 hours prior to experiment.  EGF (10 ng/mL) was 
added to each plate for one hour.  Cyclohexamide (0.1 mg/mL) was added to 
each plate for 0, 0.5, 1, 2, 4, or 6 hours.  Cells were then lysed with non-
denaturing lysis buffer and blotted for GAPDH and PAICS. 
 
Protein Atlas Data Analysis 
The Protein Atlas Database (proteinatlas.org) was utilized to analyze the 
expression of both PAICS and ADSL protein.  Data was compiled from in situ 
hybridization in cancer tissue samples was quantified and plotted by cancer type 
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or by expression pattern.  Cancer tissue data is represented as a percentage of 
the total number of samples denoted high, medium, low, or not detectable 
expression. Overall expression data is represented as the number of samples 
with high, medium, low, or not detectable levels.  Denoted levels of protein 
expression represent those determined by the Protein Atlas.
	   150	  
 
References: 
(1) Hanahan D, Weinberg, RA. (2011). Hallmarks of cancer: the next generation. 
Cell 144(5), 646. 
 
(2) Cooper GM. The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): 
Sinauer Associates; 2000. The Development and Causes of Cancer. 
 
(3) Mazurek S. (2011). Pyruvate kinase type M2: a key regulator of the metabolic 
budget system in tumor cells. Int J Biochem Cell Biol 43(7), 969. 
 
(4) Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R, 
Fleming M, Schreiber S, and Cantley L. (2008) The M2 splice isoform of pyruvate 
kinase is important for cancer metabolism and tumor growth. Nature 452, 230-
233. 
 
(5) Keller K, Tan I, and Lee YS. (2012) SAICAR stimulates pyruvate kinase 
isoform M2 and promotes cancer cell survival in glucose-limited conditions. 
Science 338, 1069-1072 
 
(6) Keller K, Doctor Z, Dwyer Z, and Lee YS. (2014) SAICAR Induces Protein 
Kinase Activity of PKM2 that is Necessary for Sustained Proliferative Signaling of 
Cancer Cells. Mol. Cell 53, 700-709 
 
(7) Batova A, Diccianni MB, Omura-Minamisawa M, Yu J, Carrera C, Bridgeman 
L, Kung F, Pullen J, Amylon, M, and Yu, A. (1999) Cancer Res 59, 1492-7. 
 
(8) Casey, P. J., and Lowenstein, J. M. (1987) Biochem Pharmacol 36, 705-9. 
 
(9) Tyagi A, and Cooney DA. (1980) Cancer Res 40, 4390-7. 
 
(11) Spiegel EK, Colman RF, Patterson D (2006). "Adenylosuccinate lyase  
deficiency". Mol. Genet. Metab. 89 (1–2): 19–31 
 
(12) Lee P, Colman RF (2007). "Expression, purification, and characterization of 
stable, recombinant human adenylosuccinate lyase". Protein Expr. Purif. 51 (2): 
227–34.   
 
(13) Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, 
Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Björling L, Ponten F. 
Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010 
28(12):1248-50. 
	   151	  
 
 
(14) Lui L, Cast T, Jones R, Keith B, Thompson C, Simon C (2006). Hypoxia-
Induced Energy Stress Regulates mRNA Translation and Cell Growth. Mol Cell 
21;4 521-531.  
 
(15) Uhlén M, Björling E, Agaton C, Szigyarto CA, Amini B, Andersen E, 
Andersson AC, Angelidou P, Asplund A, Asplund C, Berglund L, Bergström K, 
Brumer H, Cerjan D, Ekström M, Elobeid A, Eriksson C, Fagerberg L, Falk R, Fall 
J, Forsberg M, Björklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson 
M, Hedhammar M, Hercules G, Kampf C, Larsson K, Lindskog M, Lodewyckx W, 
Lund J, Lundeberg J, Magnusson K, Malm E, Nilsson P, Odling J, Oksvold P, 
Olsson I, Oster E, Ottosson J, Paavilainen L, Persson A, Rimini R, Rockberg J, 
Runeson M, Sivertsson A, Sköllermo A, Steen J, Stenvall M, Sterky F, Strömberg 
S, Sundberg M, Tegel H, Tourle S, Wahlund E, Waldén A, Wan J, Wernérus H, 
Westberg J, Wester K, Wrethagen U, Xu LL, Hober S, Pontén F. 
A human protein atlas for normal and cancer tissues based on antibody 
proteomics. Mol Cell Proteomics. 2005 4(12):1920-32. 
 
(16) Li J, Ning Y, Hedley W, Saunders B, Chen Y, Tindill N, Hannay T, 
Subramaniam S. (2002). The Molecule Pages database. Nature. 420 ,716-7. 
 
(17) Obenauer,J.C., Cantley,L.C., and Yaffe,M.B. (2003). Scansite 2.0: 
Proteome-wide prediction of cell signaling interactions using short sequence 
motifs. Nucleic Acids Res. 31,3635. 
 
(18) Protein Kinase Resource (PKR) http://pkr.sdsc.edu/html/index.shtml 
 
(19) Bateman A, Birney E, Cerruti L, Durbin R, Etwiller L, Eddy SR, Griffiths-
Jones S, Howe KL, Marshall M, Sonnhammer EL. (2002) The Pfam protein 
families database. Nucleic Acids Res. 30:276. 
 
(20) Songyang Z, Carraway K, Eck M, Harrison S, Feldman R, Mohammadi M, 
Schlessinger J, Hubbard S, Smith D, Eng C, Lorenzo M, Ponder B, Mayer B, and 
Cantley L. (1995) Catalytic specificity of protein-tyrosine kinases is critical for 














	   153	  
 
 For decades, it has been understood that cancer cells have an altered 
metabolism and also express a unique subset of proteins as compared to 
healthy, normal cells.  The metabolic hallmark of cancer cells is that these cells 
uptake more glucose, produce more lactate, are less reliant on oxygen, and often 
use alternative carbon sources to produce energy, such as glutamine.  
Additionally, a barrage of oncogenes and tumor suppressors have been 
identified, such as c-Myc, p53, and HIF1a, that contribute to the uncontrolled 
growth and proliferation observed in cancer cells.  However, there has been little 
focus on the interaction between metabolites and proteins in cancer types and 
tissues.  Furthermore, little research has focused on the implications of variable 
metabolism and a unique protein profile in other systems, such as the alteration 
made in cells during development and in the maintenance of the stem cell niche. 
In this dissertation, we identify and explore the interaction between a 
cellular metabolite SAICAR, which is elevated in cancer cells in stress conditions, 
and pyruvate kinase M2 (PKM2) that is highly expressed in a number of cancers.  
First, the discovery of the PKM2-SAICAR interaction indicates that there is an 
intimate relationship, at least for some scenarios, between cancer cell 
metabolism and the protein expression profile.  Additionally, we have found that 
the binding of SAICAR to PKM2 renders PKM2 an active protein kinase.  This is 
one of the first demonstrations that a simple allosteric interaction can lead to a 
change in protein function, rather than just protein activity.  The findings of this 
thesis are important both in the field of PKM2 regulation and cancer cell 
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metabolism, but also bring about important basic biological questions: are 
protein-metabolite interactions more ubiquitous than previously thought and if so, 
what are there functions?  Our research has brought forth the notion that there 
may be several hereto-unknown regulatory systems that further interconnect the 
pathways that have been well studied for so long. 
 
Summary of my contribution to the field 
Earlier in this dissertation, I have provided in depth discussions on the 
conclusions and relevance of our work. In this section, I will briefly summarize the 
findings of the preceding chapters and discuss the impact on both the field of 
cancer metabolism and general biology.  
 
SAICAR binds to PKM2 and promotes cancer cell survival in glucose limited 
conditions 
 Pyruvate kinase M2 is expressed in cancer cells, and like other pyruvate 
kinases, catalyzes the final step of glycolysis from phosphoenol pyruvate to 
pyruvate.  Surprisingly, PKM2 has a low intrinsic catalytic activity, as compared 
to other isoforms.  To explain this phenomenon, a model was generated that 
PKM2 acts as a glycolytic bottleneck in cancer cells, thus promoting anabolic 
processes and ultimately cell growth and proliferation.  Although this model was 
enticing, there were loopholes in the argument.  For instance, lactate production 
is drastically increased in cancer cells.  As lactate is generated from pyruvate, an 
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inactive pyruvate kinase would lead to a depletion of lactate, not an 
accumulation.  Additionally, without an active pyruvate kinase, energy would be 
rapidly depleted in low glucose conditions, which are commonly observed in a 
tumor microenvironment.  Thus, the bottleneck model is insufficient to describe 
the role of PKM2 in cancer cells. 
 PKM2 has other unique biochemical properties, including its ability to be 
regulated by cellular metabolites.  In the second chapter of this thesis, we sough 
to identify cellular metabolites that regulate PKM2 in a context-dependent 
manner.  We developed a technique to monitor protein-metabolite interactions by 
using low-temperature gel filtration and subsequent analysis by liquid 
chromatography-mass spectrometry.  Using this technique, we found that 
SAICAR, a de novo purine biosynthesis intermediate, binds to PKM2 in glucose-
limited conditions.  Subsequently, we showed that SAICAR levels increase in 
glucose-starved cancer cells to near millimolar levels.  SAICAR binds and 
activates PKM2, both in vitro and in vivo.  In cells lines with artificially altered 
SAICAR levels, we found that maintaining an inducible SAICAR concentration is 
necessary for the Warburg effect.  Finally, we found that increased cellular 
SAICAR protects cells from death in nutrient-limited conditions in a PKM2-
dependent manner.   
 The interaction between PKM2 and SAICAR shows evidence of cross talk 
between an energy generating pathway (glycolysis) and an energy-utilizing 
pathway (nucleotide biosynthesis).  During conditions of nutrient-limitation, cells 
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must tightly regulate energy production and cell division.  Our data suggests that 
PKM2 reflects the bridge point between these two competing pathways.  First, 
PKM2 serves as a bottleneck for the glycolytic pathway and allows for generation 
of glycolytic intermediates.  These metabolites can then be rerouted towards 
other anabolic pathways, including the pentose phosphate pathway, to generate 
more precursor molecules for growth and cell division.  As intermediates are 
funneled into anabolic pathways and energy is depleted, SAICAR levels 
increase.  SAICAR then can bind to PKM2, activating it, and lead to a metabolic 
flux shift towards energy generation.   This oscillatory mechanism can provide a 
cell fine tuned control when the external environment is changing, giving it an 
advantage.  Our data challenges the model that PKM2 is a stagnant protein and 
poses a more general model that PKM2 serves as a biological sensor for cancer 
cells.   
 However, the data we presented left several unanswered questions, some 
of which are touched upon in other parts of this dissertation.  First, the 
mechanisms by which a transient interaction between PKM2 and SAICAR leads 
to long-term cell survival remained unclear.  Furthermore, the mechanism leading 
to SAICAR accumulation was completely unexplored in this section.  This paper 
is not the only demonstration of SAICAR accumulation in cells, but it is the first to 
show that it is context specific and not due to a mutation in the nucleotide 
biosynthesis pathway. Finally, although we tested a few cancer cell lines, the 
breadth of SAICAR accumulation among cancer cell types and tissues was not 
	   157	  
tested, nor among different cellular conditions.  This was addressed to a 
moderate degree in chapter four of this thesis.   
Beyond the elucidation of PKM2ʼs role in cancer metabolism, the 
technique generated in this work provides a large step forward in the 
identification of protein-metabolite interactions.  As a consequence of our work, 
we have noted that there are likely hundreds of unknown interactions between 
proteins and metabolites.  This technique can be adapted to any protein that can 
be recombinantly expressed and purified in reasonable quantities.  As an 
example of the versatility of the technique, an unpublished screen was attempted 
in our lab on over 80 related proteins across all three domains.  Metabolite 
binding analysis revealed many previously unknown interactions, as well as 
confirmation of known interactions.  The utilization of this technique can open the 
door for new fields to emerge in general biology and protein biochemistry. 
 
SAICAR renders PKM2 an active protein kinase 
 During the time that we identified SAICAR as an allosteric activator of 
PKM2, new research emerged that PKM2 had an additional role as a protein 
kinase.  At this time, the known substrates for PKM2 were limited to histone H3 
and stat3.  Additionally, several research groups reported that recombinantly 
expressed PKM2 was unable to phosphorylate these protein substrates in vitro; 
only protein purified from the nucleus of cancer cells was able to act as a protein 
kinase.  At this time, the work was controversial, due to the slow catalysis and 
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the lack of robustness in the system.  It was possible that the result was an 
artifact of nuclear purification or that the reaction was in fact not enzyme 
catalyzed.  Furthermore, all published reactions were performed in enzyme 
excess conditions, so it was unclear whether PKM2 could perform multiple-
turnovers.  
 Due to our discovery of the PKM2-SAICAR interaction, and other data 
hinting that PKM2 quaternary structure was important to its function (pyruvate vs. 
protein kinase activity), we speculated that a metabolite binding event may alter 
PKM2 intrinsic function.  In chapter three of this dissertation, we identify SAICAR 
as an inducer of PKM2 protein kinase activity.  Additionally, we identified EGF as 
another inducer of SAICAR accumulation, indicating that SAICAR may act as a 
more general messenger than we previously envisioned.  Using a proteomic 
approach, we expanded the number of PKM2 substrates from two (histone H3 
and stat3) to over 100 cellular proteins.  We confirmed several hits from the 
screen, and also rigorously tested the interaction between PKM2-SAICAR and 
the MAPK cascade component Erk1.  We found that PKM2 appears to be an 
integral member of MAPK signaling, at least in the context of cancer cells.  
Finally, we found that Erk1/2 and PKM2-SAICAR participate in a positive 
feedback loop, sensitizing each other through phosphorylation for prolonged 
signaling, even in the absence of stimuli. 
 The MAPK cascade has been extensively studied for decades and most of 
the components are well defined, thus it remains surprising that PKM2 was not 
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identified as a target of this cascade until recently.  Despite the surprise, this data 
suggests the exciting possibility that potentially there are a number of members 
within this and other well described pathways that have not yet been discovered.   
Furthermore, the vast number of PKM2-SAICAR substrates indicates that PKM2 
is a promiscuous protein kinase, and supports our previous assertion that PKM2 
may act as a central regulator of cell state.   Of these substrates, we found that a 
number are protein kinases themselves.  Thus, in cancer cells, PKM2 may serve 
to trigger or expand signaling cascades upon external stimuli and ultimately 
promote cell proliferation and survival.  One enticing theory is that the expression 
of PKM2 allows cancer cells to become less dependent on growth factors, a 
commonly observed phenomenon in cancer.  If PKM2 becomes activated as a 
protein kinase, it can then go on to turn on many proteins in other pathways that 
are not part of the typical response for that particular stimulus.  For instance, we 
found that c-Myc expression is induced upon glucose starvation.  It is unlikely 
that normal cells would express a proliferation factor when starved of glucose; it 
may be that the activation of PKM2 in this circumstance activates expression of 
such factors inappropriately, allowing for uncontrolled growth while other cells 
remain quiescent.  
 From a biochemical standpoint, the findings of this chapter are exciting.  
The identification of a ligand inducing a new function in a protein is unique and 
novel, and we are unaware of another scenario in which this occurs.  Current 
views of ligand-protein interactions typically focus on the ability of a ligand to 
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initiate a gross or minor structural change in a protein that makes the protein 
more or less likely to perform its enzymatic task.  However, our work 
demonstrates that a ligand-binding event can initiate an entirely new function for 
a protein.  For clarification, we are not claiming that PKM2 can miraculously 
perform another type of reaction (i.e. phosphorylation induced to acetylation), but 
we are showing a mechanism by which PKM2 is now able to recognize an 
entirely new set of substrates that are not similar to the original substrate (ADP).    
 Although the data in this chapter describes how the transient PKM2-
SAICAR interaction leads to long-term survival of cancer cells, it brings up an 
important and seemingly contradictory element: SAICAR accumulation occurs 
both in glucose starvation and EGF addition.  This is an intriguing path to study; 
two external stimuli that are not usually linked lead to the same output.  The 
mechanism leading to SAICAR accumulation is thus critical to our understanding 
of the general role of SAICAR in cancer cells and potentially other cell systems.  
Furthermore, the identification of over 100 substrates leaves 100 potential 
projects for future scientists.  Each substrate may have a unique story with a 
distinct set of inputs or activation of PKM2 may lead to phosphorylation of all 100 
proteins in a mesh of signaling cascades.  In either case, there is much to be 
explored and discovered. 
 
PAICS protein level may be a readout for and also responsible for SAICAR 
accumulation 
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 In chapter four of this dissertation, the mechanism of SAICAR 
accumulation is explored.  Due to several pieces of data, we focused on the 
SAICAR synthetase, PAICS, as a likely candidate for regulation.  We noticed that 
PAICS protein level was elevated in phase with SAICAR accumulation in glucose 
starved cancer cells.  Additionally, we found that addition of EGF, another 
SAICAR accumulating condition, lead to an increase in PAICS protein.  We then 
tested the breadth of SAICAR accumulation in response to external stimuli and 
found that many growth factors lead to an increase in SAICAR and also an 
increase in PAICS protein.  Thus, we believe that PAICS protein level may be a 
reasonable read out for SAICAR accumulation in cancer cells. 
 In nearly every case where an elevated PAICS protein level (and SAICAR 
accumulation) was detected, all the downstream elements of PKM2 activation 
were observed, including Erk1/2 phosphorylation, histone H3 phosphorylation, c-
Myc expression, and PKM2 nuclear localization.  Furthermore, the SAICAR 
cleavage enzyme ADSL did not show the same dependence on condition, 
indicating that inhibition of ADSL is most likely not the mechanism of action.  
Interestingly, PAICS protein was also stabilized by the addition of cycloheximide, 
a translation inhibitor.  As of yet, this data is not yet explained, although it points 
to SAICAR accumulation as a cellular sensor of stress conditions.   Finally, we 
found that PAICS protein appears to be highly expressed in nearly all cancer cell 
types and tissues, while ADSL appears more variable.  This indicates that PAICS 
protein is likely important to cancer cell biology, and that likely this is due to 
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SAICAR, rather than activation of nucleotide biosynthesis (as both ADSL and 
PAICS protein would be expected to be upregulated). 
 Although this data offers a start in the analysis of SAICAR accumulation, it 
is far from complete.  A more thorough analysis of both the conditions leading to 
SAICAR accumulation and cancer cell types and tissues must be investigated.  
Additionally, there is basically no literature on the regulation of PAICS, beyond 
some very basic kinetics studies.  It is likely that PAICS is also a cellular sensor 
for external stimuli, in particular, in stress conditions.  PAICS contains a Src 
homology domain and also appears to be stabilized upon certain conditions.  It is 
not unreasonable to speculate that potentially PAICS is regulated through Src 
phosphorylation, which stabilizes the protein.  However, much is still unknown 




From the data in this thesis, a more general biological question arises.  
PKM2 is not just a cancer specific protein; it is also expressed in fetal and stem 
cells.  Fetal and stem cells often rely heavily on de novo nucleotide biosynthesis, 
in which SAICAR is a key component.  Thus, is the PKM2-SAICAR interaction 
specific to cancer or is it a phenomenon derived from development?  This 
question remains to be answered, but the idea brings about exciting possibilities.  
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SAICAR could be a metabolite important in development, or even more broadly in 
stem cell maintenance.   
Regardless of the outcome, the results of this thesis provide solid 
groundwork for those interested in perusing basic biological and biochemical 
questions about proteins and the ligands that modulate their activity.   
 
 





COMPREHENSIVE SCREEN OF ADSL ACTIVATORS AND INHIBITORS 
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INTRODUCTION 
 Cancer cells often alter their metabolic properties to proliferate and survive 
in stress conditions, commonly found in a tumor microenvironment.  Often, they 
utilize de novo synthesis in lieu of salvage pathways to generate nucleotides, 
making the involved enzymes and metabolites viable therapeutic targets (Tyagi 
et al. 1980, Casey et al. 1987).  Our lab identified SAICAR, a de novo purine 
nucleotide biosynthesis intermediate, as a metabolite that accumulates in 
nutrient-limited conditions and activates pyruvate kinase M2 (PKM2, Keller et al. 
2012).   SAICAR is necessary for cancer cell growth and survival in glucose 
deprived cancer cells and additionally is necessary for proliferative signaling 
upon epidermal growth factor (EGF) addition (Keller et al. 2014).  
SAICAR is generated by the enzyme PAICS (also known as SAICAR 
synthetase) and is cleaved by ADSL. PAICS catalyzes two sequential steps in 
the purine biosynthesis pathway (Batava et al. 1999): 
(1) AIR5 + CO2 à = CAIR6 
(2) CAIR + L-aspartate + ATP à SAICAR + ADP + Pi 
ADSL also catalyzes two reactions, however these are nonsequential (Lee et al. 
2007): 
 (3) SAICAR à AICAR7 + fumarate 
 (4) Adenylosuccinate8 à AMP + fumarate   
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5	  5ʼ-phosphoribosyl-5-aminoimidazole = AIR  
6	  5ʼ-phosphoribosyl-4-carboxy-5-aminoimidazole = CAIR	  
7	  5-­‐aminoimidazole-­‐4-­‐carboxamide	  ribotide	  =	  AICAR	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 Currently, not much is known about the regulation of either enzyme.  
 Beyond acting as the SAICAR cleavage enzyme, ADSL is also thought to 
control levels of AMP and fumarate in cells (Lee et al. 2007).  Additionally, 
deficiency of ADSL, which is a rare autosomal disease, leads to psychomotor 
defects such as mental retardation, and in extreme cases, can lead to early 
mortality (Spiegel et al. 2006).  Due to the importance of ADSL as a regulatory 
enzyme in normal cells, cancer cells, and in developmental disorders, we sought 
to identify compounds that both inhibit and activate ADSL.  We identified several 
compounds and sought to confirm a candidate.  However, of the candidates 
screened, inhibition appeared to be the result of non-specific interactions.  Thus, 
the findings of this study are inconclusive. 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
8	  Adenylosuccinate	  is	  also	  denoted	  succinyladenosine	  monophosphate	  or	  SAMP	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RESULTS AND DISCUSSION 
 To identify compounds that regulate ADSL activity, we performed a screen 
using the library of pharmacological active compounds (LOPAC), which contains 
1280 different drugs.  We monitored the degradation of adenylosuccinate to AMP 
spectroscopically.  Through this screen, we identified several compounds that 
either activate or inhibit ADSL activity (Figure A1-1).  We chose one subgroup of 
compounds and individually tested their effect on ADSL activity.  For ease, 
compounds are named numerically and the structures are noted (Figure A1-2).  
Compound 1 was an initial hit from the LOPAC screen and when tested, it 
inhibited ADSL activity significantly with an IC50 = 0.75 ± 2 mM (Figure A1-3A).  
Further testing revealed that compound 1 competitively inhibited ADSL activity 
(Figure A1-3B).   Additionally, we tested the effect of compound 1 on cell 
proliferation, as ADSL inhibition leads to an increase in cellular SAICAR.  We 
found that compound 1 increased cell proliferation in a concentration dependent 
manner (Figure A1-4). 
 We also tested compounds that were structurally related to compound 1.  
We found that all compounds tested inhibited ADSL activity, regardless of 
alteration made to the base molecule (Figure A1-5).  Analine, compound 1, 
compound 2, compound 3, and compound 4 inhibited ADSL with an IC50 of 1 
mM, 0.75 mM, 2.5 mM, 1.25 mM, and 2.5 mM (Figure A1-5).  These data 
suggest that the observed inhibition of ADSL, at least in this class of molecules, 
is likely non-specific.   































Figure A1-1. Screen of compounds that regulate ADSL activity.  ADSL was 
mixed with each compound from the Library of Pharmalogically Active 
Compounds (LOPAC).  Activity was determined by monitoring the change in the 
absorbance at 280 nm over one hour.   
 























Figure A1-2.  Compounds tested for regulation of ADSL activity based on 
hits from the LOPAC screen.  The base molecule is located in the top of the 
figure.  Each compound tested has a different “R” group, which is represented in 
the bottom four panels.  Aniline was also tested as a potential regulator of ADSL 
activity. 
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Figure A1-3.  Compound 1 is a competitive inhibitor of ADSL activity. A) 
ADSL activity was monitored at two concentrations in the presence of compound 
1.  Compound 1 inhibits ADSL with an IC50 of ~1 mM. B) The substrate 
adenylosuccinate (sAMP) concentration was titrated and the activity of ADSL was 
monitored in the presence of 0, 0.25, 0.5, 1, 5, or 10 mM compound 1.   
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Figure A1-4.  Compound 1 promotes cell proliferation of cancer cells.  
When compound 1 was added to HeLa or H1299 cells, cell number increased in 
a concentration dependent matter.  
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Figure A1-5. The effect of various compounds on ADSL activity.  The 
structures of the compounds tested are listed in figure A1-2.  Activity was 
measured by monitoring the absorbance at 280 nm due to the transition of 
adenylosuccinate to AMP.  All compounds tested inhibit ADSL activity, with 
different potencies.  Each compound tested is shown on individual plots and for 
comparative purposes, plotted together.  
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MATERIALS AND METHODS 
Compounds 
Young-Sam Lee generated compounds 1-4 synthetically. Anline was 
purchased from Sigma-Aldrich. 
 
ADSL Purification 
 Cell harboring the ADSL plasmid (Addgene) were grown in 1L LB 
supplemented with kanamycin and chloroamphenicol until the OD600 reached 
between 1-2.  Cells were induced with 0.5 mM IPTG for 18 hours at 25°C.  After 
induction, cells were centrifuged at room temperature at 6000xg for 15 minutes.  
The cell pellet was resuspended in 20 mM HEPES pH 7.4, 500 mM NaCl, 10% 
glycerol, 5 mM imidazole, and 2 mM DTT, sonicated, and centrifuged at 15000 
RPM at room temperature.  ADSL was purified with an IMAC resin and a linear 
gradient of imidazole.  Fractions containing ADSL protein were pooled and 
assessed with Coomassie for purity.  ADSL was dialyzed into 20 mM HEPES pH 
7.4, 150 mM NaCl, 10% glycerol, and 2 mM DTT.  Of note, ADSL is temperature 
sensitive.  All purification steps must be completed at room temperature. 
 
ADSL Compound Screen 
The Library of Pharmacologically Active Compounds (LOPAC)-1280 was 
acquired through the Johns Hopkins Medical Institute. Recombinant ADSL (1 uM) 
was mixed with 10 uM compound resuspended in DMSO and 20 uM 
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adenylosuccinate in buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 1 mM DTT, 1 
mM EDTA).  The absorbance at 280 nm was monitored for one hour using the 
Tecan Infinity.   
 
ADSL Activity Assays 
Recombinant ADSL (0.5-1 uM) was mixed with 0-50 uM compound 
resuspended in water and 0-60 uM adenylosuccinate in buffer (20 mM HEPES 
pH 7.4, 150 mM NaCl, 1 mM DTT, 1 mM EDTA).  The absorbance at 280 nm 
was monitored for one hour using the Tecan Infinity.   
 
Cell Culture 
 HeLa and H1299 cells were maintained in Dulbeccoʼs Modified Eagle 
Medium (DMEM) supplemented with FBS and pencillin/streptomycin at 5% CO2, 
37°C, and 80% humidity.   
 
Cell Proliferation 
 HeLa or H1299 cells were plated in a six-well dish, 2.5X10E5 cells per 
well.  Cells were incubated in Dulbeccoʼs Modified Eagle Medium (DMEM) 
supplemented with dialyzed FBS and pencillin/streptomycin for 24 hours.  
Compound 1 (resuspended in DMSO) was added to each well and incubated for 
24 hours.  Cells were trypsinized and counted using a Moxi Z counter.   
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INTRODUCTION 
Cancer cells undergo a metabolic reprogramming event called the 
Warburg effect (Hanahan et al 2011).  The Warburg effect is characterized by an 
increase in glucose uptake and oxygen-independent lactate fermentation.   
Several proteins have been implicated as important in this metabolic 
reprogramming, including pyruvate kinase M2 (PKM2).  Recently, we identified 
that the cellular metabolite SAICAR, a nucleotide biosynthesis intermediate, 
accumulates upon glucose deprivation in cancer cells (Keller et al. 2012).  We 
also found that SAICAR activates PKM2, and may help cells to balance energy 
production when the anabolic demand is overwhelming (Keller et al. 2012). To 
test the effect of SAICAR on different cellular processes, cell lines were created 
that knocked down the PAICS, the SAICAR synthetase, or ADSL, the SAICAR 
cleavage enzyme.  The resultant cells had artificially altered SAICAR levels: 
constitutively elevated (adsl-kd) or depleted (paics-kd), regardless of glucose 
conditions (Keller et al. 2012). We found that cancer cells with non-inducible 
SAICAR levels (paics-kd) have decreased glucose consumption in glucose-
limited conditions. Our findings indicate that SAICAR may affect glucose uptake 
in cancer cells, either directly or indirectly.  
Glucose transporter 1, or GLUT1, facilitates glucose transport across the 
plasma membrane of cells and is thought to be responsible for the basal rate of 
glucose uptake (Mueckler et al. 1985).  GLUT1, also known as solute carrier 
family 2 member 1 (SLCA1), is a transmembrane protein; however it is constantly 
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recycled between the plasma membrane and vesicles within the cytoplasm, 
depending on the needs of the cell (Olson et al. 2008). In glucose-limited 
conditions, GLUT1 is recruited to the plasma membrane to optimize the uptake of 
glucose, by facilitating diffusion through the membrane at a rate over 50,000 
times greater than uncatalyzed glucose diffusion (Nelson et al. 2008).  Thus, 
GLUT1 is a highly relevant protein in maintaining homeostasis within the cell in 
rapidly changing environments. 
Although GLUT1 is expressed in nearly every tissue of the human body, 
the expression is the most prevalent in the placenta, fetal tissues, and other 
tissues with high turnover rates, such as skin and lung (Gen Bank, Human 
Protein Atlas, Uhen et al. 2008).  Additionally, GLUT1 is highly expressed in a 
number of cancer types and is currently classified as a potential cancer 
biomarker (Human Protein Atlas, Uhen et al. 2008).  Furthermore, high 
expression of GLUT1 is associated with pancreatic carcinogenesis, poor 
prognosis of breast and oral squamous cell cancers, and hepatocellular 
carcinoma (Agmann et al. 2009, Eckert et. al 2008, Pizzi et al. 2009).  
As cellular SAICAR appears required for increased glucose uptake in 
nutrient-limited conditions, we hypothesized that SAICAR may influence GLUT1 
localization.  Here, we report that the GLUT1 expression is increased in cells with 
high levels of SAICAR, while appearing diminished in cells with non-inducible 
SAICAR (paics-kd).  GLUT1 localization appears altered in cells with non-
inducible SAICAR, although in an unexpected manner.  We found that GLUT1 
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primarily localizes to the nucleus in paics-kd cells.  However, we also found that 
cells with a disrupted PKM2-SAICAR interaction exhibited exclusion of GLUT1 
from the nucleus.  Finally, we determined that PKM2 and Glut1 interact either 
directly or indirectly in vivo.  These findings represent the first instance of an 
interaction between GLUT1 localization and PKM2, although the overall 
mechanism or importance of this interaction remains unclear. 
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RESULTS AND DISCUSSION 
 To establish the localization of Glut1 protein in HeLa cells and those with 
altered cellular SAICAR levels, we monitored Glut1 in cells treated with no 
glucose media over a short time course.  Unexpectedly, we found that Glut1 
primarily localized to the nucleus prior to glucose starvation.  Despite the 
surprise, the result was very reproducible.  After glucose starvation, Glut1 was 
found in the cytoplasm and noticeably in punctae within the cell (Figure A2-1).   In 
cells with high levels of SAICAR, Glut1 protein appeared elevated in all 
conditions tested (Figure A2-2).  Additionally, Glut1 was found throughout the 
cell, regardless of condition, although glucose starvation lead to more 
pronounced punctae (Figure A2-2).  In contrast, cells with non-inducible cellular 
SAICAR showed decreased Glut1 expression (Figure A2-3).  After starving cells 
of glucose over time, Glut1 expression rose and then fell, to nearly imperceptible 
levels (Figure A2-3).  Glut1 also appeared localized primarily to the region of 
membrane making contact with a nearby cell.  After glucose starvation, the 
protein appeared to enter the cell cytoplasm (Figure A2-3). 
 To further establish a role of SAICAR in Glut1 localization, we utilized a 
cell line in which the SAICAR synthetase PAICS was overexpressed (CMV-
PAICS).  Glut1 was evenly distributed throughout the cell (Figure A2-4A).  After 
thirty minutes of glucose starvation, Glut1 retained localization throughout the cell 
and appeared to be present in large punctae, possibly endosomes.  As PKM2 is 
activated by SAICAR and is important for the Warburg effect in cancer cells, we 
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wanted to test the possibility that PKM2 is involved in Glut1 localization.  For this 
purpose, we utilized a cell line where the endogenous copy of PKM2 has been 
replaced by the SAICAR-insensitive mutant, PKM2 Q393K, in HeLa cells.  
Interestingly, we found that Glut1 was robustly excluded from the nucleus 
regardless of condition (Figure A2-4B).  These data suggest that SAICAR 
influences Glut1 trafficking either directly or indirectly, and potentially through 
PKM2. 
 Due to the apparent change in expression found in the 
immunofluorescence experiments, we next confirmed these results using 
Western blots.  Extracts of HeLa cells, adsl-kd, and paics-kd cells, before and 
after glucose starvation for thirty minutes, were tested for Glut1 protein level.  In 
accordance with the immunofluorescence data, Glut1 protein was elevated in 
adsl-kd cells prior to glucose starvation, while it became elevated in all cell types 
after glucose withdrawal (Figure A2-5A).  However, this was less pronounced in 
CMV-PAICS cells (Figure A2-5B).  Finally, to determine if Glut1 and PKM2 
interact, we performed a co-IP on cells exposed to high or no glucose.   We 
found that PKM2 and Glut1 interact upon glucose starvation (Figure A2-5C). 
 This study presents a novel finding that SAICAR-PKM2 influences Glut1 
localization.  The interaction between SAICAR, PKM2, and Glut1 may provide 
insight into the mechanism by which cancer cells have altered glucose uptake 
and other metabolic abnormalities.
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Figure A2-1.  Glut1 localization changes upon glucose starvation in HeLa 
cells.  A) HeLa cells were subjected to treatment in no glucose media for 0, 0.5, 
4, or 8 hours and Glut1 localization was monitored by immunofluorescence.  Prior 
to glucose starvation, Glut1 localized primarily to the nucleus.  Upon starvation, 
Glut1 was more evenly spread throughout the cell and also became punctate.   
The images were taken at 40X.  B) Glut1 localization was monitored in HeLa 
cells after 0 and 0.5 hours of glucose starvation, at 63X. 
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Figure A2-2.  Glut1 localization is altered in SAICAR-accumulating (adsl-kd) 
HeLa cells.  A) Adsl-kd cells were starved of glucose for 0, 0.5, 4, or 8 hours and 
Glut1 localization was monitored by immunofluorescence.  Regardless of glucose 
treatment, Glut1 localized throughout the cell, although large punctae were 
noticeable.   The images were taken at 40X.  B) Glut1 localization was monitored 
in adsl-kd cells after 0 and 0.5 hours of glucose starvation, at 63X. 
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Figure A2-3.  Glut1 localization and expression appears altered in HeLa 
cells with non-inducible SAICAR levels (paics-kd).  A) Paics-kd cells were 
starved of glucose for 0, 0.5, 4, or 8 hours and Glut1 localization was monitored.  
Prior to glucose starvation, paics-kd cells appeared to have lower overall levels of 
Glut1 and Glut1 appeared localized to cell-cell contacts.  After starvation, Glut1 
levels increase and then decrease, while the protein itself became internalized.  -
The images were taken at 40X.  B) Glut1 localization was monitored in adsl-kd 
cells after 0 and 0.5 hours of glucose starvation, at 63X. 
	   185	  
HeLa PKM2 Q393K HeLa CMV-PAICS





Figure A2-4.  Glut1 localization and expression appears altered in HeLa 
cells with the SAICAR-PKM2 interaction disrupted or increased SAICAR.   
HeLa cells transfected with a SAICAR-insensitive PKM2 (Q393K) or an 
overexpression vector of PAICS, the SAICAR synthetase, were starved of 
glucose for 0 or 0.5 hours.  A) PKM2 Q393K cells showed exclusion of Glut1 
from the nucleus, especially after glucose starvation.  B) CMV-PAICS cells show 
Glut1 protein spread throughout the cell, which becomes localized more towards 
the plasma membrane upon glucose starvation.  
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Figure A2-5.  Glut1 expression is increased upon glucose starvation and interacts 
with PKM2.  A) Glut1 levels were measured in HeLa, adsl-kd, and paics-kd cells 
that were incubated either in high glucose or no glucose media for thirty minutes.  
B) Glut1 levels were measured in HeLa or CMV-PAICS cells that were incubated 
either in high glucose or no glucose media for thirty minutes. C) HeLa cells were 
lysed after treatment in high glucose (lane 1) or no glucose (lane 2) media.  
PKM2 was immunoprecipitated and the blot was probed for Glut1 protein.  Glut1 
co-immunoprecipitated with PKM2 in no glucose conditions.  
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MATERIALS AND METHODS 
Cell Culture 
 HeLa cells and their derivatives were maintained in Dulbeccoʼs Modified 
Eagle Medium supplemented with 10% fetal bovine serum (FBS), penicillin, and 
streptomycin.  Cells were incubated at 37°C, 5% CO2, and 85% humidity.  In 
glucose starvation assays, cells were incubated in DMEM with dialyzed FBS for 
at least 8 hours prior to the experiment and during the experiment. 
 
Glut1 Localization via Immunofluorescence 
HeLa cells were grown in 6-well dishes with coverslips.  After treatment 
with high glucose or no glucose media for 0, 0.5, 4, or 8 hours, cells were 
washed with PBS, fixed with 4% paraformaldehyde, and permeabilized with 
0.01% Triton X-100 in PBS.  Cells were then incubated in 5% goat serum in PBS 
for 1 hour and stained with mouse anti-Glut1 antibody (1:100, Cell Signaling 
Technologies) for two hours.  Coverslips were washed with PBS, incubated with 
DAPI, and then with a TRITC-conjugated secondary antibody (1:400, Sigma). 
Microscopic images were obtained using a Zeiss AxioVert 200 fluorescence 
microscope (Integrated Imaging Center, JHU, 40 or 63x optical zoom).  
 
Western Blot  
HeLa cells were lysed in ice-cold non-denaturing buffer (20 mM Tris HCl, 
pH 8, 137 mM NaCl, 1% NP-40, 2 mM EDTA) supplemented with 1 mM 
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phenylmethylsulfonyl fluoride and 5 mM sodium fluoride, and protein 
concentration using a Pierce 660 kit (Thermo Scientific).  SDS-PAGE gels were 
run with 10 ug of protein.  Membranes were probed with primary antibody (mouse 
anti-Glut1 or rabbit anti-GAPDH) overnight at 4oC diluted in 5% BSA.  
Membranes were probed with horseradish peroxidase (HRP) conjugated goat 
anti-rabbit IgG or goat anti-mouse IgG secondary antibodies (Bio-Rad). HRP-
conjugated secondary antibodies were then detected using a commercial 
chemiluminescence substrate kit (Pierce). Chemiluminescence images were 
acquired using a FluorChem M FM0455 imager.   
 
Co-Immunoprecipitation  
 HeLa cells were lysed in ice-cold non-denaturing buffer (20 mM Tris HCl, 
pH 8, 137 mM NaCl, 1% NP-40, 2 mM EDTA) supplemented with 1 mM 
phenylmethylsulfonyl fluoride and 5 mM sodium fluoride. Cell lysates (500 ug) 
were mixed with rabbit anti-PKM2 (1:100, Sigma) overnight at 4oC. Cell lysates 
were mixed with magnetic Protein A/G beads (Pierce) for 1 hour at room 
temperature.  Beads were cleared, washed several times in buffer, and protein 
was eluted of beads using SDS loading dye at 95oC.  A western blot was then 
performed.
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PKM2 IS STIMULATED BY AN UNKNOWN COMPOUND IN YEAST EXTRACTS 
 




 Allosteric regulation of enzymes is a major mechanism by which cells can 
respond to their environment.   Pyruvate kinase M2 (PKM2) is a glycolytic 
enzyme responsible for catalyzing the reaction from phosphoenol pyruvate (PEP) 
and ADP to pyruvate and ATP.  Regulators of PKM2 have been well 
characterized and are known to both activate and inhibit pyruvate kinase activity.  
PKM2 is activated by the upstream glycolytic intermediate fructose 1,6-
bisphosphate (FBP), by lowering the Km for its substrate PEP by stabilizing the 
tetrameric active form (Kung at al. 2012).  Serine is also an activator of PKM2.  
Additionally, our lab identified SAICAR, a de novo purine biosynthesis 
intermediate, as an activator of PKM2 (Keller et al. 2012).  Thyroid hormone (T3), 
alternatively, is an inhibitor of PKM2 and acts by disrupting the quaternary 
structure and promoting formation of the inactive monomer (Ashizama et al. 
1991).  Peptide aptamers also inhibit PKM2, leading to dimerization of the protein 
and decreased activity (Spoden at al. 2009). PKM2 has been shown to be 
important for cancer cell proliferation and survival.  Thus, identifying compounds 
that bind and regulate PKM2 activity in vivo is ideal for drug development. 
 In this study, we report that a metabolite in yeast activates PKM2 pyruvate 
kinase activity by lowering its Km for substrate and also increasing the catalytic 
efficiency.  Through several biochemical tests, we were able to partially purify this 
compound and are awaiting confirmation of its identity.   
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RESULTS AND DISCUSSION 
 To identify PKM2 regulating compounds, Saccharomyces cerevisiae cells 
were grown in high and low glucose conditions and cellular metabolites were 
extracted.  PKM2, Cdc19, and Pyk2 (yeast homologs of pyruvate kinase) activity 
was tested in the presence and absence of yeast cell extracts.  We found that 
yeast cell extract activated PKM2, but not Cdc19 or Pyk2, in a glucose-
dependent manner (Figure A3-1A).  The effect of high glucose yeast extract on 
PKM2 activity was tested (Figure A3-1B).  Also, the effect of the yeast extract on 
PEP binding to PKM2 was also tested (Figure A3-1C).  A Lineweaver-Burke plot 
revealed that the binding affinity of PEP to PKM2 was lowered from 80 mM to 3.5 
mM PEP and the kcat was increased from 0.07 to 0.49 uM/sec (Figure A3-1D-E).  
These data suggest that the PKM2 stimulating factor (P2SF) is a previously 
undiscovered metabolite, as no known stimulator increases the kcat of PKM2. 
 To further characterize P2SF, we performed a battery of biochemical 
assays.   First, we separated P2SF using a size exclusion centrifugal filter.  The 
metabolite that activated PKM2 was less than 3 kDa (data not shown).  The 
P2SF was rotary evaporated and resuspended in water, and the activating effect 
of PKM2 was confirmed using resuspended lysate, indicating that the compound 
is non-volatile and water-soluble.  Next, we examined the spectrum of the P2SF 
in the presence or absence of 0.02% formic acid.  P2SF absorbs at 202 nm; 
formic acid shifts the absorbance maximum to 215 nm.  Next, we ran the P2SF 
over a coarse anion exchange column and each fraction was added to PKM2 and 
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the effect on its activity was measured (Figure A3-2A).  P2SF did not bind to the 
column, indicating that is not strongly ionic.  Then, P2SF was run over a coarse 
cation exchange column and tested against PKM2 activity (Figure A3-2B).  
Again, P2SF did not bind the column strongly, indicating that the factor is weakly 
cationic (Figure A3-2B).   
Next, we subjected the P2SF to a reverse phase column and measured 
the effect of each fraction on PKM2 activity (Figure A3-3A).  Fractions that 
activated and were in a similar location in the elution plate were pooled.  Pooled 
fractions were incubated with PKM2 and the activity was measured (Figure A3-
3B).  Pooled fraction 4 activated PKM2 robustly and was utilized in all 
subsequent steps of purification (Figure A3-3B).  The pooled fraction was run 
over a reverse phase column for a second time, however this time using an 
acetonitrile and carbonic acid gradient, and the effect of PKM2 activity was 
monitored (Figure A3-4). The P2SF did not appear to be polar at low pH (Figure 
A3-4).  The fractions that activated PKM2 were pooled.   
The P2SF was then dried and resuspended in several rounds with either 
water or methanol and each fraction was tested for an effect on PKM2 activity 
(Figure A3-5A).  P2SF appears soluble in methanol.  Fraction 4 and 5 were 
subsequently tested on PKM2 activity and both appeared to stimulate PKM2 
activity (Figure A3-5B).  Fractions 4 and 5 were pooled together and used in 
subsequent steps.  A subset of the P2SF was dried and resuspended in acetone 
several times and each fraction was tested on PKM2.  P2SF did not appear to be 
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as soluble in acetone as it was in methanol or water (Figure A3-6A).  Next, P2SF 
dissolved in water, acetone, treated with 0.02% formic acid or 0.5 mM TCEP 
(tris(2-carboxyethyl)phosphine) was incubated with PKM2 and each sample was 
tested for its effect on PKM2 activity (Figure A3-6B).  The P2SF appears 
sensitive to oxidation, as addition of the reducing agent TCEP, increased the 
stimulation of PKM2 (Figure A3-6B). 
Finally, P2SF was dried and resuspended in water and 0.1% formic acid 
and subjected to MS/MS using a Waters Q-TOF.  The principle ion was 615.3 
m/z.  A peak at 637.3 m/z was also identified, and is likely due to the addition of 
one sodium ion (Na+).  The first round of MS/MS, at 18% collision energy, 
revealed the appearance of a peak at 597.3 m/z (M-18) and the principal ion was 
still present.  Likely, this peak is due to the loss of H2O.  The second round of 
MS/MS showed the appearance of a peak at 579.2 (M-36; potentially loss of 2 
H2O), 561.2 (M-54; potentially loss of butadiene), and 430.2 (M-185) m/z.  
Though searches of databases, including the Scripps Metabolomics Database, 
the Human Metabolomics Database, and the Yeast Metabolomics Database, 
yielded many results, the atomic mass unit obtained through mass spectrometry 
data was not exact enough to obtain an identity with certainty.   
The metabolite purified in this studied represents a new allosteric activator 
of PKM2, by increasing the proteinʼs catalytic efficiency.  As of now, no known 
compounds activate PKM2 in this manner; most increase the binding affinity for 
the substrate PEP.  This result in itself makes the findings in this study unique.  
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From the various biochemical tests, we predict that the metabolite of interest is 
likely a non-aromatic, polar compound.  We believe that this metabolite 
potentially helps make PKM2 suitable for high glycolytic flux, i.e. when PEP 
levels are high.  The effect of this metabolite must be tested on the three other 
human isoforms to determine if it is isozyme specific.  Additionally, more sensitive 
mass spectrometry much be used in order to obtain the identity of this 
compound, as the Q-TOF utilized in this study only has accuracy to the tenth 
decimal place.  Once identified, the effect of this compound on cancer cell 
proliferation, PKM2 structure, and localization must be tested.  As PKM2 is a 
viable target for the treatment of cancer, the metabolite discovered in this study 
may represent a different class of activators that could potentially be utilized in 
drug design of anti-cancer drugs. 
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Figure A3-1.  A yeast metabolite present in cells incubated in high glucose 
media activates PKM2 activity.  A) Yeast extracts grown in either high or no 
glucose media were tested on scCdc19, scPyk2, or huPKM2 to determine their 
effect on pyruvate kinase activity.  High glucose yeast extracts activated PKM2.  
B) The effect of high glucose yeast extract on pyruvate kinase activity was 
measured.  C) PKM2 activity was monitored while titrating PEP in the presence 
of high glucose yeast extract.  D) Lineweaver-Burke plot of PKM2 activity in the 
presence and absence of high glucose yeast extract while titrating PEP.  E) A 
table of the extracted kinetic parameters in the presence and absence of yeast 
extract.  




















































Figure A3-2. PKM2 stimulating factor is weakly anionic.  A) P2SF was run 
over a batch anion exchange Q-Sepharose FF column using a stepwise gradient 
of NH4OAc. The fractions were mixed with PKM2 and the activity was monitored. 
P2SF did not bind well to the column indicating that the compound is weakly 
anionic. B) P2SF was run over a batch cation exchange SP-Sepharose FF 
column using a stepwise gradient of NH4OAc. The fractions were mixed with 
PKM2 and the activity was monitored. P2SF did not bind to the column indicating 
that the compound is not cationic. 
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Figure A3-3. PKM2 stimulating factor is not polar at pH 7.0.  A) P2SF was 
separated using a Luna C18 column with a MeOH and ammonium acetate 
gradient and each fraction was tested with PKM2 and the activity was measured.  
B) Fractions from the similar part of the elution plate and also activated PKM2 
were pooled (i.e. G7-12), and the fractionʼs effect on PKM2 activity was 
measured. 







































Figure A3-4. PKM2 stimulating factor is not polar at pH 3.0.  P2SF was 
separated using a Luna C18 column with an acetonitrile and HCO3H gradient 
(blue) and the effect of each fraction on PKM2 activity (red) was measured. The 
chromatogram is shown in black.  The compound of interest absorbs at 215 nm.
































Figure A3-5.  The PKM2 stimulating factor is methanol soluble.  A) P2SF 
water-soluble fractions and methanol-soluble fractions were tested on PKM2 to 
determine their effect on activity.  B) The methanol fractions identified as PKM2 
activators (fraction 4 and 5) were titrated and PKM2 activity was measured.   





























Acetone Fraction  
Figure A3-6.  PKM2 stimulating factor is very soluble in acetone and is 
sensitive to oxidation.  A) P2SF acetone-soluble fractions were tested on 
PKM2 activity, as well as PKM2 alone or mixed with untreated P2SF (YE).  P2SF 
is not as soluble in acetone as it appeared to be in methanol.  B) PKM2 was 
incubated alone, with P2SF (YE), P2SF mixed with acetone, 0.1% formic acid 
(FA), or 0.5 mM TCEP.   
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MATERIALS AND METHODS 
PKM2 Purification and Activity Assays 
PKM2 was purified as previously described (Keller et al. 2012, Keller et al. 
2014).  The activity of PKM2 was measured as previously described (Keller et al. 
2012).  In brief, 10 nM recombinant PKM2 was incubated with 1 mM ADP, 2 mM 
NADH, 150 uM PEP, and 5 U/mL lactate dehydrogenase in buffer (20 mM 
HEPES pH 7.4, 100 mM KCl, 6.6 mM MgSO4). The change in absorbance at 340 
nm was monitored for fifteen minutes. 
 
Yeast Extract Preparation 
 Wild type Saccharomyces cerevisiae was grown overnight in synthetic 
dextrose media at 30°C while shaking.  After overnight growth, a fresh culture 
was inoculated and grown to OD600 of between 0.6-0.8.  For the initial screen, 5 
mL cultures were grown in 20 g/L or 2 g/L glucose.  For any subsequent steps, 
1.5 L cultures were grown in 20 g/L glucose. Cells were centrifuged at 3000xg for 
one hour, lysed in Yeast Protein Extraction Reagent (YPER), supplemented with 
1 mM DTT, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 0.5 mM EDTA.  
Lysates were then centrifuged at 13000 RPM for 10 minutes and the supernatant 
was taken.  The supernatant was then filtered through a centrifuge filter (MWCO 
3 kDa) and rotary evaporated.  The extract was resuspended in water, methanol, 
or acetone.   
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Metabolite Purification  
For anion exchange, a Q-Sepharose FF 5 mL column and a stepwise 
gradient of ammonium acetate was utilized (30 mM, 300 mM, 1.5 M, and 3 M); 
for cation exchange, a SP-Sepharose FF 5 mL column and a stepwise gradient 
of ammonium acetate was also utilized (30 mM, 300 mM, 1.5 M, and 3 M).  All 
reverse-phase FPLC purification were performed using a Phenomenex Luna C18 
(2) column (4.6x150 mm, 3 um beads) at 4oC at 0.5 mL/min; 1.5 mL fractions 
were collected.  The first round of purification was at neutral pH using a linear 
gradient of water to methanol, in 10 mM ammonium acetate.  The second round 
of purification was performed at a pH of 3 using a linear gradient of acetonitrile to 
carbonic acid.    
 
Biochemical Characterization 
 The PKM2 stimulating factor spectrum was measured using a Beckman 
UV-Vis Spectrometer in the presence or absence of 0.02% formic acid (v/v).  
P2SF was treated with 50% acetone, 0.1% formic acid, or 0.5 mM TCEP for 
activity assays with PKM2.   
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APPENDIX 4.   
 
EFFECT OF LIGAND BINDING AND POINT MUTATIONS ON THE 
QUATERNARY STRUCTURE OF PKM2 
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INTRODUCTION 
Pyruvate kinases catalyze the final step of glycolysis, from phosphoenol 
pyruvate (PEP) to pyruvate.  In humans, there are four isoforms of pyruvate 
kinase: PKM1, PKM2, PKR, and PKL.  Biochemically, the isoforms have different 
activities and different regulatory elements.  Structurally, all four isomers exist as 
a homotetramer, and this is thought to be the fully functional form of a pyruvate 
kinase.  The homeotetramer is actually a dimer of homodimers, and pyruvate 
kinases can transition between all three structural forms: tetramer, dimer, and 
monomer.  The dimer and monomer are generally regarded as the inactive form 
of pyruvate kinase, as the Km for its substrate PEP is much higher than 
physiological conditions.  Of the pyruvate kinase isoforms, PKM2 has been 
shown to exist both as a tetramer and dimer in cells.  Interestingly, this isoform 
has also been shown to be important in cancer cell metabolism, proliferation, and 
survival in stress conditions. 
Previous work has suggested that PKM2ʼs role in cancer comes from the 
quaternary structure transition from a tetramer to a homodimer (Landt et al. 2010, 
Mazurek et al. 2002, and Zwerschke et al. 1999).   As a tumor progresses to 
malignancy, PKM2 quaternary structure shifts from a tetramer towards a dimer 
(Landt et al. 2010, Mazurek et al. 2002, and Zwerschke et al. 1999).  Additionally, 
PKM2 has been shown become a protein kinase in the dimeric state, and is 
capable of phosphorylating a number of cellular targets leading to expression of 
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target genes (Keller et al. 2104).  We recently identified SAICAR, a de novo 
purine biosynthesis intermediate, as an activator of PKM2 protein kinase activity 
(Keller et al., 2014).  The activation of PKM2 by SAICAR is distinct from the 
previous known PKM2 activator, fructose 1, 6-bisphosphate (FBP), as a 
combination of both activators inhibits protein kinase activity (Keller et al. 2014). 
This is likely due to the fact that FBP is known to shift the equilibrium of PKM2 
quaternary structure towards the tetrameric form, which is diminished in late 
stage cancer cells (Landt et al. 2010, Mazurek et al. 2002, and Zwerschke et al. 
1999). Furthermore, because FBP levels are decreased in conditions similar to a 
tumor microenvironment (i.e. hypoxia and glucose starvation), and because PKL, 
which is also activated by FBP, is unable to support tumor growth, it is unlikely 
that FBP is relevant to the role of PKM2 in tumor growth.  Thus, it appears that 
SAICAR is likely the most relevant factor in the regulation of PKM2 in malignant 
cancer cells.   
Here, we report that SAICAR activates the dimeric form of PKM2, although 
it does not shift the equilibrium of PKM2 quaternary structure significantly.  
Additionally, PKM2 mutants were shown to have altered quaternary structure.  
Specifically, the SAICAR hypersensitive mutant R399V exists primarily as a 
dimer, while the wild type protein and SAICAR insensitive mutant is mostly a 
tetramer.  Our data indicate that SAICAR may bind and activate the dimer of 
PKM2, activating the pyruvate kinase and protein kinase activity of the protein.    
	   208	  
RESULTS AND DISCUSSION 
 As quaternary structure appears important for PKM2 activity and cancer 
cell proliferation, we decided to probe the effect of the PKM2 activator SAICAR 
on the quaternary structure.  To test this, we incubated recombinant PKM2 in the 
presence or absence of the known PKM2-binding ligands fructose 1,6-
bisphosphate (FBP), thyroid hormone (T3), or SAICAR and separated PKM2 
based on size by gel filtration chromatography.  As expected, FBP shifted PKM2 
structure towards the tetramer, while T3 shifted towards the dimer and monomer 
(Figure A4-1).  The addition of SAICAR did not substantially alter the quaternary 
structure, although there was a slight shift towards the dimer (Figure A4-1).  Next, 
we tested the activity of fractions corresponding to the tetramer, dimer, and 
monomer after incubation with no ligand, FBP, or SAICAR and separation 
through size exclusion chromatography.  As expected, most pyruvate kinase 
activity was observed in tetramer fractions for both untreated and with added 
FBP (Figure A4-2).  In contrast, most activity was observed in the dimer peaks 
upon the addition of SAICAR (Figure A4-2).  These data indicated that SAICAR 
likely activates the dimer and possibly stabilizes the dimer.   
 To further validate this finding, we separated recombinant PKM2 into the 
tetramer, dimer, and monomer by size exclusion chromatography.  Although 
there is the possibility that the protein can equilibrate, the assumption in this 
experiment is that the equilibration occurs slowly.  The activity of each fraction 
was monitored in the presence SAICAR at two concentrations of the substrate 
	   209	  
PEP (Figure A4-3).  In both conditions, SAICAR activated the dimer specifically, 
while having no effect on the tetramer or monomer.   
 In an effort to establish a connection between SAICAR sensitivity and 
PKM2 structure, we examined the quaternary structure of various PKM2 mutants.  
Recombinant PKM2, PKM2 R399V, PKM2 Q393K, and PKM2 K433E were 
subjected to size exclusion chromatography and the overall quaternary structure 
was quantified (Figure A4-4).  Wild type PKM2 and the SAICAR insensitive 
PKM2 mutant Q393K existed primarily as a tetramer (Figure A4-4).  The 
hypersensitive mutant PKM2 R399V exists primarily as a dimer (Figure A4-4).  
Interestingly, the FBP-insensitive K433E mutant appears to be equally distributed 
between tetramer, dimer, and monomer (Figure A4-4).  These data suggest that 
the hypersensitivity of PKM2 to SAICAR may be due to the increased 
dimerization of the protein. 
 Overall, our findings indicate that SAICAR binds and activates the dimeric 
form of PKM2.  As PKM2 exists primarily as a dimer in cancer cells, our data 
suggest that SAICAR may be a relevant activator in malignant tumor cells.   
Thus, the quaternary structure of PKM2 could be a viable therapeutic target for 
anti-cancer drugs.   
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Figure A4-1.  Ligands affect the quaternary structure of PKM2.  
Recombinant PKM2 was subjected to gel filtration in the absence or presence of 
ligands (1 mM FBP, 0.5 mM T3, or 1 mM SAICAR) for 37°C for thirty minutes.  
The first peak corresponds to the tetramer, second to the dimer, and third to the 
monomer.  As expected, FBP shifted PKM2 quaternary structure to the tetramer, 
while T3 shifted the structure towards a dimer and monomer.  The addition of 
SAICAR mildly shifted the structure of PKM2 towards the dimer. 















































Figure A4-2.  Ligands affect the activity of PKM2 differentially.  Recombinant 
PKM2 was subjected to gel filtration in the absence or presence of 1 mM FBP or 
1 mM SAICAR.  The spectrum of each assay is depicted with a chromatogram 
trace.  Fractions were collected and the activity of PKM2 was assessed and is 
depicted by the circles and straight-line connectors.   






























Figure A4-3.  SAICAR activates the PKM2 dimer.  Recombinant PKM2 (1 mM) 
was subjected to gel filtration and fractions were collected.  Fractions were mixed 
with 1 mM SAICAR in the presence of 0.2 or 2 mM PEP, and the activity of PKM2 
was measured.  The activity was normalized to the area of the corresponding 
peak of the chromatogram of the size exclusion column.  SAICAR activated the 
dimer peak specifically, while the tetramer and monomer were not. 
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Figure A4-4.  Point mutations of PKM2 lead to a change in quaternary 
structure.  Recombinant PKM2, PKM2 R399V, PKM2 Q393K, and PKM2 K433E 
were subjected to gel filtration chromatography. The chromatogram peaks 
corresponding to the tetramer, dimer, and monomer were integrated and the data 
are presented as a percent of the total protein peak.  The SAICAR hypersensitive 
R399V protein appears to exist primarily as a dimer, while wild type and the 
SAICAR-insensitive Q393K mutant exist primarily as a tetramer.  FBP-insensitive 
K433E mutant appears to be equally distributed. 
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MATERIALS AND METHODS 
PKM2 Purification and Activity Assays 
 The purification of PKM2 and its variants were performed as previously 
described (Keller et al. 2012).   Subsequent activity assays used 10 uL of fraction 
from size exclusion chromatography were utilized in the activity assay, instead of 
2-10 nM protein.   
 
Size Exclusion Chromatography 
 Recombinant PKM2 (1 mL of 10 uM protein) was injected into a Superdex 
10/300 column (flow rate: 5 mL/min) and 1 mL fractions were collected.  Tetramer 
peak was identified by the PKM2 and FBP peak, which is known to shift the 
equilibrium to a tetramer. 
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